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INTRODUCTION
Asthma is a highly prevalent and chronic respiratory condition affecting 300 million people 
worldwide. 1 Asthma is a potentially serious chronic disease that imposes a substantial burden 
on patients, their families and the community. It causes disability by respiratory symptoms, 
exacerbations with sometimes urgent health resource utilization, reducing the patient’s quality 
of life and may be fatal. 2 It is estimated that asthma accounted for about 345,000 deaths 
worldwide in 2010. 3 There is no cure for asthma, but it can generally be controlled through 
tailored stepwise treatment as described by asthma management guidelines. Despite available 
therapies, asthma control in clinical practice is suboptimal in real life and much lower than 
in clinical trials. To see developments in epidemiology and to understand the full burden of 
asthma, it is important to have up-to-date, real world data on treatment and exacerbations 
in population based cohorts. The computerization of medical care has largely facilitated this 
as they capture detailed and time stamped data on disease, population and medication use 
and reflect real life, which is essential to conduct these studies. In this thesis we focus on the 
epidemiology of asthma, asthma treatment and asthma control in daily practice and we used 
different Dutch and international electronic health care databases.
Symptoms and pathophysiology of asthma
Asthma is a chronic, episodic, heterogeneous disorder of the airways, characterized by wheez-
ing, shortness of breath, chest tightness and cough that vary over time. Chronic airway in-
flammation is an important aspect of asthma pathophysiology. 2 Effector cells are eosinophils, 
neutrophils, CD4+ T-lymphocytes and mast cells that contribute to the pathophysiological 
changes. 2, 4 These changes include airway inflammation, intermittent (reversible) airflow ob-
struction, which is potentially reversible either spontaneously or with pharmacological inter-
vention, bronchial hyperresponsiveness and airway wall remodelling. 2 Chronic inflammation, 
mucosal oedema due to increased vascular permeability, smooth muscle contraction and exces-
sive mucus secretion contribute to airway obstruction. The smooth muscle cells cause exagger-
ated bronchoconstriction in response to a wide range of specific and non-specific stimuli, this is 
called ‘bronchial hyperresponsiveness’. 5 In addition to the inflammatory response, character-
istic structural changes, ‘airway remodelling’, are seen in the airways of asthma patients. 2, 6 In 
asthma the remodelling usually begins early and thickening of the airway wall may be present 
before asthma is diagnosed. 6 
Epidemiology of asthma 
Asthma is a highly prevalent and chronic respiratory condition affecting 300 million people 
worldwide. 1 Data on prevalence of asthma has been described for various countries, based 
on data from cross-sectional studies. 7, 8 From these data was estimated that about 8.6% of the 
young adults experience asthma symptoms and 4.5% have been diagnosed with asthma and/
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or are taking treatment for asthma. About 14% of the children worldwide suffer from asthma 
symptoms.
There are only few recent studies on the incidence and time trends of incidence and prevalence 
of asthma in children in Europe. Studies on incidence rates for asthma in children reported 
widely varying rates, ranging between 4.26 and 20.0 per 1000 per year. 9-24 The huge variation 
in incidence rates can be explained by differences in asthma definition, differences in the pop-
ulation being studied, geographical factors, differences in calendar time, and reliability of data 
sources. 25 Data on time trends in asthma prevalence and incidence are conflicting. 26
 
Treatment of asthma
The most important goal in the treatment of asthma is to control symptoms and prevent ex-
acerbations. Therapeutic targets are suppression of airway inflammation and relaxation of 
bronchial smooth muscle. Medication for asthma can be classified into the following two main 
categories; (1) reliever (rescue) medication, taken when needed, and acting quickly to reverse 
bronchoconstriction and (2) controller medications for daily maintenance treatment. Inhaled 
corticosteroids (ICS) are the controller treatment of first choice. Corticosteroids inhibit air-
way inflammation by inhibiting multiple components of the inflammatory cascade, including 
the production of prostaglandins and leukotrienes by their action of phospholipase. They also 
inhibit cytokine gene transcription and increase gene transcription of β-receptors thereby in-
creasing the responsiveness to β2-agonists. 27
Other options for maintenance treatment are long-acting β2-agonists (LABA) or leukotriene 
antagonists (LTRA). In asthma patients, LABAs should only be used in combination with ICS. 
When used in monotherapy, LABAs may mask underlying inflammation through symptom re-
lief, as they do not control the inflammation. This increases the risk of severe asthma exacerba-
tions and could eventually result in mortality. 27-30 
LTRAs inhibit the binding of leukotrienes at the receptor level and block the inflammatory 
effects of leukotrienes. 27, 29 LTRAs are effective for long-term control of mild to moderate 
asthma. 27, 28 Several evidence-based guidelines for asthma treatment have been published. 
These include the GINA guidelines, which recommend a step-wise approach for adjustments of 
controller therapy to achieve good symptom control and minimize future risk of exacerbations. 
2, 31, 32 If asthma is not well controlled, treatment should be stepped up until control is achieved. 
In children 5 years or older, treatment of uncontrolled asthma on a low dose of ICS include 
addition of long-acting β2-agonists (LABA) or leukotriene receptor antagonists (LTRA) or dou-
bling the dose of ICS. (Figure 1) Adjustments in treatment should be done in a constant cycle of 
reviewing response, assessing symptoms and monitoring inhalation technique and adherence. 
It is not known how well guidelines are followed in real life. 
12 Chapter 1
Generic or brand medication
The expiration of the patent of brand inhalation medications, the ongoing pressure on the 
healthcare budget and preference policies have resulted in a growing market for generic in-
halation medications. The preference policy favours the use of generic drugs as alternatives 
to more expensive brand-name products, substitution to generic can be done in the pharmacy 
independent of the physician’s prescription, unless it is indicated that brand needs to be dis-
pensed. 33 Before generic medications are marketed, demonstration of clinical bioequivalence 
is needed. As the drug delivery and intended action of orally inhaled drug products for local 
action, such as dry powder inhalers (DPI) do not rely on the systemic circulation, the bioequiv-
alence cannot be demonstrated based on drug concentration in blood/plasma. 34 Therefore 
demonstration of bioequivalence of these products is more challenging. The EMA guideline on 
requirements for clinical documentation of orally inhaled products for asthma and COPD states 
that for inhalers with the same substance and required flow rate, similar in vitro performance 
is sufficient to show equivalence. 35 In vitro performance includes particle size distribution, fine 
particle fraction of emitted dose, flow rate dependency tested under validated circumstances. 
Switching of inhalation therapy often coincides with a change of inhalation device. The 
choice of type of inhaler is based on patient characteristics (like age and inspiratory force), 
on the characteristics of the inhaler (like multidose/single dose, powder/aerosol) and patient 
Figure 1. From the Global Strategy for Asthma Management and Prevention 2015, © Global Initiative for Asthma (GINA), all 
rights reserved.
* For children 6-11 years, theophylline is not recommended and preferred Step 3 is medium dose ICS
** For patients prescribed BDP/formoterol or BUD/formoterol maintenance and reliever therapy
# Tiotropium by soft-mist inhaler is indicated as add-on treatment for adults (≥18 years) with a history of exacerbations
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preference. 36 Each device requires a different inhalation manoeuvre, which needs to be care-
fully instructed. Unexpected change in inhaler device may lead to confusion, and incorrect use, 
which may lead to no or less drug inhaled. 
In addition, there is evidence that generic substitution through changes in appearance (colour, 
size, appearance and packaging) has a negative impact on adherence and disease outcomes. 37-41 
Therefore preference policy has raised concerns amongst respiratory health care providers, 
as it might increase exacerbations and therefore may have an opposite effect on health care 
budget. However, this has not been supported by real life data.
Adherence 
Despite availability of treatment, many children with asthma do not achieve good symptom 
control. 42, 43 A major cause of uncontrolled asthma is suboptimal adherence to maintenance 
treatment. 44 Nonadherence is a worldwide problem, irrespective of age. Approximately 50% 
of adults and children on long-term controller therapy for asthma fail to take medications as 
directed at least part of the time. 45 Adherence to asthma treatment is commonly low, ranging 
between 30 to 70%. 2, 46-48 However, assessment of adherence is notoriously difficult. There are 
different ways to assess adherence. 49 One of these is the medication possession ratio (MPR), 
the ratio of the total days of supply to the number of days of follow-up per patient. The MPR 
can be calculated from prescription data or pharmacy dispensing data. MPR based on prescrip-
tion data has disadvantages as it does not take dispensing, actual use or inhalation technique 
into account. It has been suggested that poor adherence to controller therapy increases the risk 
of exacerbations in children and adults, but literature on this topic is conflicting. 
Asthma control and severe asthma exacerbations
Despite treatment, asthma exacerbations may occur due to inadequate treatment, or to nonre-
sponse. 50 Clinical trials usually define a severe exacerbation according to the ATS/ERS guide-
lines as worsening of asthma symptoms which requires hospitalisation or emergency depart-
ment visit or use of systemic corticosteroids. 51 Severe asthma exacerbations are associated with 
considerable morbidity and even mortality. Reported frequencies of asthma exacerbations in 
the literature vary by the definition of an asthma exacerbation, the studied patient population, 
the severity of asthma, degree of asthma control, and the data sources. Real life data on the 
incidence rates of asthma exacerbations and potential association with mortality are sparse. 52 
Clearly, there is a need for more real life studies to assess the safety and effectiveness profile 
of inhalation medication for children with asthma in the real life setting which was the reason 
why we initiated the studies described in this thesis.
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The objectives of our research were the following:
• To generate and evaluate automated case detection algorithms to identify children with 
asthma 
• To describe the epidemiology and time trends of asthma in children
• To describe the incidence and risk factors of severe asthma exacerbations in children
• To describe overall mortality and mortality following asthma exacerbations in patients with 
asthma 
• To describe the prescription/dispensing patterns and adherence of asthma controller thera-
py in children with asthma
• To examine dispensing patterns of brand and generic controller therapy and whether switch-
ing between brand and generic controller therapy influences adherence
• To study the association of switching between generic and brand inhalation medication and 
the risk of asthma exacerbations
Data sources
In this thesis we had access to the IPCI database 53, 54, the Dutch PHARMO Database Network 55 
and the databases in the EU-ADR alliance. The EU-ADR alliance is a federated collaborative 
framework for drug safety studies, using six European population-based administrative and 
healthcare databases from Italy, the Netherlands, UK, Spain and Denmark. 56
For most of our research questions we used data from the IPCI database. This database contains 
the electronic medical records of more than one million patients throughout the Netherlands. 
This database has the advantage of data on real life practice. Within this database we estab-
lished the ESTATe cohort (Effectiveness and Safety of controller Therapy of Asthma Treatment 
in childrEn with asthma), children with asthma aged 5 and older between 2000 and 2012 were 
selected. For our research on use of generic and brand asthma drugs we used the PHARMO 
Database Network. This is a Dutch population-based patient centric data network including 
among other data, drug dispensing records from community pharmacies, hospital discharge 
records and GP records of more than two million individuals throughout the Netherlands. 55 For 
our research on the incidence of asthma exacerbations and mortality in patients with asthma, 
data from the database partners of the EU-ADR Alliance was used. 
Outline of this thesis
To study the epidemiology of asthma in children, we identified a paediatric asthma cohort (ES-
TATe cohort) within the IPCI database. In Chapter 2.1 we describe how this cohort was created 
by carefully exploring all medical records from potential asthma patients identified through 
“machine learning” techniques. In Chapter 2.2 this validated dataset was used to describe 
the incidence, prevalence and trend of age at asthma diagnosis in 2000-2012. As data on the 
real life incidence of severe asthma exacerbation are rare we identified patients with frequent 
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exacerbations, and studied risk factors. In Chapter 3.1 we describe asthma exacerbations and 
risk factors for frequent exacerbations in children with asthma. In Chapter 3.2 mortality in 
patients with asthma and the risk of mortality following a severe asthma exacerbation was 
studied. In Chapter 4.1 longitudinal prescription patterns and adherence to asthma medica-
tion are described, and characteristics of children with high adherence versus children with 
low adherence assessed. In Chapter 4.2 we put our results on adherence into perspective, by 
performing a systematic review on the relationship between low adherence and risk of severe 
asthma exacerbations. In Chapter 5 we report the prevalence of switching between generic 
and brand use of inhalation medications in Chapter 5.1 and the association between switching 
and asthma exacerbations in Chapter 5.2. Finally, in Chapter 6 we discuss the main findings 
of the studies included in this thesis and we provide suggestions for future research. 
Chapter Database Outcome Population
2.1 IPCI Case detection for asthma Children
2.2 IPCI Incidence and prevalence of asthma Children
3.1 IPCI Incidence and risk factors of asthma exacerbations Children
3.2 EU-ADR Overall mortality and mortality following asthma 
exacerbations 
Children and adults
4.1 IPCI Prescription patterns and adherence of asthma control-
ler therapy
Children
4.2 ------ Medication adherence and the risk of severe asthma 
exacerbations- a systematic review
Children and adults
5.1 PHARMO Dispensing patterns of brand and generic and switching 
of inhalation medication
Children and adults
5.2 PHARMO Switching between generic and brand inhalation medi-
cation and the risk of asthma exacerbations
Children and adults
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ABSTRACT
  AIMS   Most electronic health record databases contain unstructured free-text narratives, which 
cannot be easily analysed. Case-detection algorithms are usually created manually and often 
rely only on using coded information such as International Classification of Diseases version 
9 codes. We applied a machine-learning approach to generate and evaluate an automated 
case-detection algorithm that uses both free-text and coded information to identify asthma 
cases.
  METHODS   The Integrated Primary Care Information (IPCI) database was searched for potential 
asthma patients aged 5–18 years using a broad query on asthma-related codes, drugs, and 
free text. A training set of 5,032 patients was created by manually annotating the potential 
patients as definite, probable, or doubtful asthma cases or non-asthma cases. The rule-learning 
program RIPPER was then used to generate algorithms to distinguish cases from non-cases. 
An over-sampling method was used to balance the performance of the automated algorithm to 
meet our study requirements. Performance of the automated algorithm was evaluated against 
the manually annotated set.
  RESULTS   The selected algorithm yielded a positive predictive value (PPV) of 0.66, sensitivity 
of 0.98, and specificity of 0.95 when identifying only definite asthma cases; a PPV of 0.82, 
sensitivity of 0.96, and specificity of 0.90 when identifying both definite and probable asthma 
cases; and a PPV of 0.57, sensitivity of 0.95, and specificity of 0.67 for the scenario identifying 
definite, probable, and doubtful asthma cases.
  CONCLUSIONS   The automated algorithm shows good performance in detecting cases of asthma 
utilizing both free-text and coded data. This algorithm will facilitate large-scale studies of 
asthma in the IPCI database. 
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INTRODUCTION
Asthma is one of the most common chronic diseases of childhood globally. The main goal of 
asthma treatment is to achieve and maintain clinical control of the disease. Failing to control 
asthma can limit daily-life activities and can be fatal. In children, asthma is usually treated and 
maintained with low-dose inhaled corticosteroids (ICS). If asthma is not controlled, treatment 
is stepped up by either adding long-acting β2-agonists (LABA) or a leukotriene receptor antag-
onist (LTRA) to low-dose ICS or increasing the dose of ICS until control is achieved. 1
Safety concerns have been raised on the long-term toxicity of ICS, the risk of mortality, and 
asthma exacerbations with the use of LABAs in monotherapy and the risk of neuropsychiatric 
events and hepatotoxicity in children treated with LTRAs. 2–8 Randomized controlled trials 
(RCTs) on the efficacy and safety of these drugs in children are rare. In addition, the few trials 
conducted in children are often not designed to detect safety issues because of the limited 
sample size and short duration of follow-up. In general, observational studies are suited for 
research on drug safety because they usually have large sample size with long-term follow-up. 
Electronic medical records are valuable resources and are increasingly being used in epidemi-
ological observational studies to detect safety issues. 9–15
One of the challenges of using electronic medical records is to determine whether and when a 
medical outcome of interest has occurred. When coded information such as International Clas-
sification of Diseases version 9 (ICD-9) and Logical Observation Identifiers Names and Codes 
(LOINC) codes are available, outcomes are typically identified by searching for a combination 
of codes in the patient record. However, the recording of these codes can be incomplete and 
inaccurate, or the codes themselves might be ambiguous or have the wrong granularity for the 
research question at hand. It is therefore recommended that the performance of this search 
using codes is evaluated through manual chart review, where researchers often rely on the free-
text narrative in the medical record. There are also databases where the coding is simply too 
incomplete. For example, in the Integrated Primary Care Information (IPCI) database 16, almost 
60% of the record lines are narratives and do not contain coded information. These narratives 
may contain important information such as patient-reported symptoms, signs, or summaries 
of specialists’ letters. In these databases, the search for outcomes is even more labor intensive. 
Usually, a broad text query is defined including all possible words and codes that might be 
relevant, and subsequently all narratives returned by the query are manually reviewed. With 
the increase in size of these databases, this practice is becoming prohibitively laborsome and 
expensive. 
For this reason we used an alternative approach to identifying asthma cases, which uses the 
free-text narrative in an automated fashion. We apply a machine-learning approach to derive 
an automated case detection algorithm that uses both text and coded data if available. We not 
only show the performance of this algorithm in terms of positive predictive value (PPV), sensi-
tivity and specificity, but also demonstrate how sensitivity and specificity can be tuned to best 
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meet the requirements of our study. We apply this approach to the Dutch IPCI database, but 
the same procedure to construct a case detection algorithm could be used on other databases, 
in other languages. 
METHODS
Electronic medical record database
Data in this study were taken from the IPCI database. 16 The IPCI database is a longitudinal 
observational database of electronic medical records (EMRs) from Dutch general practitioners 
(GPs). The electronic records contain coded data and data on patient demographics, symptoms 
and diagnoses, clinical findings, referrals, laboratory findings, and hospitalization of more than 
1.1 million patients. The IPCI database uses the International Classification of Primary Care 
(ICPC) 17 coding system. A list of ICPC codes related to asthma is presented in the Appendix. 
The cohort for the underlying study included children between age 5 and 18 that were present 
in the database between January 1, 2000 till January 31, 2012. A minimum registration period 
of six months was required to guarantee sufficient medical history data.
Clinical case definition
To create a labelled training set for machine-learning methods, we used a manually-defined 
clinical case definition. Patients were categorized into ‘definite asthma’, ‘probable asthma’, 
‘doubtful asthma’, or ‘no asthma’ according to the following validation criteria. 
For definite asthma patients, at least one entry in their medical record containing an asthma di-
agnosis confirmed by a specialist (paediatrician or pulmonologist) was required. For probable 
asthma patients, at least one entry should contain evidence of asthma diagnosed by the GP and 
there should be at least one more entry in the patient record suggestive of asthma (ICPC code, 
free text, lung function measurements, or use of specific bronchodilating drugs/anti-inflamma-
tory drugs for the indication of asthma) within the next 12 months, or at least two additional 
entries in the patient record suggestive of asthma. For doubtful asthma patients, there should 
be at least one entry containing an indication of asthma without satisfying the criteria for a 
definite or probable asthma case. Patients with drug entries only (i.e., without evidence in ICPC 
code or free text) were considered non-asthma cases, as were patients with no indication of 
asthma in any entry of their patient record. 
Training set for machine learning
We use machine learning methods to automatically learn case detection algorithms on the basis 
of a training set of entries, i.e., a set of positive and negative examples. To generate a training 
set for our machine-learning method, we first identified all potential asthma patients using a 
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broad automated search on ICPC asthma disease codes, asthma drug prescriptions, and free 
text. The broad query is presented in the Appendix. Because of the generic asthma-related key-
words used in the broad query, many of the retrieved patients were likely not to have asthma.
One medical doctor reviewed the entire medical record of the patients identified by the broad 
search strategy in random order for one month. A total of 5,032 patients were validated from 
63,618 patients returned by the broad query. The doubtful patients were further reviewed by 
a senior medical doctor. Patients were labelled as definite asthma (n=308), probable asthma 
(n=1,133), doubtful asthma (n=160), or non-asthma (n=3,431). A patient’s medical record 
consists of one or more entries, where each entry pertains to a patient visit, a letter from a 
specialist, prescribed drugs, and so on. The entries in the medical record of a patient were 
reviewed in chronological order and a patient was labelled positive whenever an asthma cri-
terion (for definite, probable, and doubtful) was satisfied. The remaining entries in the med-
ical record were not reviewed, and only the entries containing the indication of asthma were 
included in the training set as positive examples. If none of the entries of the patient record 
contained positive evidence of asthma, the patient was considered a negative case and one of 
the entries was randomly picked as a negative example in the training set.
To make the text in the entries better fit for machine learning approaches, we removed un-
informative words (so-called stop words). Although some standard Dutch stop word lists are 
available 18, they are not entirely suitable for the clinical text because some of the words may 
have importance in the clinical context, e.g., ‘op’ (English ‘on’) could be an abbreviation of 
‘operation’. We therefore used a small stop word list, only containing ‘en’ (English ‘and’), ‘een’ 
(‘a’), ‘de’, and ‘het’ (both ‘the’). 
All ATC codes related to respiratory drugs and starting with R03 (drugs for obstructive airway 
diseases) were replaced by a single keyword ‘r03drug’. To remove negated and speculative 
assertions, we used the Dutch assertion filter proposed in 15, similar to NegEx. 19 Any words 
appearing between negation or speculation keywords and the end of sentence (demarked by 
a punctuation mark) were removed from the entry. All sentences containing an alternatives 
keyword were completely removed.
The text in the entries was converted to lower case and split into individual words. These 
individual words were treated as features for our machine-learning method (bag-of-words rep-
resentation). Schuemie et al. 15 previously showed the advantage of using assertion filtering 
and bag-of-words representation on Dutch EMRs. For computational purposes, we reduced the 
number of features by chi-square feature selection. 20 A p-value of less than 0.05 was used as a 
feature selection criterion. Chi-square feature selection decreased the number of features in the 
data set by about a factor of 10 without affecting the performance of the classifiers but greatly 
reducing their training time. 
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Automated generation of case definitions
Considering the hierarchical nature of the asthma labels (definite  probable  doubtful  
non-asthma), we tackled the automated generation of case definitions as a hierarchical multi-
class classification problem. 21–23 We followed an approach in which the hierarchy is structured 
as a decision tree and separate classifiers are built for the nodes in the tree (Figure 1). 
We trained two machine-learning classifiers, one to separate definite cases from all other cases 
and the other to distinguish probable and doubtful asthma from non-asthma cases. The second 
classifier considered probable and doubtful cases as one (positive) group because the distinc-
tion between these cases is difficult to learn automatically. This distinction was made in a third 
classifier, which implemented two rules based on the manual case definition criteria: (1) if a 
patient had two positive asthma entries (according to the second classifier) within a period of 
15 months and (2) one of the entries is not a medication/drug entry, the patient was consid-
ered a probable asthma case. A medication entry only contains prescription. The training set 
for the first, ‘definite asthma’ classifier consisted of the entries of the definite asthma patients as 
positive examples, and entries of the probable, doubtful, and non-asthma cases as negative ex-
amples. For the second, ‘probable, doubtful, and non-asthma’ classifier, we used the entries of 
the probable and doubtful cases as positive examples and the entries of the non-asthma cases 
as negative examples. The probable or doubtful asthma patients classified as definite asthma by 
the first classifier were removed from the training set of the second classifier, and the definite 
asthma patients missed by the first classifier were added as positive examples.
Figure 1 - Hierarchical classification scheme for asthma.
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To shift the balance of sensitivity and specificity, we used a method called “over-sampling”. 
Several over-sampling methods are described in a paper by Chawla. 24 Normally over-sampling 
is done by simply reusing the same examples multiple times, but Schuemie et al. 15 showed that 
using additional entries of non-cases could lead to an increased performance. Our over-sam-
pling was focused on increasing the specificity of the classifiers. For a non-asthma patient, all 
entries were manually reviewed and no evidence of asthma was found. Although initially one 
entry was randomly selected for training the classifiers, the other entries can also be used as 
additional negative examples. We created a set of all these additional entries, and randomly 
sampled from this set to expand our training set. In total, we used 10 over-sampling percent-
ages in the experiments. In each over-sampling run, a specified percentage of entries (of the 
original negative examples in the training set) from the additional entries set were added to 
the training set. The experiment without the over-sampling entries was considered a baseline.
Training and testing
The rule-learning algorithm RIPPER 25 was used on the training set to automatically generate 
rules for each of the asthma case definition. Schuemie et al. 15 evaluated several well-known 
machine-learning algorithms for the classification of EMRs in a similar experimental setting, 
and found RIPPER to be one of the best performing algorithms. RIPPER produces an ordered 
set of decision rules. The advantages of such machine-learning algorithms are their ability to 
produce output that is understandable by humans, their ease of use, and their applicability to 
a wide range of problems. 26 We used an implementation of the RIPPER algorithm called JRip, 
which is available in the open-source machine learning package Weka. 27
We used five-fold cross-validation to evaluate our classifiers. Cross validation was done at the 
patient level (subject-level cross-validation 28) i.e., the data set was randomly divided in five 
equally sized subsets of patients (folds). In five cross-validation runs, each time the entries 
pertaining to four folds were used as a training set and the entries of the remaining subset were 
used for testing. We used all entries of the patients in the test fold because in real-life situations 
we do not know the labels of the entries pertaining to the patients returned by the broad query. 
Cross-validation was used to obtain unbiased performance estimates of the classifiers, but all 
data was used to generate the final sets of rules.
We used PPV, sensitivity, and specificity as measures to evaluate the performance of the classifi-
ers. PPV is defined as the fraction of positively identified cases that are true positive: number of 
true positives / (number of true positives + number of false positives). Sensitivity is defined as 
the true-positive rate: number of true positives / (number of true positives + number of false 
negatives), whereas specificity is the true-negative rate: number of true negatives / (number of 
true negatives + number of false positives). 
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RESULTS
We present results of the asthma classification using three different scenarios. Each can be 
used to meet the requirement of a particular study. In the first scenario (Figure 2), only definite 
asthma cases were considered relevant for the study. The probable and doubtful asthma cases 
were ignored. In the second scenario (Figure 3), the definite and probable asthma cases were 
considered relevant for the study. The definite and probable asthma cases were combined as 
positive asthma cases and doubtful cases were disregarded. In the third scenario (Figure 4), the 
definite, probable, and doubtful asthma cases were combined as positive asthma cases. 
The sensitivity, specificity, and PPV of the classifiers using over-sampling and cross-validation 
methods for the three scenarios are presented in Figures 2-4. 
Figure 2 - Performance of the classifiers using cross-validation when only definite asthma cases were considered as positive 
asthma ignoring probable and doubtful cases. 
Figure 3 - Performance of the classifiers using cross-validation when definite and probable asthma cases were combined as 
positive asthma ignoring doubtful cases.
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The first experiment with 0% over-sampling was considered as the baseline in our experi-
ments. The classifiers showed consistent behaviour during the over-sampling experiments. The 
specificity and PPV gradually increased and sensitivity decreased as we increased the number 
of negative examples in the training set. For this particular study, we selected the model us-
ing 300% over-sampling as the final classification model because of its high sensitivity and 
specificity. A confusion matrix of the selected classification model is presented in Table 1. The 
confusion matrices for all over-sampling experiments using cross-validation are presented in 
the Appendix.
From 1,601 asthma cases (definite, probable, and doubtful), only 77 (5%) were misclassified 
as non-asthma cases. From 3,431 non-asthma cases, 1,137 (33%) were misclassified as asthma 
cases. The automatic case definition for definite asthma is shown in Table 2 and for probable 
and doubtful asthma in Table 3. Where necessary, the English translation of the terms is includ-
ed between parentheses.
The term ‘cmi’ indicates an incoming communication (i.e., a letter) from a specialist or outpa-
tient GP. There are codes to identify specialties in IPCI and the numbers ’20’ and ‘15’ are used 
for paediatrics and pulmonology, respectively. Because specialists do not code events in their 
communications with GPs, none of the rules contains an ICPC or ATC code. The drugs ‘flix-
otide’, ‘ventolin’, and ‘pulmicort’ are used for obstructive airway diseases. The terms ‘r96’, ’00’ 
and ‘01’ are part of the asthma ICPC codes ‘R96.00’ and ‘R96.01’. Our pre-processing algorithm 
separated the codes as ‘R96’, ‘00’, and ‘01’ and because of the bag-of-words representation, 
these were treated as individual features. The term ‘s’ is part of the ‘SOEP’ registration used 
by the GPs in the Netherlands. The ‘S’ in ‘SOEP’ stands for ‘subjective’, and refers to patient 
history and symptoms. Since the SOEP and ICPC codes can be entered by the GPs only, entries 
containing these terms indicate that these are GP entries. The keyword ‘r03drug’ marks the 
presence of an ATC code starting with R03, indicating a respiratory drug. The terms ‘pulm’, 
‘inh’, and ‘vag’ are short for ‘pulmonary’, ‘inhaler’, and ‘vesiculair ademgeruis’ (‘vesicular breath 
Figure 4 - Performance of the classifiers using cross-validation when definite, probable, and doubtful asthma cases were 
combined as positive asthma.
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Definite 
asthma
Probable 
asthma
Doubtful 
asthma Non asthma Patients
Definite asthma 228 47 29 4 308
Probable asthma 166 682 245 40 1133
Doubtful asthma 16 15 96 33 160
Non asthma 120 130 887 2294 3431
Total classified 530 874 1257 2371 5032
1. "20" and "astma"  true
2.  "cmi" and "astma" and not "00" and not "van" and not "s"  true
3.  "cmi" and "flixotide" and not "ventolin" and not "medicatie" and "20"  true
4.  "cmi" and "kindergeneeskunde" and "ventolin" and not "te"  true
5.  "cmi" and "astma" and "15"  true
6.  "cmi" and "20" and "pulmicort"  true
7.  "cmi" and "longziekten"  true
8.  DEFAULT  false
English translation and explanation of the terms
cmi Incoming letter from a specialist or an outpatient GP
van “from”, “of”
medicatie “medication”
kindergeneeskunde “pediatrics”
te “too”
longziekten “lung diseases”, also used to refer to pulmonology
20 IPCI code that refers to pediatrics
15 IPCI code that refers to pulmonology
pulmicort Drug name
Table 1 - Confusion matrix of the case detection algorithm generated with 300% over-sampling using cross-validation.
Table 2 - Automatically generated case detection rules for definite asthma.
sound)’, respectively. The term ‘diskus’ indicates a type of dry powder inhaler. For the words 
‘van’ (English ‘from’ or ‘of’) and ‘te’ (English ‘too’) we have no reasonable explanation why 
RIPPER found them useful. Almost all rules for probable and doubtful asthma classification 
contain a mixture of codes and free text. 
To assess the impact of different types of information (codes, medications, free text) on clas-
sification performance, we compared the performance of our selected model (using 300% 
over-sampling), generated using all information in the medical records, with models that were 
generated using subsets of information (also using 300% over-sampling). The results in Table 
4 show that the models that only used codes or codes and medications have much lower per-
formance than the models that use free text. None of the models comes close to our selected 
model with regard to sensitivity, while specificity and PPV of the reference model is comparable 
to those of the other models using free text for scenarios 1 and 2. 
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DISCUSSION
We created and evaluated an automated case detection algorithm to identify children with asth-
ma within the IPCI database. The case detection algorithm was generated using a rule-learning 
algorithm which incorporated both information contained in the unstructured free-text and 
coded data in electronic medical records. We evaluated the automated algorithm in the context 
of three scenarios, and each scenario had different performance characteristics suitable for a 
different asthma study goal. 
1. "r03drug" and "r96" and not "01"  true
2. "r03drug" and not "hoesten" and not "pulm" and "flixotide"  true
3. "r03drug" and not "hoesten" and not "pulm" and not "piepende" and not "hoest"  true
4. "astma" and "r96"  true
5. "r03drug" and not "pulm" and "inh"  true
6. "ventolin" and not "pulm" and "r96"  true
7. "ventolin" and "astma" and not "vag"  true
8. "r03drug" and not "piepen" and not "hoest" and "diskus"  true
9. DEFAULT  false
English translation and explanation of the terms
r03drug Respiratory drug with an ATC code starting with R03
r96 ICPC code for asthma
hoesten “coughing”
piepende “wheezing”
hoest “cough”
piepen “wheeze”
vag Abbreviation of “vesiculair ademgeruis” (“vesicular breath sound”)
inh Short for “inhaler”
flixotide Drug name
ventolin Drug name
Table 3 - Automatically generated case detection rules for probable and doubtful asthma.
Table 4 - Performance of case detection algorithms that were generated using different combinations of information present 
in the electronic medical records.
Scenario 1 Scenario 2 Scenario 3
Information Sens Spec PPV Sens Spec PPV Sens Spec PPV
Codes 0.53 0.87 0.21 0.56 0.85 0.57 0.62 0.76 0.55
Codes+Medications 0.86 0.67 0.18 0.67 0.67 0.42 0.69 0.60 0.45
Free text 0.88 0.96 0.64 0.62 0.94 0.78 0.68 0.81 0.63
Free text+Codes 0.85 0.95 0.62 0.61 0.94 0.77 0.65 0.84 0.66
Free text+Medications 0.84 0.97 0.68 0.62 0.94 0.79 0.68 0.81 0.63
Free text+Codes+Medications 0.98 0.95 0.66 0.96 0.90 0.82 0.95 0.67 0.57
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By using over-sampling techniques we could vary the performance of the resulting detection al-
gorithm. By adding more negative examples of asthma cases, PPV and specificity increased, at 
the cost of decreased sensitivity (cf. Figures 2-4). Varying the amount of over-sampling allows 
researchers to generate a case detection algorithm suitable for a specific study. For example, 
when investigating incidence and prevalence, where the goal is to find the number of cases in 
a population in a given time period, a case detection algorithm with high sensitivity would be 
preferred. For our particular asthma study, we selected the algorithm with 300% over-sampling 
mainly because of both its high specificity and sensitivity. The selected case detection algorithm 
had a PPV of 0.66, sensitivity of 0.98 and specificity of 0.95 for the scenario when only definite 
cases were considered relevant for the study (cf. Figure 2), PPV of 0.82, sensitivity of 0.96, 
and specificity of 0.90 for the scenario when definite and probable asthma cases combined 
were considered relevant (cf. Figure 3), and PPV of 0.57, sensitivity of 0.95, and specificity of 
0.67 for the scenario when definite, probable, and doubtful asthma cases were combined and 
considered relevant for the study (cf. Figure 4). Our experiments with subsets of information 
available in the medical record (codes, medications, free text) indicate that, overall, best clas-
sification performances are obtained with an algorithm that uses all information in the medical 
record. 
Interestingly, none of the 7 rules in the case detection algorithm generated for definite asthma 
contains an ICPC code for asthma, i.e., R96, or any R03drug (cf. Table 2). The presence of the 
terms ‘flixotide’, ‘ventolin’, and ‘pulmicort’, which are all R03drugs, suggests that the special-
ists’ letters do not (or not very often) contain ATC drug codes. The RIPPER algorithm was able 
to pick up both the terms used to indicate the specialty of pediatrics or a pediatrician in the IPCI 
database, i.e., ‘kindergeneeskunde’ and the IPCI database code ‘20’. Similarly, the algorithm 
also picked up both the terms used for the specialty of pulmonary diseases or a pulmonologist, 
i.e., ‘longziekten’ and the IPCI database code ‘15’. For probable and doubtful asthma cases, the 
algorithm picked up both the ICPC asthma code R96 and R03drug (cf. Table 3). The algorithm 
was also able to pick up specific drug names such as ‘flixotide’, ‘ventolin’, and ‘pulmicort’ and 
abbreviations such as ‘inh’ for ‘inhaler’ and ‘vag’ for ‘vesiculair ademgeruis’ (vesicular breath 
sound) used within the IPCI database. A comparison with the broad query (see Appendix) 
shows that the automated case definitions contain more specific keywords (and combinations) 
used within the database. This suggests that rules with database specific keywords are compli-
cated to construct manually for use in the broad query.
There were some study limitations. The RIPPER algorithm used a training set of positive and 
negative examples of asthma cases from the IPCI database. The generated case detection algo-
rithm is therefore specific to the IPCI database and it may not be applicable to other databases 
to detect asthma cases. A new training set is required to generate an automated case detec-
tion algorithm for a new EHR database. The automated case detection algorithm is applicable 
within the results of the broad query. Any asthma case initially missed by the broad query will 
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also be missed by the automated case detection algorithm. However, such asthma cases can 
potentially be identified by applying the automated case detection algorithm onto the complete 
EHR database, although we do not know how well this would work. 
Usually the only way to extract or identify cases from the electronic health record databases is 
using codes such as ICPC or ICD-9 because the free-text narratives cannot be easily analysed. 
Recently, Flynn et al. 29 used free-text clinical reports to develop an algorithm using manual 
rules to identify ischaemic stroke and intracerebral haemorrhage. The approach we used in 
this study to generate a case detection algorithm to identify asthma patients has a number of 
advantages. Our approach not only used the structured information, as is usually done, but 
also took advantage of the free-text narratives present in the EHR database. Another advantage 
relates to patient confidentiality, which is a matter of concern when dealing with free-text in 
electronic health records. In our approach, once a model has been generated, cases can auto-
matically be identified without need to anonymize data. We also demonstrated how sensitivity 
and specificity of the algorithms can be tuned to best meet the requirements of our study. An 
automatic case detection algorithm with high specificity can reduce the workload of manual 
annotation, by removing non-relevant records. Another advantage of automated case detection 
algorithm is that they can allow for more uniform and consistent annotations as compared to 
several manual annotators. Although the case detection algorithm for asthma discussed here 
is specific to the IPCI database, the approach used to generate the algorithm can be used in 
different databases. 
In databases such as IPCI, manual review of all results of the broad query is currently man-
datory in order to identify asthma cases. Using the automated algorithm described here, it is 
now feasible to automatically identify definite, probable, and doubtful asthma patients with 
acceptable performance, using both free-text narratives and coded information when available, 
allowing large scale epidemiology studies.
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SUPPLEMENTS
The following broad query was used to identify potential asthma patient:
Confusion matrices of all over-sampling experiments using cross-validation
“astma” OR 
“asthma” OR
“wheez” OR
(“piep” and not “piepen-” and not “geen” and not “niet”) OR
“R96.” OR
(“kort” and “adem”) OR
(“dyspn” and not “dyspnoe-” and not “geen”)
English translation and explanation of the terms
wheez Short for wheezing
piep Short for piepen (“wheezing”)
geen “no”
niet “not”
R96 ICPC code for asthma
kort “short”
0% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 236 50 19 3 308
Probable asthma 326 630 155 22 1133
Doubtful asthma 39 22 75 24 160
Non asthma 705 212 820 1694 3431
Total classified 1306 914 1069 1743 5032
100% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 240 46 19 3 308
Probable asthma 184 711 211 27 1133
Doubtful asthma 16 15 102 27 160
Non asthma 157 177 1044 2053 3431
Total classified 597 949 1376 2110 5032
200% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 243 37 23 5 308
Probable asthma 197 646 247 43 1133
Doubtful asthma 16 10 93 41 160
Non asthma 150 127 911 2243 3431
Total classified 606 820 1274 2332 5032
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300% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 228 47 29 4 308
Probable asthma 166 682 245 40 1133
Doubtful asthma 16 15 96 33 160
Non asthma 120 130 887 2294 3431
Total classified 530 874 1257 2371 5032
400% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 217 56 29 6 308
Probable asthma 146 696 250 41 1133
Doubtful asthma 10 11 99 40 160
Non asthma 122 125 900 2284 3431
Total classified 495 888 1278 2371 5032
500% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 207 65 31 5 308
Probable asthma 136 712 248 37 1133
Doubtful asthma 9 14 95 42 160
Non asthma 87 130 955 2259 3431
Total classified 439 921 1329 2343 5032
600% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 205 58 37 8 308
Probable asthma 141 654 285 53 1133
Doubtful asthma 10 10 91 49 160
Non asthma 90 93 828 2420 3431
Total classified 446 815 1241 2530 5032
700% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 220 45 31 12 308
Probable asthma 143 610 310 70 1133
Doubtful asthma 10 12 81 57 160
Non asthma 95 74 762 2500 3431
Total classified 468 741 1184 2639 5032
800% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 201 47 45 15 308
Probable asthma 101 580 316 136 1133
Doubtful asthma 8 6 84 62 160
Non asthma 53 70 588 2720 3431
Total classified 363 703 1033 2933 5032
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900% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 185 52 45 26 308
Probable asthma 116 549 340 128 1133
Doubtful asthma 3 9 86 62 160
Non asthma 63 63 536 2769 3431
Total classified 367 673 1007 2985 5032
1000% Definite asthma Probable asthma Doubtful asthma Non asthma Patients
Definite asthma 191 47 43 27 308
Probable asthma 112 471 374 176 1133
Doubtful asthma 4 4 77 75 160
Non asthma 56 39 450 2886 3431
Total classified 363 561 944 3164 5032
Table Coding systems used in IPCI
ICPC translation
R96 Asthma
R96.01 Airway hyperresponsiveness
R96.02 Allergic asthma
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ABSTRACT
  BACKGROUND   Current knowledge on the prevalence of asthma is mainly based on cross sectional 
questionnaire data. Current population based data on the incidence of asthma in children are 
scarce. 
  AIMS   To study the incidence, prevalence, and age at diagnosis of asthma in children in the 
Netherlands over the study period 2000-2012. 
  METHODS   A population-based cohort study was conducted in the Integrated Primary Care In-
formation database. The cohort consisted of 176,516 children (379,536 person-years (PY) of 
follow-up), aged 5-18 years between 2000-2012. All medical records of children with physician 
diagnosed asthma were validated. Incidence rates, annual percent change (APC) and preva-
lence for asthma were calculated. Influence of age and gender on incidence rates and change 
in age at diagnosis were studied.
  RESULTS   We identified an asthma cohort of 14,303 children with 35,181 PY. The overall inci-
dence rate was 6.7/1000 PY (95% CI, 6.45-6.97). Until 2008 the incidence rate was signifi-
cantly increasing (APC 5.79% (95% CI 1.43 to 10.34), from 2008 onwards a non-significant 
decrease was observed (APC -12.16 (95% CI -23.07 to 0.28). Incidence for girls was lower than 
for boys, this difference decreased with increasing age. (p<0.001) Overall, the age at diagnosis 
increased over calendar time and was lower for boys. (linear trend p<0.001) 
  CONCLUSIONS   Our population-based cohort study observed an incidence rate of 6.7 per 1000 
PY of physician diagnosed asthma in children in the Netherlands over 2000-2012. The asthma 
incidence rate was increasing until 2008. Further studies are needed to confirm the decrease in 
asthma incidence rate from 2008 onwards.
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INTRODUCTION
Asthma is the most common chronic disease in children in the Western world and an increase in 
asthma prevalence has been shown in the developing world. 1 Although the prevalence of asth-
ma has been described for various countries, these are mainly based on data from cross-section-
al studies. 2, 3 The differences in study period, study population, asthma case definition and the 
reliability of the data sources result in highly differing trends within and between countries. 4 
As a consequence of the lack of European longitudinal studies, there are only few recent studies 
on the incidence of asthma in children in Europe.
The most recent study on the incidence in asthma, performed in Canada using health adminis-
trative data, demonstrated a significant increase in incidence from 1992 to 2008 across multiple 
birth cohorts. 5 Data on the time trends in asthma prevalence and incidence are conflicting. 6 
Some studies report an increase in asthma prevalence and incidence whereas other studies 
report a decline which might be attributed to earlier detection and treatment of children with 
asthma. 1, 7
We investigated time-trends in the incidence, prevalence, and the age at diagnosis of physi-
cian-diagnosed asthma in children in the Netherlands by conducting a retrospective cohort 
study over a study period of 12 years, using a large general practitioners database containing 
the complete electronic medical records of more than 1 million patients. 
METHODS
Setting
We conducted a retrospective population-based cohort study within the Integrated Primary 
Care Information database (IPCI), a longitudinal observational dynamic database which con-
tains the complete electronic medical records of more than 450 GPs in the Netherlands. 8 In 
the Dutch health care system, patients are registered with a single GP who acts as a gatekeeper 
for secondary care. 9 Details of the database have been published elsewhere. 8, 10 Briefly, the 
database contains the complete electronic medical records of approximately 1,500,000 partic-
ipants. These records contain anonymous longitudinal data on demographics, symptoms and 
diagnosis (coded and free text), referrals, laboratory findings, discharge letters, and drug pre-
scriptions. To maximize completeness of the data, GPs participating in the IPCI project are not 
allowed to maintain a system of paper-based records besides the electronic medical records. 
The system complies with European Union guidelines on the use of data for medical research 
and has been proven valid for pharmaco-epidemiological studies. 10 The scientific and ethical 
advisory board of the IPCI database approved the study.
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Study cohort
The dynamic source population (n=176,516) comprised all children aged 5-18 years with a 
database history of at least twelve months. The study period was from 1st January 2000 to 1st 
January 2012. Follow-up started on 1st January 2000, or on the date on which the required 1 
year of follow-up was obtained or on the date the age of 5 years was reached, whichever came 
last. Follow-up time of children below 5 or above 18 years of age during the study period was 
excluded from the study. All patients were followed from study entry until the end of the study 
period, or until leaving the GP practice, or death, or the day on which the patient turned 18 
years, whichever occurred first. 
Asthma Case identification and validation
All children who were 5-18 years old during the study period with physician diagnosed asthma 
were identified. First, all potential asthma cases were retrieved by a broad automated search on 
ICPC (international classification of Primary Care) asthma codes (“R96”) and asthma-relevant 
free text. Asthma was defined as “definite” if diagnosed by a paediatrician. “Probable asthma” 
was defined as asthma diagnosed by the GP with at least 2 additional records/prescriptions 
of asthma medications in the 1 year following the initial diagnosis of asthma. A patient was 
labelled to have “possible asthma” in case of only 1 asthma record or inconsistency between 
records. Children were classified as not having asthma if the identified symptoms were not 
related to asthma or if the symptoms could be ascribed to other respiratory conditions (e.g. 
pneumonia, cystic fibrosis). If at any time during the follow-up asthma was diagnosed, the 
child was considered asthmatic from date of first diagnosis until the end of follow-up. As this 
broad automated search resulted in a high number of potential asthma cases (n=63,618), 
machine learning was used to facilitate the validation, as described in detail elsewhere. 11 The 
validity of this machine learning approach was reasonable good with a sensitivity of 95% and 
a specificity of 67% within the testset of 5032 manually annotated medical records. 11 For ver-
ification of the total asthma cohort, the medical records of all predicted definite asthma cases 
and 25% of probable asthma cases were manually reviewed by one of the authors, a medical 
doctor (ME). Manual review implied that the whole electronic medical chart of each case was 
reviewed, and searched for asthma diagnosis and asthma medication. If asthma diagnosis and/
or asthma medication was observed, the case was categorized according to the predefined 
algorithm, as described above.
Patient characteristics / comorbidities
For all children the following comorbidities were extracted based on ICPC codes: allergic rhi-
nitis, eczema, and conjunctivitis.
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Statistical analysis
Descriptive analyses were used to describe the total cohort and asthma cohort. Chi square test 
was used to test the difference in comorbidities between subgroups. 
Age- and gender-specific incidence rates were determined by dividing the total number of 
children newly diagnosed with asthma by the total number of person-years (PY) accumulat-
ed in the study population. Children were censored on the date of first diagnosis of asthma. 
Children with prevalent asthma did not contribute person-time to the denominator. Because of 
the dynamic nature of the population, the annual incidence was calculated per 1000 PY rather 
than per person. PYs were stratified by calendar year, age (assessed on the 1st January of each 
follow-up year), and gender. 95% confidence intervals (CI) around the incidence rates were 
estimated based on the Poisson distribution. 12
Trends in incidence over time were assessed using Joinpoint Regression Software 13, for details 
see Kim et al. 14 Briefly, this method starts with a straight line, no joinpoints, to describe a trend 
over time and tests if the addition of 1 or more joinpoints identifies a significant change in 
the trend. We used Hudson’s method for estimating joinpoints, which allows the joinpoints to 
occur anywhere between observations, while the alternative Grid search method only tests a 
discrete number of locations. 15, 16 In our data it is more realistic that the joinpoints may take 
any value within the observed data range. A maximum of two joinpoints was allowed for each 
analysis; this is the maximum feasible for 12 data points (2000-2012), as there should be a 
minimum of 4 datapoints between joinpoints. Trends were described by annual percent change 
(APC) and the corresponding 95% CI for each segment and an average annual percent change 
(AAPC) with 95% CI for the whole study period. 
Poisson regression models were used to fit incidence rates over age categories adjusted for gen-
der. Linear regression was used to analyse age at diagnosis over calendar time and by gender. 
The asthma prevalence was calculated by dividing the number of patients already diagnosed 
with asthma at study entry by the total number of patients. 
The cumulative asthma prevalence between 2000 and 2012 was calculated by dividing the 
number of children with prevalent asthma (of a certain age) by the total number of children 
of that age present in the study population on the first of January of each calendar year. The 
cumulative prevalence was calculated by age category with 95% CI on the basis of the Wilson 
score interval. 12 P-value of <0.05 was considered statistically significant. Analyses were con-
ducted using SPSS for Windows version 20.0, Joinpoint Regression Program (Version 4.1.1.1), 
and Episheet. 12 
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RESULTS
The source population comprised 176,516 children with at least 1 year of valid history in the 
IPCI database. After a broad free text search, 63,518 potential cases of asthma were detect-
ed. Upon automated text validation, these were classified in 22,699 asthma cases (definite, 
probable and possible cases). After manual validation, the final asthma cohort consisted of 
14,303 children (3,340 definite and 10,963 probable asthma cases) with 35,118 PY of fol-
low-up. 2,542 children were classified as incident asthma cases, as those children were not yet 
diagnosed with asthma prior to study start.
Baseline characteristics of the final asthma cohort are described in Table 1. Briefly 3,340 
children (23%) had specialist confirmed asthma and 58.7% were boys. Mean age at asthma 
diagnosis was 6.8 years (SD ± 4.6). Children with a diagnosis of asthma were more often 
diagnosed with eczema, rhinitis, or conjunctivitis than children without asthma. (all p<0.001)
Incidence and prevalence of asthma 
Over the follow-up period of 12 years the overall incidence rate of asthma was 6.71 per 1000 
PY (95% CI, 6.45-6.97) (Figure 1). Age specific incidence rates by gender are shown in Figure 
2. The incidence rate of asthma was higher in boys than girls until the age of 13. After the age 
of 13, the gender difference reversed. 
Joinpoint Regression selected a model with 1 join point. Until 2008 the incidence rate was 
increasing (APC 5.79% (95% CI 1.43 to 10.34) and from 2008 onwards a decreasing trend was 
observed. (APC -12.16 (95% CI -23.07 to 0.28) (Figure 3).
Poisson regression with age (categorical), gender and the interaction of age (continue) and 
gender as explanatory variables, showed that incidence rates for girls were lower than for boys, 
and this difference decreased with increasing age. (p for interaction <0.001) 
Total Cohort Incident cohort
Non-asthma
Asthma
(incident+prevalent) P-value*
Number of patients (n) 162,212 14,303 2,542
Gender Boys (%) 51% 59% <0.001 53%
Eczema 14% 30% <0.001
Allergic rhinitis 8% 23% <0.001
Conjunctivitis 3% 8% <0.001
Specialist diagnosed asthma (n (%)) na 3,340 (23%) 558 (22%)
Age at asthma diagnosis (mean ± sd) 6.8 ± 4.6 11.0 ± 3.8
Table 1 - Baseline characteristics of the total cohort, asthma cohort and incident asthma cohort.
N = number, % = percentage, sd = standard deviation, na = not applicable
* P-value based on the Pearson Chi-square comparing the asthma and non-asthma cohorts.
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Figure 1 - Incidence rate of asthma in 2000-2012 in 5-18 year old children per 1000 PY. 
Figure 2 - Gender and age specific incidence rates of asthma in 5-18 year old children per 1000 PY in 2000-2012.
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The age at asthma diagnosis in children in the incident asthma cohort, over calendar years is 
shown in Figure 4. We observed that the age at diagnosis increased over calendar time, with 
increasing age at diagnosis with 0.12 year per calendar year (95% 0.07-0.17) (linear regres-
sion, p<0.001). Over the study period girls were on average 1.1 year (95% CI 0.82-1.40) older 
at time of asthma diagnosis than boys. (p<0.001)
The asthma prevalence at study start was 6.7% (95% CI 6.6-6.8). The cumulative prevalence 
of asthma was 8.1% (95% CI 8.0-8.2). The age-specific cumulative prevalence of asthma was 
higher in boys than in girls in all age categories.
DISCUSSION
This large longitudinal population based cohort study, covering a study period of 12 years, pro-
vides age- and gender-specific incidence rates as well as the prevalence of physician diagnosed 
asthma. The overall asthma incidence was 6.7 per 1000 PY, and increased significantly from 
2000 to 2008 and decreased non-significantly after 2008. 
Few studies have reported incidence rates for pediatric asthma in the general population. Of 
those studies that provide data on asthma incidence, the reported rates vary widely, ranging 
from 0.6 to 29.5 per 1000 persons for children and adults combined 17 and from 3.4 to 4.6 
per 1000 PY for adults. 18 The huge variation in incidence rates can be explained by differ-
ences in asthma definition, differences in the population being studied, geographical factors, 
Figure 3 - Join point analysis: trends in the incidence rate of asthma in 2000-2012 in 5-18 year old children per 1000 PY.
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Figure 4 - Age at asthma diagnosis in 5-18 year old children in 2000-2012 for total (a) and for boys (b) and girls (c).
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differences in calendar time, differences in study length and reliability of data sources. 4 The 
incidence rates as observed in our study are in line with the results from recent studies report-
ing asthma incidence rates in children ranging between 4.26 and 20.0 per 1000 per year. 19-34 
(Online supplement Table 1) 
Our asthma incidence rate is slightly lower than the asthma incidence rates of 9.23 (girls) and 
13.46 (boys) per 1000 children aged 0-14 years as reported by the Dutch Ministry of Health. 22 
However, their incidences rates in the age categories 5-9, 10-14, and 15-18 are in line with 
our data. The overall higher rates from the Ministry of Health probably reflect a higher asthma 
incidence rate in young children. In general, rates are higher in studies that include children 
below 5 years, possibly due to misclassification of viral wheezing, a common condition in these 
young children. 27, 20, 35
Radhakrishnan et al. studied time trends in asthma incidence and reported an increase in 
asthma incidence from 1992 till 2008. 5 This increase in asthma incidence was confirmed in 
our study, but was no longer present after 2008. 
The decrease after 2008 in incidence rate is not necessarily a true decline, but might reflect the 
impact of the revised Dutch national asthma guidelines in 2008, stating that infants and pre-
school children who wheeze are not necessary asthmatics, but may wheeze secondary to viral 
infections. 36 A diagnostic shift from ‘asthma’ to labels such as ‘wheeze’ or ‘acute respiratory 
infection’ is likely. 37 
Similar to other studies, we observed that the incidence of asthma was higher in girls than in 
boys after the age of 13. 22, 27 
More data are available in the literature on the prevalence of asthma than on incidence of 
asthma, but here again, large variations are reported because of differences in methodology. 
1, 7, 38 Our prevalence was comparable with recent international studies, reporting prevalences 
of 7.3-8.4% in the USA 39 and 8% in the Netherlands. 40 In general, the asthma prevalence is 
higher in studies that used questionnaire data or prescription data, probably due to misclassi-
fication or diagnostic bias. 26, 30, 35, 41 
In 2010 a Dutch study reported that asthma was one of the diseases with the largest increase 
in prevalence. 42 Studies from Switzerland, Norway, Australia and the Netherlands showed 
that the rising trend in asthma prevalence might have come to an end. 6, 43-46 This decline in 
asthma prevalence has been partly attributed to earlier detection and treatment of children 
with asthma. 1, 7 However, in our study we could not confirm that age at asthma diagnosis 
decreased over time. 
The main strengths of our study are the use of a large population based cohort with detailed 
information on symptoms, diagnosis, drug prescriptions and comorbidities over a study period 
of more than 10 years. This study design precluded selection bias due to non-responder or 
recall bias. In addition the potential of selection bias is unlikely as almost all inhabitants of 
the Netherlands are registered with one GP and data were collected as part of routine patient 
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care, irrespective of research questions. Patients with asthma were selected based on ICPC 
codes in combination with free text searches. We avoided misclassification by combining initial 
validation through machine learning with extensive manual validation according to a strict 
validation algorithm.
Our study has potential limitations as well. As mentioned above, we validated according to 
a predefined rigorous validation algorithm and used data from specialist referral letters to 
define “definite” cases of asthma. However, as not all GP computer systems track all specialist 
letters, we might have underestimated the actual asthma incidence and prevalence of specialist 
diagnosed asthma. Furthermore potential misclassification might be introduced by combining 
only definite and probable asthma cases, and discarding all possible cases. Possible cases were 
excluded from the analysis as asthma diagnosis was uncertain.
CONCLUSION
Our large population-based cohort study over 2000-2012 found an incidence rate of 6.7 per 
1000 PY of physician diagnosed asthma in children in the Netherlands. The incidence rate was 
higher in boys than in girls up to the age of 13. 
Asthma incidence rates increased until 2008, and showed a non-significant decrease from 2008 
onwards. Further research is needed to confirm this decrease and to investigate possible expla-
nations for this decrease. 
52 Chapter 2.2
REFERENCES
1. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epide-
miological studies. Allergy. Feb 2010;65(2):152-167.
2. Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the Inter-
national Study of Asthma and Allergies in Childhood (ISAAC). Thorax. Sep 2007;62(9):758-766.
3. Janson C, Anto J, Burney P, et al. The European Community Respiratory Health Survey: what are the main results so far? 
European Community Respiratory Health Survey II. Eur Respir J. Sep 2001;18(3):598-611.
4. Chawla J, Seear M, Zhang T, Smith A, Carleton B. Fifty years of pediatric asthma in developed countries: how reliable are 
the basic data sources? Pediatr Pulmonol. Mar 2012;47(3):211-219.
5. Radhakrishnan DK, Dell SD, Guttmann A, Shariff SZ, Liu K, To T. Trends in the age of diagnosis of childhood asthma. J 
Allergy Clin Immunol. Jun 27 2014.
6. van Schayck CP, Smit HA. The prevalence of asthma in children: a reversing trend. Eur Respir J. Oct 2005;26(4):647-650.
7. von Hertzen L, Haahtela T. Signs of reversing trends in prevalence of asthma. Allergy. Mar 2005;60(3):283-292.
8. van der Lei J, Duisterhout JS, Westerhof HP, et al. The introduction of computer-based patient records in The Netherlands. 
Ann Intern Med. Nov 15 1993;119(10):1036-1041.
9. Schrijvers A. Health and health care in the Netherlands: a critical self assessment of Dutch experts in medical and health 
sciences. Utrecht: De Tijdstroom. 1997.
10. Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI 
project. Methods of information in medicine. Dec 1999;38(4-5):339-344.
11. Afzal Z, Engelkes M, Verhamme KM, et al. Automatic generation of case-detection algorithms to identify children with 
asthma from large electronic health record databases. Pharmacoepidemiol Drug Saf. Aug 2013;22(8):826-833.
12. Rothman K, Greenland,S ,Lash T. Modern epidemiology. 3rd ed. New York2008.
13. Joinpoint Regression Program [computer program]. Version 4.1.1.1, October 2014: National Cancer Institute; 2014.
14. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. 
Statistics in Medicine. Feb 15 2000;19(3):335-351.
15. Hudson DJ. Segmented Curves Whose Join Points Have To Be Estimated. J Am Stat Assoc. 1966;61:1097-1129.
16. Yu BB, Barrett MJ, Kim HJ, Feuer EJ. Estimating joinpoints in continuous time scale for multiple change-point models. 
Comput Stat Data An. Feb 1 2007;51(5):2420-2427.
17. King ME, Mannino DM, Holguin F. Risk factors for asthma incidence. A review of recent prospective evidence. Panminerva 
Med. Jun 2004;46(2):97-110.
18. Eagan TM, Brogger JC, Eide GE, Bakke PS. The incidence of adult asthma: a review. Int J Tuberc Lung Dis. Jun 
2005;9(6):603-612.
19. Winer RA, Qin X, Harrington T, Moorman J, Zahran H. Asthma incidence among children and adults: findings from 
the Behavioral Risk Factor Surveillance system asthma call-back survey--United States, 2006-2008. J Asthma. Feb 
2012;49(1):16-22.
20. Wendt JK, Symanski E, Du XL. Estimation of asthma incidence among low-income children in Texas: a novel approach 
using Medicaid claims data. Am J Epidemiol. Oct 15 2012;176(8):744-750.
21. Broms K, Norback D, Sundelin C, Eriksson M, Svardsudd K. A nationwide study of asthma incidence rate and its determi-
nants in Swedish pre-school children. Eur J Epidemiol. Sep 2012;27(9):695-703.
22. Gommer AM (RIVM) PMR. Astma: prevalentie, incidentie en sterfte naar leeftijd en geslacht. Volksgezondheid Toekomst 
Verkenning, Nationaal Kompas Volksgezondheid. 2011; <http://www.nationaalkompas.nl> Nationaal Kompas Volks-
gezondheid\Gezondheidstoestand\Ziekten en aandoeningen\Ademhalingswegen\Astma.
23. To T, Wang C, Guan J, McLimont S, Gershon AS. What is the lifetime risk of physician-diagnosed asthma in Ontario, Cana-
da? Am J Respir Crit Care Med. Feb 15 2010;181(4):337-343.
24. Simpson CR, Sheikh A. Trends in the epidemiology of asthma in England: a national study of 333,294 patients. J R Soc 
Med. Mar 2010;103(3):98-106.
25. Gershon AS, Guan J, Wang C, To T. Trends in asthma prevalence and incidence in Ontario, Canada, 1996-2005: a population 
study. Am J Epidemiol. Sep 15 2010;172(6):728-736.
53Epidemiology of asthma
2.2
26. Demir AU, Celikel S, Karakaya G, Kalyoncu AF. Asthma and allergic diseases in school children from 1992 to 2007 with 
incidence data. J Asthma. Dec 2010;47(10):1128-1135.
27. Punekar YS, Sheikh A. Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children 
and adolescents using routinely collected data from general practices. Clin Exp Allergy. Aug 2009;39(8):1209-1216.
28. Larsson M, Hagerhed-Engman L, Sigsgaard T, Janson S, Sundell J, Bornehag CG. Incidence rates of asthma, rhinitis and 
eczema symptoms and influential factors in young children in Sweden. Acta Paediatr. Sep 2008;97(9):1210-1215.
29. Burgess JA, Dharmage SC, Byrnes GB, et al. Childhood eczema and asthma incidence and persistence: a cohort study from 
childhood to middle age. J Allergy Clin Immunol. Aug 2008;122(2):280-285.
30. Rudd RA, Moorman JE. Asthma incidence: data from the National Health Interview Survey, 1980-1996. J Asthma. Jan-Feb 
2007;44(1):65-70.
31. Thomsen SF, Ulrik CS, Kyvik KO, et al. The incidence of asthma in young adults. Chest. Jun 2005;127(6):1928-1934.
32. Jaakkola JJ, Hwang BF, Jaakkola N. Home dampness and molds, parental atopy, and asthma in childhood: a six-year 
population-based cohort study. Environ Health Perspect. Mar 2005;113(3):357-361.
33. Dik N, Tate RB, Manfreda J, Anthonisen NR. Risk of physician-diagnosed asthma in the first 6 years of life. Chest. Oct 
2004;126(4):1147-1153.
34. Kujala V, Remes J, Latvala J, Jarvelin MR. Incidence of asthma in twelve thousand Finnish adults born in 1966. Int J Occup 
Med Environ Health. 2005;18(3):255-258.
35. Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti-asthma medication use 
in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol. Apr 2010;66(4):399-406.
36. NVK. Richtlijn astma bij kinderen Nederlandse Vereniging voor Kindergeneeskunde2013.
37. Simpson CR, Lee AJ, Taylor MW, Helms PJ. Changing incidence of respiratory presentations in primary care fact or arte-
fact? Arch Dis Child. Sep 2005;90(9):982-983.
38. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic 
rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. 
Lancet. Aug 26 2006;368(9537):733-743.
39. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 
2001-2010. NCHS Data Brief. May 2012(94):1-8.
40. Willeboordse M, van den Bersselaar DL, van de Kant KD, Muris JW, van Schayck OC, Dompeling E. Sex Differences in the 
Relationship between Asthma and Overweight in Dutch Children: a Survey Study. PLoS One. 2013;8(10):e77574.
41. Gilliland FD, Berhane K, Islam T, et al. Obesity and the risk of newly diagnosed asthma in school-age children. Am J 
Epidemiol. Sep 1 2003;158(5):406-415.
42. van der Lucht F PJ. Van gezond naar beter. Volksgezondheid Toekomst Verkenning 2010. Rijksinstituut voor Volksgezond-
heid en Milieu RIVM, CBS, Consument en Veiligheid, EUR (BMG, MGZ), GGD Nederland, NiDI, NIGZ, NIVEL, Prismant, RUG, 
Rutgers Nisso, SCP, STIVORO, TNO, Trimbos, UvA, Voedingscentrum.
43. Braun-Fahrlander C, Gassner M, Grize L, et al. No further increase in asthma, hay fever and atopic sensitisation in adoles-
cents living in Switzerland. Eur Respir J. Mar 2004;23(3):407-413.
44. Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asth-
ma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol. Jul 
2007;63(7):693-698.
45. Mommers M, Gielkens-Sijstermans C, Swaen GM, van Schayck CP. Trends in the prevalence of respiratory symptoms and 
treatment in Dutch children over a 12 year period: results of the fourth consecutive survey. Thorax. Feb 2005;60(2):97-99.
46. Toelle BG, Ng K, Belousova E, Salome CM, Peat JK, Marks GB. Prevalence of asthma and allergy in schoolchildren in 
Belmont, Australia: three cross sectional surveys over 20 years. BMJ. Feb 14 2004;328(7436):386-387.
54 Chapter 2.2
SUPPLEMENTS
Author Year
Data / Country /
Age (years)
Number
(cohort/cases) Year of study Incidence Estimate
Radhakrishnan 
et al.(5)
2014 Healthcare database
Canada
0-8 years
1,059,511 cohort
201,958 asthma
1992-2008:
3 cohorts: each 8 
year of follow-up
8 year cumulative incidence: 
19.1%
Broms et al.(16) 2012 Questionnaires 
Sweden
1 and 6 years
4,255 2007: 5 year 
(cross sectional 
at age 1 and 6)
6-12/1000 year
Wendt et al.(15) 2012 Claim database
Texas
1-17 years
2,164,463 2005-2007 overall: 4.26 per 100 PY 
5-9y: 4.33 per 100 
10-14y: 3.27 per 100 PY 
15-17y: 2.92per 100 PY
Winer et al.(14) 2012 Questionnaires
USA
Children and adults
children/cases 
164,327/ 592 
adults/cases: 
733,437/1,033
2006-2008 Adults: 3.8/1000 at risk
Children: 12.5/1000 at risk
Gommer et al.(17) 2011 5 GP networks asthma codes
Netherlands
All ages
97,700 cases 2007 0-14 y:9.23-13.46 per 1000
15-64y: 3.96-5.98 per 1000 
Demir et al.(21) 2010 Questionnaires
Turkey
7-12 years
474/56 cases 1992-2007 0.9/100 children
To et al.(18) 2010 3 Healthcare databases
Canada
All ages
9,041,085 cohort
/533,671 cases
1991-2007 Overall: 4.3/1000PY 
0-9y: 16.2/1000PY 
10-19y: 5.1/1000PY 
40-59y: 2.9/1000 PY
Gershon et al.(20) 2010 healthcare database
Canada
All ages
12 million 
cohort, 975,000 
cases
1996 and 2000 
and 2004
overall 2004; 5.1 per 1000 PY  
5-9y 10.9/1000py 
10-14y: 5.6/1000py 
15-39y: 2.9 PER 1000py
Simpson et al. 
(19)
2010 GP Database
United Kingdom
All ages
3 million cohort
333,294 cases
2001 and 2005 5-14y:  
2001: 11.4 per 1000 PY 
2005: 8.4 per 1000 PY
Punekar et al.(22) 2009 GP database
United Kingdom
0-18 years
3,68 million 
cohort in 434 GP 
practice
1990-2008 13.6/1000
Burgess et al.(24) 2008 Questionnaires
Tasmania
7-44 years
5,729 cohort 1974 and 1986 
and 2004
4.37/1000
Larsson et al.(23) 2008 Questionnaires
Sweden
0-6 years
4,779 cohort 2005 5 year incidence: 4.9%  
per year 1/100 children/year ( 
1%) wheezing excluded: 0.6%
Rudd et al.(25) 2007 Questionnaires
USA
0-18 years
16,000 cohort 1980-1996 9.6 per 1000 at risk in 1996
Jaakkoola et 
al.(27)
2005 Questionnaires
Sweden
1-6 years
1,916 cohort 1991 and 1997 12.5/1000 PY
Thomsen et 
al.(26)
2005 Questionnaires
Denmark
12-41 years
1,9349 cohort Follow up 8 
years
838 cases in 2002: 
Male: 4.5 per 1000 PY
Female: 6.4 per 1000 PY
Kujala et al.(29) 2005 Prescription database 
Finland
15-38 years
11,946 cohort
466 cases
23 years 
(birthcohort)
15-20 years: 8.6-11.5/10000 
PY at risk over 23 years
Dik et al.(28) Administrative database
USA
0-6 years
170,960 cohort  2004 0-2 years: 2.9%
5-6 years: 2%
14% cumulative incidence by 
the age of 6 
Online Table 1 - Overview of all published studies (that include children) regarding asthma incidence from 2004 onwards.
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ABSTRACT
  BACKGROUND   Real-life data on the incidence rates (IR) and risk factors of severe asthma ex-
acerbations in children are sparse. We aimed to assess IR and risk factors of severe asthma 
exacerbations in children in real life.
  METHODS   We conducted a population-based cohort study using a Dutch GP database containing 
complete medical records of >1 million patients. All records of children with physician-diag-
nosed asthma aged 5-18 years between 2000-2012 were examined for exacerbations, defined 
as either hospitalization, emergency department visit or need of systemic steroids for asthma. 
IR was expressed as number of exacerbations per person year (PY). 
  RESULTS   We identified 14,303 asthmatic children with 35,118 PY of follow-up and 732 exac-
erbations. The overall IR was 2.1/100 PY (95% CI 1.9-2.2), 4.1/100 PY (3.8-4.4) for children 
on asthma treatment. Re-exacerbation occurred in 2% (1.3-4.3) of patients within 1 month, 
in 25% (20.6-28.8) within 1 year. Predictors for (frequent) exacerbations were age, gender, 
specialist visits, ICS prescriptions and prior exacerbations (all p<0.05). 
  CONCLUSIONS   The overall IR of severe asthma exacerbations was 4/100 PY in children on asthma 
treatment, highest in spring and fall. 25% of the patients with an exacerbation will experience 
a next exacerbation within 1 year. More severe asthma is a predictor of subsequent and future 
exacerbations. 
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INTRODUCTION
Asthma continues to be a public health concern due to its high prevalence in industrialized 
countries. 1, 2 Poor asthma control resulting from inadequate treatment or non-response to 
available treatments was associated with adverse long-term outcomes. 3 Asthma can usually be 
well controlled by treatment as described in asthma management guidelines. 4 A severe asthma 
exacerbation is defined as a hospitalisation or emergency department (ED) visit because of 
worsening asthma, or need of systemic corticosteroids because of asthma.5 Reported frequen-
cies of severe asthma exacerbations in the literature vary by the definition of an exacerbation, 
patient population, the severity of asthma, degree of asthma control, and the data source and 
incidence rates (IR) are sparse. 6 Most data on IR of severe asthma exacerbation derive from 
adults in clinical trials. These showed IRs ranging between 0.24-0.92/PY 7-11 and in cross-sec-
tional data, IRs that ranged between 0.23-0.41/PY. 12, 13 As far as we know, only 4 studies 
investigated the rate of exacerbation in children, showing IR ranging from 0.04-0.64/PY. This 
broad range can be explained by differences in patient selection, sample size or study duration. 
7, 14, 15 Asthma related hospitalization rates in asthmatic children ranged from 4-15% per year, 
depending on factors like age, sex, and asthma severity. 12, 16 The CAMP study observed an 
exacerbation-requiring-hospitalization-rate of 2.5/100 PY in children from 5-12 years of age 
with mild-to-moderate asthma. 17 Surveys in real-life indicated that the true incidence of severe 
asthma exacerbations may be higher than in clinical trials. 6 Insight in the real life incidence 
of severe asthma exacerbations and characteristics of children with frequent exacerbations is 
important to optimize management in those who are prone to exacerbations. Hence, the pur-
pose of the present study was to evaluate the incidence of severe asthma exacerbations and to 
identify characteristics of children with severe asthma exacerbations over a 12 year period in a 
large cohort of children with physician-diagnosed asthma. 
METHODS
We conducted a retrospective population-based cohort study within the Integrated Primary 
Care Information (IPCI) database, a longitudinal observational dynamic database containing 
the complete electronic medical records of more than 450 general practitioners (GPs) in the 
Netherlands. In the Dutch health care system, people are registered with a single GP who has 
a crucial role as a gatekeeper for and receiver of information from secondary care. 18 Details 
of the database have been published elsewhere. 19, 20 Briefly, the database contains the com-
plete electronic medical records of approximately 1,500,000 patients, containing anonymous 
longitudinal data on demographics, symptoms and diagnosis in coded and free text, referrals, 
laboratory findings, discharge letters, and drug prescriptions. The system complies with Eu-
ropean Union guidelines on the use of data for medical research and has been proven valid 
for pharmaco-epidemiological studies. 20 The scientific and ethical advisory board of the IPCI 
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database approved the present study. (no 07/55 2011)
Asthma cohort
The dynamic source population (n=176,516) comprised all children aged 5-18 years with a 
database history of at least 12 months. The study period was from the 1st of January 2000 until 
the 1st of January 2012. 
Within this population a cohort of children with asthma was identified. Asthma cases were 
retrieved by an automated search on both International Classification of Primary Care asthma 
codes 21 (ICPC code R96) and free text that was relevant to asthma. As this automated search 
resulted in a high number of potential asthma cases (n=63,618), we used machine learning 
to facilitate the validation, as described in detail elsewhere. 22 Asthma was defined as ‘definite’ 
if diagnosed by a paediatrician. ‘Probable asthma’ was defined as asthma diagnosed by the GP 
with at least 2 additional records of asthma diagnosis or prescriptions of asthma treatment in 
the 1 year following the initial diagnosis. To assess the validity of this approach, the medical 
records of 100% of predicted definite asthma cases and 25% of predicted probable asthma 
cases were manually reviewed by one of the authors. 
Follow-up started on the latest of the following dates: start of study period, date on which the 
required 1 year of follow-up was obtained, the 5th birthday, or date of asthma diagnosis (for 
prevalent asthma cases, who had diagnosis before start of study period asthma diagnosis was 
not used as criterion). All patients were followed from study entry until the earliest of the 
following dates: end of the study period, transferring out of GP practice or age 18 years. 
Severe asthma exacerbations
Severe asthma exacerbations were defined as any of the following; hospitalization, emergency 
department (ED) visit, or prescription of systemic corticosteroids for at least 3 days, all because 
of asthma. In case there were less than 7 days between two exacerbations, these were consid-
ered as one single exacerbation. 
All potential exacerbations were identified in the electronic medical records and validated 
by a medical doctor (ME). To identify patients with ED visit or hospitalisation for reasons of 
asthma, the medical file was searched for asthma-specific disease codes in combination with 
information on hospitalisation, hospital referral and discharge letters. Use of systemic cortico-
steroids was retrieved from prescriptions via an automated search on the corresponding ATC 
codes. The indication of use was searched for in a window of 7 days before and 7 days after 
the prescription date.
Covariates 
Covariates included age at study start, gender, age at time of exacerbation, eczema (yes/no), 
allergic rhinitis (yes/no), conjunctivitis (yes/no), number of respiratory infections, number of 
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prescriptions for any asthma medication, number of prescriptions for inhaled corticosteroids 
(ICS), number of specialist visits for asthma and number of prior severe asthma exacerbations. 
Baseline covariates were retrieved in the 365 days prior to cohort entry. 
Statistical analysis 
Continuous variables were expressed as mean and standard deviation (SD). We used t-test, 
χ2 test or Mann-Whitney test to compare baseline characteristics of children with and without 
exacerbations. 
Rates of exacerbations
For each child the person time (in years, PY) of follow-up was stratified by calendar year, cal-
endar month, gender and age (on January 1st of each year). Because of the dynamic nature of 
the population we used PY rather than persons. The incidence rate (IR) of exacerbations was 
calculated by dividing the number of exacerbations by the person time.
To assess seasonal effects, we compared monthly IRs in primary school (<13 years) and high 
school children (≥13 years of age) using Poisson regression. 
IR for re-exacerbation was assessed in the following time-windows: 0-30, 0-90, 0-180 and 
0-365 days after exacerbation, and in subsequent 90-day time-windows: 0-90, 90-180, 180-
270 and 270-365 days. Cumulative incidences for re-exacerbation were calculated by multiply-
ing the IR with the time duration. 
Risk factors for exacerbations
Risk factors for exacerbations were estimated using Poisson regression. For the analysis of the 
total cohort, follow-up of each child was divided in episodes by year of age, the first episode 
started at the date of asthma diagnosis, or study entry whichever came last. For analysis of 
episodes after a previous exacerbation, start was at the first exacerbation or at study entry (for 
prevalent cases), whichever was last. Subsequent episodes started at each birthday. Covariates 
were retrieved during the 365 days prior to the start of each episode and could change over 
time for the different episodes. Analysis incorporated the potential effect of age, gender and 
interaction between age (quadratic) and gender. 
As specialist visits because of asthma might be related to number of exacerbations, number of 
ICS prescriptions or number of asthma treatment prescriptions, analyses for these covariates 
were adjusted for number of specialist visits. Poisson regression analyses was repeated in the 
subgroup of patients with 1 or more exacerbations before or during follow-up.
Logistic regression was used to evaluate possible predictors of frequent exacerbations by com-
paring episodes with 2 versus <2 exacerbations per episode) (online Figure 1). A sensitivity 
analysis was done using ≥3 versus <3 exacerbations per episode.
Finally, a Cox regression was performed to determine risk factors for first exacerbation. For 
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this analysis, only time to first severe asthma exacerbation during follow-up was considered. 
P<0.05 was considered statistically significant. Analyses were conducted with SPSS 20.0 for 
Windows (SPSSinc Chicago). 
RESULTS
The source population comprised 176,516 children aged 5-18 years. After validation the asth-
ma cohort consisted of 14,303 asthmatic children with 35,118 PY of follow-up (median 2.33 
PY). Baseline characteristics of the asthma cohort and cases with exacerbation (n=481) are 
described in Table 1. Cases had a total of 733 exacerbations during follow-up, the median 
number of exacerbations per patient was 1 (range 1-18). Detailed numbers of exacerbations 
and follow-up time of the cases are shown in online Table 1. 
Baseline characteristics
(n,%) unless stated otherwise
Total asthma 
cohort
≥1 exacerbation 
during FU
No exacerba-
tion during FU 
 p-value*
Patients 14,303 481 13,822  
Gender (female) 5,903 (41) 196 (41) 5,707 (41) ns
Age at cohort entry (years) (mean, sd) 10.5 (4.1) 10.1 (3.8) 10.5 (4.1) 0.016
Specialist diagnosed asthma 3,340 (23) 243 (51) 3,097 (22) <0.001
Follow-up (years) (mean, sd) 2.46 (1.56) 1.17 (1.25) 2.44 (1.55) <0.001
Prior to cohort entry:
Conjunctivitis 821 (6) 26 (5) 759 (6) ns
Eczema 3,852 (27) 159 (33) 3,693 (27) 0.002
Allergic rhinitis 2,541 (18) 77 (16) 2,464 (18) ns
Exacerbations ever 1,868 (13) 481 (100) 1,387 (10) <0.001
In 12 months prior to cohort entry:
Exacerbations 415 (3) 129 (27) 286 (2) <0.001
Paediatrician visits for asthma (yes/no) 816 (6) 71 (15) 745 (5) <0.001
Prescription for asthma medication 9,275 (65) 410 (85) 8,865 (64) <0.001
Children on ICS 5,547 (39) 262 (54) 5,285 (38) <0.001
Children on LABA 292 (2) 27 (6) 265 (2) <0.001
Children on LTRA 357 (3) 40 (8) 317 (2) <0.001
Children on FDC-ICS/LABA 1,481 (10) 81 (17) 1,400 (10) <0.001
Children on SABA 7,027 (49) 345 (72) 6,682 (48) <0.001
Table 1 - Baseline characteristics of the total asthma cohort and of the subgroups without and with exacerbation during 
follow-up.
N = number, % = percentage, sd = standard deviation, ns = not significant
* P-value based on the χ² or t-test comparing characteristics of the patients with no exacerbation during follow-up with 
patients with ≥1 exacerbation during follow-up. 
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The overall incidence rate of exacerbations was 2.1 per 100 PY (95%CI 1.9-2.2) and increased 
to 4.1 when restricted to children who did not only had a diagnosis of asthma but had also 
medications. (Figure 1) In both groups the rate was highest in the youngest and oldest children. 
(p<0.001 for quadratic term with age). The IR did not change over different years in the study 
period (p=0.19). (Figure 2) Significant seasonal effects (p=0.005 for calendar month) were 
observed with peaks in March-April and September-November, with highest rates (IR=2.8/100 
PY) in November and lowest (IR=1.6/100 PY) in June. (Figure 3) The seasonal effect was not 
significantly different between pre-school or high-school aged children. (data not shown)
Figure 1 - IR for exacerbation by age and gender, all children and children on asthma treatment (≥1 prescription for asthma 
medication during follow-up).
Figure 2 - Severe asthma exacerbation incidence rates for treated cohort by calendar year.
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Re-exacerbation
The incidence rate of re-exacerbation was constant over time. The cumulative incidence shows 
that within one year of a severe asthma exacerbation, 25% (95% CI 20.55-28.82) of the pa-
tients will have a new exacerbation. (Table 2)
Risk factors 
Risk factors for severe asthma exacerbations estimated by Poisson regression analyses are 
shown in Table 3. Each Poisson model included age and age2. As both gender and the interac-
tion term between age and gender were not significant, we did not include these. Covariates 
that remained independent risk factors of exacerbations after adjustment for age were number 
of visits to the specialist, number of prescriptions of any asthma medication and specifically 
of ICS, and number of exacerbations in the previous year. No significant associations were 
observed with gender, eczema, allergic rhinitis, conjunctivitis, or respiratory infections. When 
repeating the Poisson regression analyses in only patients with exacerbations, the same risk 
factors as in the total cohort were found. (Table 3) 
Factors that were associated with frequent exacerbation episodes estimated by logistic regres-
sion, were specialist visits, prescriptions of any asthma medication, prescriptions of ICS and 
exacerbations during the previous year. (Table 4)
Eczema, respiratory infections, specialist visits for asthma, exacerbations, and ICS prescrip-
tions were significant predictors adjusted for gender and age and their interaction, when study-
ing predictors of first exacerbation during follow-up using Cox-regression. Only the number 
of prior exacerbations and number of ICS prescriptions remained significant predictors after 
additional adjustment for number of visits to specialist. (Table 5)
Figure 3 - Severe asthma exacerbation incidence rates by calendar month for the total asthma cohort.
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Table 2 - Number of re-exacerbations, IR of asthma re-exacerbation (per PY) and cumulative incidence in percentage (%).
Table 3 - Risk factors for severe asthma exacerbation for all episodes of the total asthma cohort and for episodes of children 
with ≥1 severe asthma exacerbation based on Poisson regression.
Time Window after 
exacerbation
Number of 
re-exacerbations IR / PY 95% CI
Cumulative 
incidence (%) 95% CI
<30 days 12 0.31 0.16-0.54 2.5 1.31-4.34
<90 days 28 0.26 0.17-0.37 6.1 4.11-8.72
<180 days 53 0.26 0.20-0.34 12.1 9.39-15.44
<270 days 78 0.28 0.22-0.35 18.6 15.02-22.81
<365 days 99 0.28 0.23-0.34 24.7 20.55-28.82
Total asthma cohort Children with ≥1 exacerbation ever
Patients (n) 14,303 1,868
Episodes 46,423 5,940
RR 95% CI p-value RR 95% CI p-value
Basic model:
Age 0.67 (0.48-0.92) 0.02 0.72 0.54-0.96 0.03
Age² 1.02 (1.00-1.03) 0.02 1.02 1.00-1.03 0.03
Gender (male)* 1.02 (0.69-1.50) 0.94 0.86 0.59-1.26 0.44
Conjunctivitis* 1.36 0.70-2.65 0.37 1.15 0.62-2.14 0.66
Eczema* 0.76 0.42-1.36 0.35 0.68 0.39-1.18 0.17
Allergic rhinitis* 0.75 0.47-1.21 0.24 0.75 0.47-1.18 0.21
Respiratory infections (number)* 1.04 0.97-1.12 0.23 1.03 097-1.10 0.39
Specialist visits because of asthma* 1.71 1.39-2.10 <0.001 1.25 1.16-1.34 <0.001
Prior exacerbations* 1.99 1.40-2.83 <0.001 1.60 1.37-1.88 <0,001
*# 2.39 1.01-5.65 <0.05 1.70 1.27-2.27 <0.001
ICS prescriptions* 1.25 1.18-1.33 <0.001 1.16 1.09-1.22 <0.001
*# 1.27 1.20-1.34 <0.001 1.17 1.11-1.23 <0.001
Any asthma treatment* 1.16 1.12-1.19 <0,001 1.10 1.07-1.13 <0.001
*# 1.16 1.13-1.19 <0.001 1.10 1.07-1.13 <0.001
Variables in bold are statistically significant. 
* = adjusted for age and age2 # = additionally adjusted for specialist visits for asthma
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Table 4 - Risk factors for frequent exacerbation episodes.
Table 5 - Risk factors for time until an exacerbation (Cox-regression).
<2 versus ≥2 exacerbations <3 versus ≥3 exacerbations
Episodes 5,801 versus 139 5,873 versus 67 
OR 95% CI p-value OR 95% CI p-value
Basic model:
Age 0.77 0.55-1.06 0.11 1.02 0.63-1.65 0.95
Age² 1.01 1.00-1.03 0.11 1.00 0.98-1.02 0.89
Gender (female)* 1.06 0.70-1.61 0.80 1.07 0.58-1.96 0.83
Eczema* 0.65 0.30-1.39 0.27 0.90 0.37-2.16 0.81
Allergic rhinitis* 0.70 0.34-1.44 0.33 0.82 0.30-2.23 0.70
Respiratory infections* 0.99 0.89-1.10 0.81 1.05 0.93-1.20 0.41
Specialist visits because of asthma* 1.31 1.15-1.50 <0.001 1.47 1.28-1.69 <0.001
Exacerbations* 2.11 1.66-2.68 <0.001 2.43 1.84-3.23 <0.001
*# 2.12 1.57-2.87 <0.001 2.31 1.59-3.37 <0.001
ICS prescriptions * 1.15 1.08-1.24 <0.001 1.21 1.12-1.31 <0.001
*# 1.16 1.08-1.24 <0.001 1.22 1.12-1.32 <0.001
Any asthma treatment* 1.11 1.08-1.15 <0.001 1.12 1.08-1.17 <0.001
*# 1.11 1.08-1.15 <0.001 1.12 1.08-1.17 <0.001
Variables in bold are statistically significant. 
* = adjusted for age and age2, #= additionally adjusted for specialist visits for asthma
  HR 95% CI p-value
Gender (male) 0.57 0.33-0.96 0.04
Age 0.97 0.94-1.00 0.04
Age x gender 1.06 1.01-1.11 0.02
 Variables retrieved prior to baseline: HR* 95% CI p-value
Conjunctivitis * 0.94 0.63-1.39 0.75
Eczema * 1.28 1.06-1.55 0.01
Allergic rhinitis * 0.92 0.72-1.18 0.51
Respiratory infections within 1year prior to baseline * 1.13 1.05-1.21 <0.001
Specialist visits because of asthma within 1year prior to baseline * 2.53 2.24-2.85 <0.001
Exacerbations * within 1year prior to baseline 4.04 3.68-4.43 <0.001
*# 3.65 3.16-4.22 <0.001
ICS prescriptions within 1year prior to baseline * 1.18 1.14-1.23 <0.001
*# 1.16 1.11-1.21 <0.001
Variables in bold are statistically significant. 
* = adjusted for age, gender and age x gender, HR = Hazard Ratio
*# = additional adjusted for specialist visits for asthma
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DISCUSSION
This longitudinal population-based study covering 12 calendar years showed patterns, rates 
and risk factors of asthma exacerbations and demonstrated rates vary by season but are similar 
over the 12 calendar years, the most important risk factor/predictor of exacerbation is having 
a prior exacerbation. Patients with an exacerbation have 25% chance to have a subsequent 
exacerbation within a year.
Our incidence rates are consistent with the rates observed in the CAMP study 17 and study of 
Blais et al. 7 Zeiger et al. studied a cohort of children with persistent asthma and reported a 
threefold higher rate than we observed 15, this may be explained by their inclusion of only 
patients with severe asthma. The annual IR of exacerbation remained stable over time, which 
is in line with recent findings in a cohort of asthmatic adults, where the number of exacerba-
tions per subject per year did not change between 2007 and 2011. 23 An earlier study showed 
a decrease in hospital admissions over time, however this study used data from 1990-2001. 24 
Our study confirms seasonal variability within a year with exacerbation peaks in spring and 
autumn. Exposure to pollen and other aeroallergens may account for the observed peaks. In 
September the increase was more obvious among children of kindergarten- and school age 
although the interaction with age was not significant. In other studies this September peak was 
related to the start of the school year. 6
In the present study, the most important risk factors for severe asthma exacerbation and fre-
quent exacerbations were prior exacerbation, which is in agreement with prior studies 9, 23, 25 
Other risk factors of severe asthma exacerbation were the number of ICS prescriptions and the 
number of specialist visits, factors which we consider as proxy for asthma control. 
The main strength of the present study is the size of the cohort with more than 14,000 children 
with asthma and the validation of the asthma diagnosis and asthma exacerbations which limits 
the risk of false positives. Selection bias was unlikely as almost all inhabitants of the Nether-
lands are registered with one GP and data are collected as part of routine patient care, irrespec-
tive of any research question. Still, as this is an observational study using data from electronic 
healthcare data, the risk of bias and/or confounding is substantial. As the IPCI database has no 
linkage with hospital admission- and discharge data, hospitalization and ED visits for asthma 
were retrieved either via disease-specific codes in combination with codes for hospitalization 
or via review of the discharge letters. This might underestimate exacerbations. Within the pre-
scription file, information on the indication of prescribing of systemic corticosteroids was not 
always complete. If missing, we searched for asthma disease codes in a window of 7 days be-
fore or after the prescription date. Treatment information may be misclassified as the database 
captures prescribing data not dispensing data, patients can refill the drugs but may not actually 
take the drugs, and specialist initiated prescriptions may be missed if this is not captured in the 
records. This was probably minimal as the GP plays a gatekeeper role for patient care, implying 
that prescriptions as initiated by the specialist will often be continued by the GP. 26 
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What is the clinical relevance of our findings? 
This study showed that 4 out of 100 children on asthma treatment will have a severe asthma 
exacerbation when followed over 1 year. Furthermore, 25% of all children with an asthma 
exacerbation will have a next exacerbation within 1 year. In this study the IR of exacerbation 
was stable over time. The most important risk factors for exacerbations were prior exacerba-
tions, which emphasizes the importance of close monitoring of children after a severe asthma 
exacerbation. 
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SUPPLEMENTS
  All patients Patients with treatment
agecate-
gory gender
exacerba-
tions (n)
Follow up 
time (days)
Incidence 
rate all
exacerba-
tions (n)
Follow up 
time (days)
Incidence 
rate treated
5 1 55 474358 4.23 51 278318 6.69
5 2 26 303910 3.12 21 176770 4.34
6 1 49 514926 3.48 45 250565 6.56
6 2 26 344359 2.76 22 175976 4.57
7 1 24 552919 1.59 22 273825 2.93
7 2 17 380984 1.63 16 179198 3.26
8 1 37 582058 2.32 36 290184 4.53
8 2 23 390387 2.15 18 172814 3.80
9 1 22 595705 1.35 20 282048 2.59
9 2 26 400987 2.37 22 181475 4.43
10 1 27 603820 1.63 23 275847 3.05
10 2 19 397315 1.75 18 179945 3.65
11 1 34 628654 1.98 33 294192 4.10
11 2 22 404889 1.98 22 173729 4.63
12 1 34 651655 1.91 26 283131 3.35
12 2 26 421936 2.25 23 187145 4.49
13 1 30 667628 1.64 26 284234 3.34
13 2 15 426870 1.28 14 185000 2.76
14 1 28 655235 1.56 26 254869 3.73
14 2 17 439407 1.41 16 185714 3.15
15 1 21 619243 1.24 14 232191 2.20
15 2 20 437183 1.67 18 191178 3.44
16 1 34 571721 2.17 32 209881 5.57
16 2 28 437317 2.34 23 197101 4.26
17 1 32 520578 2.25 29 176360 6.01
17 2 41 426438 3.51 36 200443 6.56
Online Table 1 - Number of exacerbations, follow-up time, cases and incidence rate per gender, per total asthma cohort and 
per patients with asthma treatment.
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Online Figure 1 - Association between age and incidence rate of exacerbations.
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ABSTRACT
  AIMS   To assess the all-cause mortality, mortality following an exacerbation and risk factors for 
mortality in patients with asthma and severe asthma.
  METHODS   Asthma patients aged ≥5 years and with ≥1 year of follow-up were identified in six 
European electronic health record databases from the Netherlands, Italy, UK, Denmark and 
Spain in 2008-2013. Severe asthma was defined as use of high dose inhaled corticosteroids + 
controller therapy for >120 days. Exacerbations were defined as either emergency department 
(ED) visits, hospitalizations or systemic corticosteroid courses for asthma; severe exacerbations 
as ED-visits or hospitalizations. Risk factors for mortality were examined amongst adults with 
incident asthma only.
  RESULTS   The cohort consisted of 855,806 asthma patients; proportion of severe asthma ranged 
between 1.7-10.0% in the different databases (mean age 53.7-62.6 years; Pedianet: 9.3 years). 
All-cause mortality rates ranged between 6.0-12.8/1000 PY in asthma, and 16.0-33.4/1000 PY 
in severe asthma. In severe asthma, mortality in the 1st week following an exacerbation was 
26.3-109.5/1000 PY compared to 57.9-239.4/1000 PY following severe exacerbations. Risk 
factors for mortality were age, comorbidity (COPD, diabetes, cerebrovascular disease or can-
cer), smoking and previous exacerbation. These risk factors were consistent in most databases.
  CONCLUSIONS   Mortality following an exacerbation is high, especially in patients with severe 
asthma, and in the first week following a severe exacerbation (up to 11%). Adult asthma pa-
tients with prior exacerbations, smoking, increasing age or comorbidity have an increased risk 
of mortality. Prevention of asthma exacerbations as well as smoking cessation are important to 
reduce associated mortality.
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INTRODUCTION
Asthma is a highly prevalent and chronic respiratory condition affecting 300 million people 
worldwide. 1 Asthma is a major cause of disability, health resource utilization, and significantly 
reduces the patient’s quality of life. 2 There is no cure for asthma, but it can generally be con-
trolled through treatment as described by existing asthma management guidelines. 3 However, 
real world surveys among asthmatic patients indicate that the incidence of exacerbations is 
much higher than observed in clinical trials. 4 Asthma exacerbations are associated with in-
creased healthcare costs, reductions in health related quality of life, and increased mortality. 5 
In some countries, asthma related mortality has decreased over the last decade. 6, 7 Still, on a 
global scale it is estimated that asthma accounts for about 250,000 deaths per year. 1 GINA 
published in 2004 mortality estimates of 5.2 per 100,000 asthma patients aged 5-34 years in 
the United States, with wide variations across Europe (e.g. 1.6 per 100,000 in Finland and 9.3 
per 100,000 in Denmark). 8 
There is growing evidence that patients with the asthma-COPD overlap syndrome (ACOS) 
have an increased risk of asthma exacerbations and hospitalization, and are at increased risk 
of mortality. 9,10 Commonly, this patient group is excluded from clinical trials, and therefore 
observational research is essential to study underlying COPD as risk factor for mortality in 
patients with asthma.
In this study we aimed to estimate all-cause and asthma related mortality, risk factors (includ-
ing concurrent COPD) for mortality, and mortality following exacerbations, in patients with 
asthma and severe asthma, using one protocol and harmonized methods, across five different 
European countries. 
METHODS
Design and setting 
A retrospective cohort study was conducted using data from six European electronic health 
care databases: the Integrated Primary Care Information Project (IPCI) from the Netherlands, 
the Health Search Database (HSD) and Pedianet from Italy, Clinical Practice Research Datalink 
(CPRD) from the UK, the Sistema d'Informació per al Desenvolupament de la Investigació en 
Atenció Primària (SIDIAP) from Spain and the Aarhus University Prescription Database (AUH) 
from Denmark. Detailed descriptions of these databases have been published before 11-16 and 
are available in the online supplement. All databases comprise detailed information on drug 
prescriptions or dispensing, outpatient diagnoses and hospitalizations, comorbidity and mea-
surement data (e.g. lab results, spirometry, BMI). These databases contain information on mor-
tality either through linkage with hospital data and death registries (AUH, SIDIAP and CPRD) 
or via information from discharge letters via GP (HSD, Pedianet and IPCI) or death records 
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registered by the GP. (CPRD, IPCI, Pedianet and SIDIAP) All participating databases comply 
with EU guidelines on the use of medical data for research and are registered in the European 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) database. 17
Cohort definition
A cohort of patients with asthma was defined in each database. To enter the cohort, patients 
needed to be at least 5 years old, with a minimum of 1-year database history and diagnose code 
of asthma. Asthma was defined as the presence of at least one asthma specific disease code 
(see online supplement) in combination with prescriptions/dispensing of asthma drugs within 
3 months before or after an asthma disease code. Asthma drugs consisted of the following: 
inhaled corticosteroids (ICS), short-acting β2-agonists (SABA), long-acting β2-agonists (LABA), 
fixed combination of ICS+LABA, leukotriene modifier (LTRA), short-acting muscarinic antag-
onist (SAMA), fixed combination of SABA+SAMA, xanthines, systemic corticosteroids for the 
treatment of asthma and anti-IgE treatment. Information on drug use was retrieved by an ATC 
specific search from the drug prescription or drug dispensing records. Based on the asthma 
index date (first date of an asthma disease code at or after study entry), patients were catego-
rized into prevalent or incident asthma. 
Within the cohort of patients with asthma, a sub-cohort of patients with severe asthma was nest-
ed. According to international guidelines, severe asthma was defined as asthma which requires 
treatment with high dose ICS plus a second controller (and/or systemic corticosteroids). 3,18 
Only those who fulfilled these criteria for a consecutive period of at least 120 days were includ-
ed. For Pedianet, children were considered as having severe asthma based on criteria above, 
but without the extra requirement of use of at least 120 days, because only 1 patient fulfilled 
this extra requirement. The study period started at the first of January 2008 and ended 31st 
December 2013. 
Follow-up
For each patient, cohort follow-up started from the maximum date of the following; start of 
study period, diagnosis of (severe) asthma, age of 5 years or after reaching a minimum of 365 
days of database history. Further, to account for immortal time bias, follow-up in the severe 
asthma cohort started on day 120 of consecutive use of high dose ICS with additional control-
ler therapy. 19 Follow-up ended when leaving the database, death or end of the study period 
whichever came first. 
For the analysis of mortality following asthma exacerbations, follow-up ran from the date of 
an asthma exacerbation until the end of the respective time windows following an asthma 
exacerbation (7, 30, 90, 180 or 365 days), a next exacerbation, end of study period, or death, 
whichever date came first. 
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Outcome
In all databases, death and date of death are well documented. Information on cause of death 
was only systematically available for IPCI, AUH (available up to 2011) and Pedianet. Where 
available, cause of death was classified into “asthma related” or “non-asthma related death”. 
Covariates
“Asthma exacerbation” was defined as any of the following: acute use of systemic corticoste-
roids, ED visit or hospitalisation for an asthma exacerbation. 20 “Severe asthma exacerbations” 
were defined as ED visits or hospitalization for an asthma exacerbation. 
The indication of corticosteroid use was retrieved from the prescription/description file or 
through an automated search on asthma or asthma exacerbation disease codes in a 7-day 
window before or after the prescription date. Continuous use of systemic corticosteroids, de-
fined as consecutive use of 30 days or more, was not considered as an asthma exacerbation. 
If the time between 2 prescriptions of systemic corticosteroids was less than 2 weeks, this was 
considered as one asthma exacerbation.
In addition, we investigated the prevalence of the following comorbidities: atopy (allergic rhi-
nitis, atopic eczema/dermatitis, chronic rhinosinusitis, or nasal polyposis), COPD; gastro-oe-
sophageal reflux disease (GERD), depression and anxiety, overweight and obesity, diabetes 
mellitus, cardio- and cerebrovascular diseases and cancer. Smoking status was classified as 
“current smoker”, “past smoker”, “non-smoker” or “smoking status unknown”. Comorbidities 
and smoking status were assessed at the start of follow-up (using information in the entire 
period prior, even before cohort entry) and at each exacerbation. 
Analysis
Categorical data were presented in counts and proportions. For continuous data, the number 
of observations (n), mean, and standard deviation were presented.
The overall mortality rate was calculated by dividing the number of deaths by the respec-
tive number of person-years of follow-up. Mortality rates were calculated by gender and age 
category (5 to 12; 12≤18, 18≤25 and subsequent 10-year age categories). To account for 
differences in age distribution between databases, direct standardization was applied using the 
distribution of the largest population (CPRD) as the reference population. 21
Mortality rates were calculated in predefined follow-up time windows (7, 14, 30, 90, and 365 
days) following an asthma exacerbation. 
Mortality rate ratios with 95% CI were obtained using Poisson regression comparing ACOS 
patients to patients without ACOS adjusted for age, gender, and smoking status. ACOS was 
defined as patients with asthma who also had a diagnosis of COPD (in their medical history 
or during follow-up). To elucidate on the potential confounding effect of COPD on mortality, 
posterior analysis were stratified by COPD status. 
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A meta-analysis was performed on the overall mortality rates estimated in the databases. Het-
erogeneity was quantified by the I2 statistics. If I2 was greater than 50% the random effect 
estimates were presented as the meta-analysis result and no pooling of data was done. If I2 was 
less than or equal to 50%, then the fixed effect estimate was used for pooling and presented as 
the meta-analysis result. 22
Furthermore, Kaplan-Meier curves for cumulative survival probability in the period after asth-
ma exacerbation were calculated. 
Risk factors of all-cause mortality in adult incident asthma patients, ie. without asthma di-
agnosis in their medical history, were assessed by means of univariate and multivariate Cox 
regression analyses, including all of the following covariates: age at asthma diagnosis, gender, 
smoking status, medical history (COPD, cancer, cardiovascular disease, cerebrovascular disease 
or diabetes mellitus) and two time-dependent covariates; time since previous exacerbation 
(classified in up to 30 days, 31 to 90 days, 91 to 365 days and more than 365 days) and asthma 
severity. Pooled results for the hazard ratios for time since exacerbation were obtained using 
multivariate meta-analysis. 23 
RESULTS
The source population comprised 16,259,085 individuals during the study period and the asth-
ma cohort size was 855,806 patients. Within the total asthma cohort, 66,148 patients (7.7%) 
with severe asthma were identified. The percentage of severe asthma was similar across da-
tabases (6.0-8.7%) except for SIDIAP (1.7%) and Pedianet (1.7%). Baseline characteristics of 
the asthma cohorts are further described in Table 1, Table 2 and Online Table 1. Briefly, the 
mean age at start of follow-up was 7.2 years for Pedianet (a paediatric database), and ranged 
between 33.2-46.6 years for the other databases. In all databases, apart from Pedianet (36.1% 
females) and AUH (49.3% females), there was a preponderance of females (53.5-56.8%). This 
trend became stronger in patients with severe asthma (56.6-65.6% females). The prevalence 
of atopy (consisting of atopic eczema and/or allergic rhinitis) ranged between 11.3-36.7% and 
was not different in patients with severe asthma. The prevalence of chronic rhinosinusitis and 
nasal polyposis in patients with asthma ranged between 0.2%-8.6% and 0.4-2.3%, respectively, 
and increased in patients with severe asthma (0.7-13.0% and 0.8-5.5%, respectively). The 
prevalence of concurrent COPD ranged between 2.4-15.4% in all asthma patients and was 
higher in the subgroup of patients with severe asthma (11.2-36.5%).
In total, 24,537 deaths were observed during follow-up. Patient characteristics of patients who 
died are further described per database in Table 3. Asthma related death was reported in 2.4% 
of deaths in AUH, 0.4% in IPCI, 4.2% in SIDIAP, and 1.7% in CPRD. It should be noted that 
cause of death was not available in a substantial proportion in SIDIAP (57.9%) and CPRD 
(79.2%). 
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The overall age standardized mortality rates were 6.1/1000 PY in IPCI, 4.8/1000 PY in HSD, 
6.3/1000 PY in SIDIAP, 7.8/1000 PY in CPRD and 13.2/1000 PY in AUH. No deaths were 
observed in Pedianet. (Table 4) The mortality rates were higher in patients with severe asthma 
(Table 5) and with increasing age. (online Table 2 and Figure 1). Heterogeneity of the mortal-
ity rates was substantial (I2=97.5), which makes pooling of these rates meaningless. (online 
Figure 1)
The mortality rate in the first 7 days following any asthma exacerbation ranged between 14.6-
88.4/1000 PY across databases. Mortality rates were highest in the first 7 days following severe 
asthma exacerbation and decreased thereafter. (Table 6 and Figure 2) Mortality rates were 
higher in patients with more severe asthma; however, this trend was less clear in SIDIAP and 
HSD. 
From these mortality rates the cumulative incidences of death were calculated. (Table 6) With-
in 7 days following an asthma exacerbation, 0.0-0.2% of asthma patients and 0.1-0.2% of 
severe asthma patients died and this cumulative incidence increased to 0.1-0.3% in all asthma 
and 0.1-0.5% in severe asthma patients when only considering severe asthma exacerbations. 
Within 1 year following an asthma exacerbation, 0.9-3.1% of asthma patients and 1.7-4.9% 
of severe asthma patients had died and here again the cumulative incidence increased when 
considering severe asthma exacerbations only. 
Mortality rates during cohort time in asthma patients were 1-3 fold higher in asthma patients 
with concomitant COPD compared to without COPD, irrespective of asthma severity. (Figure 
3 and online Table 3). Mortality rates following an asthma exacerbations were also higher in 
ACOS patients; within 1 year following an asthma exacerbation, 1.0-5.0% of patients without 
COPD died, compared to 2.2-8.7% in ACOS patients. (online Table 4)
Risk factors for mortality
In the incident adult asthma patients (n=166,618) a previous asthma exacerbation was a 
risk factor for mortality in almost all databases, except for the AUH database. (online Table 
5) In the multivariate analysis, age, previous exacerbations, smoking status, history of cancer, 
history of diabetes, and history of cerebrovascular disease were associated with exacerbations 
in most databases. (Table 7) History of COPD increased the risk of mortality up to 76% in IPCI, 
AUH, CPRD and SIDIAP. Current smoking increased the risk with 59-153% in IPCI, HSD, CPRD 
and SIDIAP. It should be noted that the smoking status of patients was often unknown. 
Hazard ratios for the different periods after exacerbation are shown both per database and 
pooled. (Figure 4) The pooled HRadj of dying for time since exacerbation decreased from 1.93 
(95% CI 1.47-2.53) in the first 30 days after an exacerbation to 1.35 (95% CI 1.21-1.51) after 
1 year. 
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Figure 1 - Mortality rates by age category in patients with severe asthma.
Figure 2 - Mortality rates following asthma exacerbation in the total asthma cohort and the severe asthma cohort.
* = severe definition without criterion of consecutive 120 days of high dose ICS
Asthma Severe asthma
Overall MR Overall MR - Standardized Overall MR Overall MR - Standardized
IPCI 6.02 6.15 17.50 19.39
AUH 12.78 13.23 33.42 36.16
HSD 6.73 4.84 16.02 15.98
CPRD 7.76 7.76 27.49 27.49
SIDIAP 7.15 6.33 26.29 19.20
Table 4 - Age standardized mortality rate (distribution of CPRD as reference population) (MR = number of deaths/1000 PY).
severe asthma = defined as asthma which requires treatment with high dose ICS and controller therapy for a consecutive 
period of at least 120 days
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Figure 3 - Mortality rates in the total asthma cohort and the severe asthma cohort, stratified by history of COPD per database.
Figure 4 - Hazard ratios of mortality in incident adult asthmatic patients for time periods after exacerbation (0-30 days, 31-90, 
91-365, >365 days after exacerbation).
* adjusted for gender, age at start, asthma severity, history of COPD, history of cancer, history of cardiovascular disease, history 
of cerebrovascular disease, history of diabetes mellitus and smoking.
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DISCUSSION
In this study, we investigated overall mortality rates and mortality rates following an asthma 
exacerbation in 6 asthma cohorts from 5 European countries, using one protocol and harmo-
nized methods. The overall age standardized mortality rate in patients with asthma ranged 
between 4.8-13.2/1000 PY per database, and increased in patients with severe asthma and 
with increasing age. 
Mortality following exacerbations was the highest in the first week (14.6-88.4/1000 PY) after 
exacerbation and decreased thereafter, both in the different databases as well as in the pooled 
meta-analysis. The risk of dying within 1 week following an asthma exacerbation ranged across 
countries between 0.1% and 0.5%.
The WHO reported asthma related mortality in patients aged 5-34 years of age, ranging between 
0-5/100,000 people with asthma in Italy and the UK and 5.1-10/100,000 people in Spain, The 
Netherlands and Denmark.1 These mortality rates are lower than the overall mortality rates 
that we reported for these respective countries. However, we studied all-cause mortality in 
adult patients with asthma. In 2014, To et al. reported the results of a 10-year population study 
on asthma related mortality and all-cause mortality using data from the health administrative 
database from Ontario, Canada. The age and gender adjusted, all-cause mortality declined 
from 9.9/1000 in 1999 to 8.5/1000 in 2009 which is in line with the rates in our study. 24
In 2006, Krishnan et al published US data on mortality following hospital admission for asthma 
and reported an in house mortality of 0.5%. 25 This estimate is comparable with the cumula-
tive incidence of mortality of 0.1-0.5% within 7 days following asthma exacerbation in our 
European study. Similar results were recently described by Kaur et al. who reported that 1% of 
patients die in the hospital following admission for asthma exacerbation. 26 In 2013, age stan-
dardized mortality rates in 30 days following an admission for status asthmaticus in Denmark 
were published. 27 Between 2008-2011, the 30-day mortality rate was 1.5% which is in line 
with the 0.6% (95% CI 0.1-2.3) that we reported for Denmark. Although mortality following 
asthma exacerbation has already been studied, to our knowledge, we are the first to study 
previous asthma exacerbations as independent risk factor of mortality. 
In our study, adjusted mortality rate ratios comparing patients with a history of COPD to pa-
tients without history of COPD were up to 2.8. A recent observational study by Yamauchi et al. 
compared in-hospital mortality in patients with asthma, COPD and ACOS. 28 The proportion 
of patients who died during hospitalization was 9.7% in patients with COPD, 2.3% in patients 
with ACOS and 1.2% in patients with asthma. Although our cumulative incidence (0.4 and 
0.1%) is smaller than reported in this study by Yamauchi et al., our results confirm that COPD 
is an independent risk factor of mortality in patients with asthma.
As this is an observational study, using data from electronic health care databases, there is a 
possible risk of bias and/or confounding. First, for all electronic health care databases, it should 
be noted that the primary aim of data collection is patient management and not research. This 
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implies that only events that are deemed to be relevant to the patient’s care are collected. Sec-
ond, for those databases without linkage with hospital admission or discharge database (HSD 
and IPCI), severe asthma exacerbations were retrieved either via disease specific codes in com-
bination with codes for hospitalization or via review of the discharge letters. Underestimation 
of severe asthma exacerbations is likely and plausible for HSD where incidence rates of severe 
asthma exacerbations are indeed very low. (data not shown)
For AUH and SIDIAP, dispensing data instead of prescription data were used, which reduced 
misclassification of exposure, however dosing information was missing. Therefore dosing was 
estimated based on the strength per device and the window between prescriptions. This meth-
od is susceptible to misclassification of severe asthma, that was based on at least 120 consecu-
tive days with high dose ICS. This might explain the low proportion of severe asthma patients 
in SIDIAP.
The presence of asthma and underlying co-morbidity was assessed via disease specific codes 
only. Misclassification of asthma and co-morbidity is possible and might be differential between 
databases but it is unlikely that this resulted in an overestimation of the mortality rates. Mor-
tality rates were higher for AUH compared to the other databases, which might be explained by 
the fact that AUH collects disease codes from hospital data (ambulatory or hospitalised) only, 
implying that asthma patients in AUH all required secondary or tertiary care and probably had 
more severe asthma. 
The proportion of patients with underlying COPD was high, especially in patients with severe 
asthma, where 1 in 3 patients was diagnosed with COPD. ACOS is well described and we know 
that the proportion of patients with ACOS increases with age. 29, 30 It is also well-known that 
GPs are often unable to make a differential diagnosis between asthma and COPD. 31 As no 
manual validation of asthma or COPD was performed, there is a potential of misclassification 
of both asthma and COPD. This risk of misclassification is probably higher in older patients 
which could have affected our analysis on risk factors of mortality which was only conducted 
in patients with adult incident asthma to guarantee complete information on medical history 
of asthma exacerbations and complete follow-up from asthma diagnosis to mortality or end of 
study. Also, the pathogenesis and immunologic mechanisms are different in incident asthma 
patients compared to prevalent asthma patients. 32 Lack of asthma control, measured by means 
of asthma symptom scores, is an independent risk factor of asthma mortality. 33 Unfortunately, 
the databases that were used do not systematically collect information on asthma control.
The main outcome in this study was mortality, assessed either through direct linkage with 
death registries (CPRD, AUH and SIDIAP) or via information as collected by the GP. The overall 
mortality rates are comparable between databases (apart from AUH), suggesting that misclas-
sification of the outcome is limited. 
We studied risk factors for mortality in patients with asthma and investigated the effect of 
life style factors (smoking), asthma severity, previous asthma exacerbations and underlying 
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comorbidity. Current smoking was a major risk factor for mortality in most databases, which is 
a modifiable risk factor where clinicians and patients can make a difference. 
In conclusion, our data demonstrate that mortality in patients with asthma, and especially 
severe asthma, is substantial and is highest in the first 7 days after hospitalisation for asthma 
exacerbation. Moreover, patients with a history of asthma exacerbation, increasing age and un-
derlying comorbidity including COPD have an increased risk of mortality. Prevention of asthma 
exacerbations as well as smoking cessation are important to reduce associated mortality.
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Online supplement: Description of databases
The Integrated Primary Care Information (IPCI) database is a Dutch database containing the 
complete medical record of more than 1.5 million patients provided by more than 450 GPs 
geographically spread over the Netherlands. 11 In the Netherlands, all citizens are registered 
with a GP practice which acts as a gatekeeper in a two-way exchange of information with 
secondary care. The medical records can therefore be assumed to contain all relevant medical 
information including medical findings and diagnosis from secondary care. The International 
Classification of Primary Care (ICPC) is the coding system but diagnoses and complaints can 
also be entered as free text. Prescription data contain information on product name, quantity 
prescribed, dosage regimens, strength, indication and ATC codes. 
The Health Search CSD Longitudinal Patient Database (HSD), is a longitudinal observational 
database that is representative of the Italian general population. HSD contains data from com-
puter-based patient records from a selected group of GPs (covering a total of 1.5 million pa-
tients) located throughout Italy. The database includes information on age, gender, patient and 
GP identification, which is linked to prescription information, clinical events and diagnoses and 
date of death. All diagnoses are coded according to the International Classification of Diseases, 
9th Revision. Drug names are coded according to the ATC classification. 13, 14
In 1998 Pedianet has been established in Italy to collect epidemiological information for clin-
ical research from family paediatricians. Pedianet is a paediatric general practice research da-
tabase that contains the clinical, demographic, prescription and outcome data of the children 
routinely seen by about 130 PCPs equally distributed throughout Italy (all Italian children aged 
less than six years are registered with a PCP as part of the country’s national health service), 
and which has been used for various epidemiological and pharmacovigilance studies. The data 
are generated during routine patient care using common software, and are anonymously sent 
monthly to a centralised database for validation. The reasons for the contacts and diagnoses 
(free text or coded using the ICD-9 system) are recorded in the medical file, and the database 
also contains information about specialist referrals, procedures, hospitalisations, medical ex-
aminations, health status (according to the Guidelines of Health Supervision of the American 
Academy of Paediatrics), and centile diagrams.
Clinical Practice Research Datalink (CPRD) is a large validated computerized database of 
anonymized longitudinal medical records for primary care. Data comprise approximately 12 
million patients with around 5.4 million of these being currently alive and registered from 
680 primary care practices spread throughout the UK. The database contains the entire an-
onymized electronic medical record of each patient, including medical codes associated with 
consultations and referrals; details of all drugs prescribed; life style factors and laboratory 
tests. 15 Information on hospitalization is collected through linkage HES and information on 
mortality is retrieved through linkage with the Office of National Statistics (ONS) Mortality 
data. 
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The Aarhus University Prescription Database comprises clinical and prescription data from 
the Central Denmark Region and the North Denmark Region. It covers a total of 1.2 million 
inhabitants and is representative of the population of Denmark. 12 Data are available on demo-
graphics, life style factors, dispensing data, hospitalizations and procedures. Dispensing data 
comprise the filled prescriptions for all ambulatory patients and contains information on name 
of the drug, ATC code, package identifier (strength and route of administration), and the date 
of refill. These data are linked to the national registry 34 of patients that comprises information 
on admissions to Danish somatic hospitals, emergency rooms and outpatient clinics, diagnosis 
codes and procedures to the to the Central Registration system 35 that records information on 
mortality and to the Danish Registry of Cause of death. 16
The SIDIAP Database comprises the electronic medical records of a representative sample of 
patients attended by GPs in Catalonia (North-East Spain), covering a population of more than 
5.1 million patients (about 80% of the total of 7.5 million population of Catalonia) from 274 
primary care practices. The SIDIAP data comprises the clinical and referral events (coded by 
ICD-10), demography information, prescription and dispensing, specialist referrals, life style 
factors, laboratory test results, and hospital admissions and their major outcomes. 36
Online supplement: Asthma Disease codes
Terms ICD10 ICD9CM Read Codes ICPC
Asthma J45* 493* H33* R96*
Asthma confirmed 102..00
Extrinsic asthma with asthma attack 663d.00 
663m.00
Asthma severity 663V*
Number of asthma exacerbations in past year 663y.00
Emergency admission, asthma 8H2P.00
Status asthmaticus J46*
Induced asthma 173A.00
Asthma trigger 173c.00
173d.00
178*.00
Asthma; emergency attendance since last visit 663m.00
Asthma; emergency admission since last appointment 663d.00
Asthma and exercise 663e.00
663e000
663e100
663f.00
663w.00
663x.00
Asthma currently dormant 663h.00
Asthma currently active 663j.00
Asthma treatment compliance satisfactory 663n.00
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Terms ICD10 ICD9CM Read Codes ICPC
Asthma treatment compliance unsatisfactory 663p.00
Asthma disturbing sleep 663N.00
66YP.00
663N000
663N100
663N200
663O.00
663O000
66YP.00
66Yq.00
66Yr.00
66Ys.00
Asthma limits activities 663P*
Asthma daytime symptoms 663q.00
Asthma not limiting activities 663Q.00
Asthma causes night symptoms 1 to 2 times per month 663r.00
Asthma never causes daytime symptoms 663s.00
Asthma causes daytime symptoms 1-2/month 663t.00
Asthma causes daytime symptoms 1-2/week 663u.00
Asthma causes daytime symptoms 663v.00
Asthma prophylactic medication used 663W.00
Asthma medication review 8B3j.00
Absence due to asthma 66YC.00
66Yu.00
Health education about asthma 679J.*
Asthma control 8793.00
8794.00
8795.00
8796.00
8797.00
8798.00
Asthma quality indicators 9hA*.00
Asthma exacerbation
Definition of asthma
Asthma exacerbation was defined as the use of acute systemic corticosteroids, ER visit, or 
hospitalisation for reasons of asthma exacerbation. 21 To identify patients with a severe asthma 
exacerbation, defined as ER visit or hospitalisation for reasons of asthma, an automated search 
was done on codes specific for severe asthma exacerbation. In addition, the medical file was 
searched for asthma specific disease codes (thus not only asthma exacerbation codes) in com-
bination with codes for hospitalisation. Hospitalization was retrieved either via linkage with 
hospital admission/discharge database (AUH, CPRD ( HES)), combination of disease codes 
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with information from hospital referral (HSD, SIDIAP and IPCI) and discharge letters (SIDIAP 
and IPCI) or combination of disease codes with source codes (hospital discharge letters) (CPRD 
 for those patients where we do not have HES).
The following disease codes also did fit the criteria of asthma exacerbation:
Terms ICD10 ICD9CM Read Codes ICPC
Emergency admission, asthma 8H2P.00
Status asthmaticus J46
J45.22
J45.32
J45.42
J45.52
J45.902
493.01
493.11
493.21
493.91
H33z000
Severe asthma attack H33z011
Asthma accident and emergency attendance since last visit 663m.00
Emergency asthma admission since last appointment 663d.00
Online Figure 1 - Heterogeneity precluding pooling of the data on overall mortality rates.
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Chapter 4.1
Prescription patterns, adherence and 
characteristics of non-adherence in 
children with asthma in primary care
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ABSTRACT
  BACKGROUND   Adherence to treatment remains important for successful asthma management. 
Knowledge about asthma medication use and adherence in real-life offer opportunities to im-
prove asthma treatment in children. 
  AIMS   To describe prescription patterns, adherence and factors of adherence to drugs in chil-
dren with asthma. 
  METHODS   Population-based cohort study in a Dutch primary care database (IPCI), containing 
medical records of 176,516 children, aged 5-18 years, between 2000-2012. From asthma med-
ication prescriptions, age, gender, seasonal and calendar year rates were calculated. Adherence 
was calculated using medication possession ratio (MPR) and ratio of controller-to-total-asth-
ma-drug (CTT). Characteristics of children with high vs. low adherence were compared. 
  RESULTS   The total asthma cohort (n=14,303; 35,181 person-years (PY) of follow-up) was 
mainly treated with short-acting β2-agonists (SABA; 40users/100 PY) and inhaled corticoste-
roids (ICS;32/100 PY). Median MPR for ICS was 56%. Children with good adherence (Q4= 
MPR>87%) were younger at start of ICS, more often visited specialists and had more exacer-
bations during follow-up compared to children with low adherence (Q1=MPR<37%). 
  CONCLUSIONS   In Dutch primary care children with asthma were mainly prescribed SABA, and 
ICS. Adherence to ICS was relatively low. Characteristics of children with good adherence were 
compatible with more severe asthma suggesting that adherence is driven by treatment-need or 
intensity of medical follow-up.
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INTRODUCTION
Respiratory drugs are frequently prescribed in children. 1 According to the Global Initiative 
for Asthma (GINA), paediatric asthma can be treated with quick relievers, inhaled short-act-
ing β2-agonists (SABA) and/or controllers: inhaled corticosteroids (ICS) with or without con-
comitant use of long-acting β2-agonists (LABA), or leukotriene receptor antagonists (LTRA). 2 
Despite treatment, many children with asthma are not achieving good symptom control. A 
major cause of uncontrolled asthma is suboptimal adherence to maintenance treatment. 3 In 
practice, adherence to asthma treatment is commonly low, ranging between 30 to 70% 4-7, and 
lower in real life than in clinical trials. Improving adherence to ICS may reduce the burden 
of uncontrolled asthma resulting in fewer asthma-related emergency department visits and 
hospitalizations. 3, 8 Observational studies consistently show that asthma therapy is not always 
used in concordance with guidelines: massive consumption of SABAs and underuse of ICS has 
been reported. 9 Furthermore, some patients use LABA without concomitant ICS, whereas in 
asthma, LABAs are advised only in combination with ICS because LABAs might mask ongoing 
symptoms, do not treat the underlying inflammation and, when given alone, carry a possibly 
higher risk of death from asthma. 10-12 The extent to which LABA monotherapy actually occurs 
in children is unknown. Knowledge on the use of and adherence to asthma treatment in real 
life may offer opportunities to optimize asthma treatment in children by new adherence in-
terventions. Therefore we investigated prescription patterns of asthma drugs and treatment 
adherence to asthma controller therapy, by conducting a cohort study using primary care data 
from a large database containing complete electronic medical records of more than 1 million 
patients.
METHODS
Setting
We conducted a population-based cohort study within the Integrated Primary Care Informa-
tion database (IPCI), a longitudinal observational dynamic database containing the complete 
electronic records of >450 general practitioners (GPs) throughout the Netherlands. 13 In the 
Dutch healthcare system, patients are registered with a single GP who acts as a gatekeeper for 
secondary care. 14 Details of the database have been published elsewhere. 13, 15 Briefly, IPCI con-
tains the complete electronic medical records of ±1,500,000 patients, containing anonymous 
longitudinal data on demographics, symptoms and diagnosis (coded and free text), referrals, 
laboratory findings, discharge letters, and prescriptions. The system complies with European 
Union guidelines on the use of data for medical research and has been proven valid for phar-
maco-epidemiological studies. 15 The scientific and ethical advisory board of IPCI approved this 
study (nr 07/55 2011).
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Study cohort
The dynamic study cohort source population comprised all children aged 5-18 years with a 
database history of ≥12 months (n=176,516). The study period was from the first of January 
2000 until the first of January 2012. Follow-up started on the first of January 2000, the date on 
which the required 1 year of follow-up was obtained, or on their 5th birthday, whichever came 
last. All patients were followed from study entry until the end of the study period, until they 
left the GP practice or until their 18th birthday, whichever occurred first. 
Asthma Case identification and validation
All children who were 5-18 years old during the study period with physician diagnosed asthma 
were identified. First, all potential asthma cases were retrieved by an automated search on 
ICPC (International Classification of Primary Care) asthma codes (‘R96’) and free text relevant 
to asthma. Asthma was defined as “definite” if diagnosed by a paediatrician. “Probable” asth-
ma was defined as asthma diagnosed by the GP with at least 2 additional records of asthma 
diagnoses or prescriptions of asthma medications in the 1 year following the initial diagnosis 
of asthma. If at any time during the follow-up asthma was diagnosed, the child was considered 
asthmatic from date of first diagnosis until the end of follow-up. As this broad automated 
search resulted in a high number of potential asthma cases (n=63,618), machine learning 
was used to facilitate the validation, as described in detail elsewhere. 16 The validity of this 
machine learning approach was reasonable good with a sensitivity of 95% and a specificity of 
67% within the testset of 5,032 manually annotated medical records. 16 For verification of the 
total asthma cohort, the medical records of all predicted definite and 25% of probable asthma 
cases were manually reviewed by one of the authors (ME). 
Prescriptions
To describe patterns of use, all prescriptions for asthma drugs were selected by ATC code R03. 17 
These prescriptions were further categorized into SABA, LABA, SAMA, ICS, fixed combination 
of ICS+LABA (FDC-ICS/LABA), cromones, xanthines, or LTRA. (Detailed overview in online 
Table 1) Further analysis did not include SAMA, cromones or xanthines, due to low numbers. 
Detailed information on further categorization of type and dose of ICS, adapted from the GINA 
guidelines, is showed in online Table 2. 
Annual user prevalence rates of asthma drugs were determined by the number of children that 
received ≥1 prescription of that drug in a given calendar year divided by the number of per-
son-years in that calendar year. Annual user prevalence reflects the proportion of children that 
used a specific drug class in a specific year. If a child received prescriptions of 2 drug classes, 
this child contributed to both drug classes. If >1 prescription of the same drug was used in 1 
year, this was only counted once in the numerator. Prevalence of use was stratified by calendar 
year, age (assessed on the 1st January of each follow-up year), and gender. 95% confidence 
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intervals (CI) around the prevalence were estimated based on the Poisson distribution. 18 
The overall month - and seasonal user rates over 2000-2012 were determined by the total 
number of children receiving ≥1 prescription of ICS or FDC-ICS/LABA in a given month (or 
season) summed for 2000-2011 divided by the number of person-months in that month (or 
season) summed for 2000-2011. 
Among ICS users, the proportion of FDC-ICS/LABA prescriptions among the total ICS prescrip-
tions was calculated per calendar year. Single ingredient LABA (SI-LABA) prescriptions were 
further classified as ‘SI-LABA without ICS’ or ‘SI-LABA with ICS’, either in 1 inhaler or in 2 
separate inhalers. 
Adherence
Adherence to asthma medication was assessed using both the medication possession ratio 
(MPR) and the controller to total ratio (CTT). The MPR for each class of controller medication 
was calculated by dividing the total number of days’ supply of that medication prescribed by 
the total days of follow-up, multiplied by 100, and expressed as a percentage: MPR = (Days of 
drug supply / (follow-up (days))) x 100. Where days of drug supply equals the number of days 
that prescriptions should last based on the dosing instructions of the prescriber (Days of drug 
supply = number of doses in a prescription divided by the dosing frequency). The follow-up 
period was the interval between first and last prescription for that patient. MPR was truncated 
to 200 if MPR>200. MPR could be higher than 100% when there was overlap in prescriptions 
or in case patients use a higher dose (number of puffs/day) than originally prescribed. 
Adherence assessed by CTT was defined as [prescriptions of controllers] divided by [prescrip-
tions of controllers + relievers] as described by Schatz et al.19 Patients with a ratio of ≥0.5 or 
higher were classified as high-ratio patients, and those with a ratio of <0.5 were classified as 
low-ratio patients.
To compare characteristics of high vs. low adherent children, we selected all children with ≥2 
ICS prescriptions and at least 2 years of follow-up, follow-up was censored at 2 years. In these 
children, the ICS MPR was calculated and patient characteristics of the highest quartile (Q4) 
were compared to the lowest quartile (Q1). 
Co variables
To analyse differences in adherent and non-adherent children, the following characteristics 
were collected: gender, age at start ICS/LABA, severe asthma exacerbation rate, specialist visit 
rate, number of infections during follow-up, and underlying comorbidity of eczema, conjunc-
tivitis or allergic rhinitis. Asthma exacerbations were defined as emergency department visits 
or hospitalizations or oral corticosteroid prescriptions, all for asthma. Asthma exacerbations 
within 7 days after a previous exacerbation were counted as only 1 exacerbation.
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Statistical analysis
Descriptive analyses were used to describe patient characteristics. Chi square test or Mann-
Withney-U-tests or Poisson regression models were used to test the differences/rates in char-
acteristics/rates between subgroups e.g. adherent and non-adherent groups, and SI-LABA vs. 
SI-LABA+SI-ICS groups. Kruskal-Wallis test was used to test differences between MPRs. Pois-
son regression models were used to fit annual ICS user rates over calendar time. A p-value of 
<0.05 was considered statistically significant. Analyses were conducted using SPSS for Win-
dows version 20.0 (SPSS INC, Chicago, IL, USA) and Episheet. 18
RESULTS
The source population comprised 176,516 children between 5-18 years during the study peri-
od. Upon automated text validation, these were classified in 16,139 asthma cases. After manu-
al validation, the final asthma cohort consisted of 14,303 children (3,340 definite and 10,963 
probable asthma cases according to the predefined algorithm as described above) with 35,118 
PY of follow-up. Baseline characteristics of the asthma cohort are described in Table 1. 
During 2000-2012 children with asthma mainly received prescriptions for SABA (38 users/100 
PY) and ICS (31 users/100 PY). Detailed numbers are reported in online Table 3. 
Asthma drug prescriptions were most frequent in the younger age categories with no differenc-
es between boys and girls up to the age of 13 years. From the age of 13 onwards, SABA, ICS 
and FDC-ICS/LABA were more prescribed to girls (Figure 1). Most children were prescribed 
Fluticasone propionate in low or middle dose, only 10% received a high dose. (online Table 4) 
With regard to type of device, most children between 5-8 years of age used an MDI to inhale 
ICS, more details are shown in online Table 5. Concomitant prescriptions of LTRA during ICS 
were observed in 216 children, during FDC ICS/LABA in 197 children and during LABA in 31 
children (online Table 6). None of the GPs prescribed or continued Omaluzimab for a child in 
the asthma cohort. 
Total asthma cohort - n (%)
Subjects (n) 14,303
Gender (male) 8,400 (59%)
Age at cohort entry (years)(mean, sd) 10.2 (4%)
Follow-up time after asthma diagnosis (years)(mean, sd) 2.5 (2%)
Eczema (till cohort entry) 3,852 (27%)
Allergic rhinitis (till cohort entry) 2,541 (18%)
Conjunctivitis (till cohort entry) 821 (6%)
Lower economic status (ever) 501 (4%)
Table 1 - Baseline characteristics for the total asthma cohort.
n = number of subjects, sd = standard deviation
113Asthma treatment
4.1
We observed a seasonal pattern with more prescriptions for ICS during the winter and a peak 
in September, this pattern was observed in all calendar years and for the total study period. 
(online Figures 1 and 2) Poisson regression analyses showed that the proportion of ICS users 
decreased with increasing calendar time. (p<0.001) The use of SI-ICS decreased, while the 
proportion of FDC-ICS/LABA users increased over time from 2 users/100 PY in 2000 to 10 
users/100 PY in 2011. (Figure 2)
The overall annual prevalence of LABA use was 27.8/100 PY of which the majority was FDC-
ICS/LABA (24.3/100 PY). LABA was more prescribed to older children and to girls, especially 
after the age of 13 years. The prevalence of SI-LABA + SI-ICS (as 2 separate inhalers) was 
2.9/100 PY and of SI-LABA use without concomitant ICS was 1.8/100 PY. (Figure 3) Use of 
SI-LABA decreased over time with prevalence rates of 1.44/100 PY (SI-LABA without ICS) and 
1.52/100 PY (SI-LABA with ICS) in 2011. Of all children receiving SI-LABA (n=305), 122 chil-
dren (40%) had no concomitant ICS use. They had less severe asthma, were older at the first 
LABA prescription (13.5 vs. 11.5 years, p<0.001), had fewer specialist visits and fewer severe 
asthma exacerbations compared to children with SI-LABA with ICS. (online Table 7)
Figure 1 - Asthma drug use per 100 PY in the total asthma cohort by age (years) and gender.
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Figure 2 - Annual prevalence of total ICS use categorized into SI-ICS and FDC-ICS/LABA users per 100 PY in children with 
physician diagnosed asthma and treated during follow-up in 2000-2012.
Figure 3 - All LABA users (SI-LABA without SI-ICS, SI-LABA with SI-ICS, and FDC- ICS/LABA) per 2 years of age stratified by 
gender, in children with physician diagnosed asthma and treated during follow-up.
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Adherence
Median MPRs for LTRA, FDC-ICS/LABA, and ICS were significantly different, with MPRs 77.1, 
61.3, and 56.0%, respectively. (p<0.001) (Figure 4) Good adherence (MPR>0.8) was ob-
served in almost 46% of the LTRA users and in 34% of the FDC-ICS/LABA users. For ICS, only 
33% of the users had good adherence (MPR≥0.8). 
Univariate Poisson regression analyses of users with ≥2 prescriptions of ICS and 24 months 
of follow-up (n=2,397) showed that patients with a high MPR (Q4 MPR>87) were younger 
at start of ICS, had more specialist visits and more severe asthma exacerbations compared to 
patients with a low MPR (Q1 MPR<37). Differences were similar when comparing patients 
with MPR≥0.8 to MPR<0.8. (Table 2)
The CTT ratio was calculated for all patients using controllers and/or relievers. Sixty percent 
of the patients (n=5,519) had a high CTT ratio (CTT≥0.5) and used a mean of 5.0 controllers, 
whereas patients with a low CTT ratio used 1.5 controllers. Patients with a good adherence 
(CTT ratio>0.5) were younger at asthma diagnosis (c², p=0.004) and at start of medication 
(p=0.009) compared to patients with a low CTT ratio.
DISCUSSION
This longitudinal, population based cohort study, covering a study period of 12 years, provides 
annual- and seasonal prescription patterns for asthma medication in children in the Nether-
lands. SABA and ICS were most frequently used, whereas SI-LABA was rarely prescribed and 
decreased over time. Adherence to asthma medications was suboptimal as only 31% of the ICS 
users had an MPR>0.8. Adherence to LTRA was significantly higher than to ICS, which may be 
due to the fact that this is oral medication, also ‘steroid phobia’ may play a role.
ICS was the most frequently prescribed controller medication. SI-ICS decreased over time, 
whereas the use of FDC-ICS increased. Only 1.8 users/100 PY received SI-LABA without con-
comitant ICS use, which is comparable to other studies. 20-22 SI-LABA as monotherapy does not 
comply with current national 23, 24 and international asthma guidelines. 25 
We observed seasonal patterns in ICS use, with the lowest rate in august and an increase in 
the winter. After checking our data, this coincides with severe asthma exacerbation patterns in 
this asthma cohort. 
Overall, the prevalence of ICS prescriptions decreased over time. This might partly be caused 
by the fact that recent asthma guidelines advise to taper ICS to the minimum effective dose or 
to stop if possible. 25 
Adherence to controller medications was low, in line with recent literature. 26 Actual MPRs are 
probably even lower, as we only considered prescription data and not dispensing data, and 
even if all prescribed medication would be dispensed, not all dispensed medication would be 
actually (correctly) taken. It was emphasized by the European Respiratory Society Task Force 
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Figure 4 - Medication Possession Ratio (MPR) boxplot by drug.
⌷ = 25th-75th percentile, ⊢⊣⊢⊣ = minimum-median-maximum, ◆ = mean
MPR Q1
MPR<37
MPR Q4
MPR>87 p-value MPR<0.8 MPR≥0.8 p-value
Number of patients (n) 599 598 1,659 738
Gender (boys) 59% 56% ns 60% 56% ns
Age at start ICS (years, sd) 10.0 (3.4) 9.1 (3.4) <0.001 9.5 (3.3) 9.1 (3.4) 0.001
Age at start asthma drug 
(years, sd)
7.9 (3.9) 7.0 (3.9) <0.001 7.4 (3.8) 7.0 (3.9) 0.001
Eczema* 184 (31%) 212 (36%) ns 552 (33%) 261 (35%) ns
Allergic rhinitis* 159 (27%) 165 (28%) ns 423 (26%) 208 (28%) ns
Conjunctivitis* 56 (9%) 42 (7%) ns 148 (9%) 54 (7%) ns
Children with ≥1 specialist 
visits during follow-up 
33 (6%) 91 (15%) <0.001 152 (9%) 114 (15%) <0.001
Children with exacerbation 
during follow-up
26 (4%) 42 (7%) <0.05 80 (5%) 49 (7%) ns
rate/PY 
(95% CI)
rate/PY 
(95% CI)
Poisson RR 
(95% CI)
p-value rate/PY 
(95% CI)
rate/PY 
(95% CI)
Poisson RR 
(95% CI)
p-value
Specialist visits during 
follow-up ^
0.04
(0.03-0.05)
0.12
(0.10-0.14)
1.50
(1.34-1.68)
<0.001 0.06
(0.06-0.07)
0.12
(0.10-0.14)
1.23
(1.15-1.31)
<0.001
Severe asthma exacer-
bations during follow-up^^ 
0.03
(0.04-0.06)
0.05
(0.02-0.04)
1.21
(1.05-1.40)
0.009 0.03
(0.03-0.04)
0.05
(0.04-0.06)
1.14
(1.03-1.26)
0.012
Table 2 - Characteristics of children with >1 ICS prescription and 24 months of follow-up comparing Q1 vs. Q4 MPR and 
MPR<0.8 vs. ≥0.8. 
Ns = not significant, Sd = standard deviation, 95% CI = 95% confidence interval
* diagnosed prior to 1st ICS prescription
^ Specialist visit rate = number of visits to the specialist (for asthma) per person-year 
^^ Exacerbation rate = number of severe asthma exacerbations (hospitalizations, ED visit or corticosteroid course for asthma) 
per person-year 
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that Correct inhaler technique is one of the prerequisites of successful asthma treatment and 
this inhalation technique should be taught, taught back and checked . 27 Internet based training 
offers possibilities to enhance correct inhalation techniques, e.g. the webpage ADMIT, this is a 
European place for information about obstructive pulmonary diseases and different treatment 
options with focus on inhalation therapy. Here patients as well as health care professionals can 
find various supports in order to achieve asthma control. Recently, a Dutch website on inhala-
tion techniques in the Netherlands has been launched. 28
The fact that the adherence in our study is relatively low might be due to the chosen methodol-
ogy (=MPR) to assess adherence. Children might be adherent to ICS, stop due to few symptoms 
(but use rescue medication as needed) and be adherent to ICS again when symptoms return.
We performed a cluster analysis were we checked the timing of prescriptions. Four clusters 
were identified, but none of these clusters identified patients with periodic asthma (periodic 
prescribing at regular time intervals). Use of MPR to assess adherence might probably be too 
conservative in patients with periodic asthma. Future studies should investigate optimal adher-
ence measures based on asthma phenotypes. 
The low adherence to ICS can also be explained by the fact that in contrast to guidelines, many 
children use ICS as rescue medication, and that as a result of improper ICS prescribing, where 
patients are not asked to return for a follow-up visit, children who need long-term ICS therapy 
experience unmonitored discontinuation of therapy without corresponding order from their 
physician. 29
Variations in adherence rates have been reported due to different study designs, adherence 
measures, and populations studied. 8 Characteristics of children with good adherence were 
compatible with more severe asthma, suggesting that adherence is driven by treatment need 
or intensity of medical follow-up. The design of our study was not suitable to investigate the 
association between adherence and exacerbations as we did not censor on severe asthma 
exacerbation. 
Knowledge about asthma drug use and real life adherence may offer opportunities to optimize 
asthma treatment in children.
Promising results have been shown by targeting new adherence interventions, like speech rec-
ognition telephone calls, or by other e-health tools, or disease management programmes. 30-32 
Another opportunity to improve adherence is to enhance the promising pharmacist-led target-
ed interventions in patients with asthma. In the Netherlands, the pharmacist’s role is shifting 
from a compounder, dispenser, and specialist of medication toward a patient-oriented health-
care professional. 33
A recent published review presents seven national asthma programmes across Europe, includ-
ing the asthma programme of the Netherlands. 34 A programme was defined as a well described 
activity, developing strategies to reduce asthma mortality and morbidity across Europe. Pub-
lished data of the three evaluated programmes showed that, thanks to rigorous efforts, it is 
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possible to improve patients’ quality of life and reduce hospitalisation, asthma mortality, sick 
leave and disability pensions. The direct and indirect costs, both for the individual patient and 
for society, can be significantly reduced.
The main strengths of our study are the large population based cohort with detailed informa-
tion on prescriptions and comorbidities over a long study period. The design precluded selec-
tion bias due to non-responder or recall bias, and because patients were registered with one GP, 
where data were collected as part of routine patient care, irrespective of any research question. 
In addition, we were able to study age- and gender-specific asthma treatment patterns as 
the database captured all GP prescriptions with detailed information on dosage and duration. 
Limitations are the lack of dispensing data and actual drug intake. Our adherence rates might 
be underestimated as specialist prescribing is not routinely captured in the database. However, 
this bias is probably non-substantial as GPs play a central role in the care of patients and pre-
scriptions initiated by the specialist are often continued by the GP. 35
CONCLUSION
In Dutch primary care children with asthma were mainly prescribed SABA and ICS. ICS adher-
ence was low, with only 31% of the patients having an MPR≥0.8. Characteristics of children 
with good adherence were suggestive of more severe asthma, and driven by treatment need or 
intensity of medical follow-up. These findings indicate that there is room for improvement of 
adherence to treatment, especially in children with milder forms of asthma. 
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SUPPLEMENTS
Online Table 1 - ATC codes grouped by drug class and drugname.
ATC code Drug class Drug ATC code Drug class Drug
R03AC02 SABA aerolin R03BB01 SAMA atrovent
R03AC02 SABA airomir R03BB01 SAMA ipratropium
R03AC02 SABA salbutamol R03BB01 SAMA ipraxa
R03AC02 SABA ventolin R03BB04 LAMA spiriva
R03AC03 SABA bricanyl R03BB04 LAMA tiotropium
R03AC03 SABA terbutaline R03BC01 cromones cromoglicinezuur
R03AC04 SABA berotec R03BC01 cromones lomudal
R03AC04 SABA fenoterol R03BC03 cromones nedocromil
R03AC12 LABA salmeterol R03BC03 cromones tilade
R03AC12 LABA serevent R03CC02 SABA salbutamol
R03AC13 LABA atimos R03CC02 SABA ventolin
R03AC13 LABA foradil R03CC03 SABA terbutaline
R03AC13 LABA formoterol R03DA04 xanthines theofylline
R03AC13 LABA oxis R03DA04 xanthines theolair
R03AK03 fixb2atro berodual R03DC03 LTRA montelukast
R03AK03 fixb2atro fenoterol/ipratropium R03DC03 LTRA singulair
R03AK04 fixb2atro combivent
R03AK04 fixb2atro salbutamol/ipratropium
R03AK06 FDC-ICS/LABA salmeterol/fluticason
R03AK06 FDC-ICS/LABA seretide
R03AK07 FDC-ICS/LABA budesonide/formoterol
R03AK07 FDC-ICS/LABA beclometason/formoterol
R03AK07 FDC-ICS/LABA foster
R03AK07 FDC-ICS/LABA symbicort
R03AK07 FDC-ICS/LABA sinestic
R03BA01 ICS aerobec
R03BA01 ICS becloforte
R03BA01 ICS beclometason
R03BA01 ICS becotide
R03BA01 ICS beclodin
R03BA01 ICS qvar
R03BA02 ICS budesonide
R03BA02 ICS pulmicort
R03BA05 ICS flixotide
R03BA05 ICS fluticason
R03BA08 ICS alvesco
R03BA08 ICS ciclesonide
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ICS ATC
(single)
ATC 
(fixed combination)
Children 5-11 years
(dose in microgram)
Adults and adolescents
(dose in microgram)
low medium high low medium high
Beclomethasone dipropi-
onate (HFA MDI)
R03BA01 R03AK08 50-100 >100-200 >200 100-200 >200-400 >400
Beclomethasone (DPI) R03BA01 R03AK08 100-200 >200-400 >400 200-500 >500-1000 >1000
Budesonide (MDI) R03BA02 Not available 100-200 >200-400 >400 200-400 >400-800 >800
Budesonide (DPI) R03BA02 R03AK07 100-200 >200-400 >400 200-400 >400-800 >800
Budesonide (NEB) R03BA02 Not available 250-500 >500-1000 >1000 500-1000 >1000-2000 >2000
Ciclesonide (HFA MDI) R03BA08 Not available 80 >80-160 >160 80-160 >160-320 >320
Fluticasone propionate 
(DPI)
R03BA05 R03AK06, R03AK10, 
R03AK11
100-200 >200-400 >400 100-250 >250-500 >500
Fluticasone propionate 
(HFA MDI)
R03BA05 R03AK06, R03AK10, 
R03AK11
100-200 >200-500 >500 100-250 >250-500 >500
Fluticasone (NEB) R03BA05 Not available 100-250 >250-500 >500 100-250 >250-500 >500
Online Table 2 - Categorization of ICS doses into ‘low’, ‘medium’ and ‘high’ (adapted from GINA guidelines).
Online Table 3 - Prevalence of asthma drug use per 100 PY in the asthma cohort by age and gender.
 ICS LTRA SABA LABA FDC ICS/LABA
 Age Boys Girls Boys Girls Boys Girls Boys Girls Boys Girls
5 75.0 78.5 3.5 3.2 81.3 86.4 1.0 1.9 7.3 6.3
6 46.9 47.6 2.2 2.6 47.2 45.3 1.2 0.9 3.9 5.6
7 44.0 43.1 2.5 3.2 43.2 41.4 1.4 1.1 6.4 7.4
8 40.9 38.3 2.7 2.3 42.2 37.5 1.7 1.1 8.3 7.5
9 37.9 35.7 2.9 2.6 43.0 38.1 1.8 1.6 10.1 9.2
10 34.7 35.4 3.0 3.5 41.9 39.4 2.2 1.8 11.0 9.6
11 31.9 31.5 2.7 2.8 39.8 38.5 2.0 1.7 10.7 10.9
12 31.7 30.5 2.8 2.7 40.4 39.7 1.9 2.9 10.9 11.7
13 26.9 26.6 2.8 3.0 38.8 39.0 1.6 2.5 11.9 11.5
14 24.5 24.0 2.5 2.1 35.5 39.0 2.4 2.7 11.8 12.7
15 21.4 24.5 2.7 2.0 33.8 41.2 1.7 2.8 12.5 14.6
16 18.6 21.5 2.6 2.3 32.1 40.4 1.3 3.0 12.1 15.4
17 17.7 23.7 2.2 2.9 30.8 40.7 1.9 2.9 13.4 17.9
18 20.8 31.9 1.9 3.8 33.4 53.9 2.1 4.0 15.2 24.0
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Drug 
(≥1 prescription during follow-up)
Children 
(number)
ICS 5,749
FDC-ICS/LABA 1,987
LTRA 507
LABA 386
SABA 7,544
Other asthma drugs (R03) 448
Concomitant drugs  
ICS+LTRA 216
FDC-ICS/LABA+LTRA 197
LABA+LTRA 31
Online Table 5 - Categorization of children with prescriptions per device stratified by age category.
Online Table 6 - Number of patients with prescriptions per medication class and with prescriptions with concomitant use of 
LTRA.
ICS = inhaled corticosteroids, LTRA = leukotrienreceptorantagonist, FDC = fixed dose combination, LABA=long-acting β2-ago-
nist, SABA= short-acting β2-agonist
* patients could belong to more than 1 age category during the study period.
Pt = patient, % = percentage, n = number, ICS = inhaled corticosteroids, MDI = metered dose inhaler, DPI = dry powder inhaler, 
NEB = nebulizer
Type Device ICS Patients (n) Prescription (n)
Proportion prescriptions
per age category (%)
5-8 years DPI 463 1,337 12
MDI 2,674 9,407 87
NEB 16 57 1
total 10,801
9-12 years DPI 1,131 3,778 48
MDI 1,449 4,015 51
NEB 9 14 0
total 7,807
12-15 years DPI 1,513 4,591 67
MDI 859 2,215 32
NEB 13 22 0
Total 6,828
15-18 years DPI 1,537 4,736 80
MDI 480 1,160 20
NEB 5 11 0
total 5,907
total 31,343
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Online Table 7 - Children with SI-LABA; categorized in patients with and without concomitant SI- ICS.
Ns = not significant, 95% CI = 95% confidence interval
Specialist visit rate* = number of visits to the specialist (for asthma) per person-year 
Exacerbation rate** = number of severe asthma exacerbations (hospitalizations, ED visit or corticosteroid course for asthma) 
per person-year 
* The total number of patients within the different asthma therapies is not equal to the number of patients receiving asthma 
therapy, as patients can use several therapies during follow-up.
Online Figure 1 - ICS (SI-ICS plus FDC-ICS/LABA) user rate per month (per 100 person months) per calendar year during the 
study period 2000-2012.
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no SI-ICS SI-LABA+SI-ICS RR* p-value Poisson
Number of patients (n) 122 183 X2 p<0.001
Age first LABA prescription (years, sd) 13.5 (3.1) 11.5 (3.8) X2 ns
Gender (boys) (%) 47% 55%
Specialist visit rate* till first LABA
(rate/PY, 95% CI)
0.12 (0.07-0.19) 0.34 (0.25-0.54) 2.92 (1.60-5.31) p<0.001
Specialist visit rate* after first LABA 
(rate/PY, 95% CI)
0.13 (0.09-0.18) 0.27 (0.23-0.33) 2.13 (1.42-3.20) p<0.001
Exacerbation rate** till first LABA
(rate/PY, 95% CI)
0.08 (0.04-0.15) 0.55 (0.43-0.69) 6.57 (3.40-12.72) p<0.001
Exacerbation rate** after first LABA 
(rate/PY, 95% CI)
0.04 (0.02-0.07) 0.09 (0.07-0.12) 2.57 (1.21-5.50) p=0.015
Online Figure 2 - Total ICS (SI-ICS plus FDC-ICS/LABA) user rate per month (per 100 person months) and per season during 
the study period 2000-2012.
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ABSTRACT
  BACKGROUND   The benefits of drug therapy for asthma have been well established, but ad-
herence to treatment is poor, and this might be associated with an increased risk of asthma 
exacerbations.
  AIMS   To review the literature on the association between adherence to asthma controller 
treatment and risk of severe asthma exacerbations in children and adults.
  METHODS   A systematic literature search in PUBMED, EMBASE and Web of Science from in-
ception until January 2014 was performed. Studies were included if data on the association 
between medication adherence and severe asthma exacerbations were presented. Quality was 
assessed using a modified version of the Newcastle-Ottawa Scale. 
  RESULTS   The search yielded 2,319 unique publications of which 23 met the inclusion criteria 
and underwent data extraction and quality scoring. High levels of heterogeneity across studies 
with regard to adherence and exacerbation measurements, designs and analysis precluded a 
formal meta-analysis. Although effect measures varied widely, good adherence was associated 
with fewer severe asthma exacerbations in high quality studies. 
  CONCLUSIONS   Good adherence tended to be associated with lower risk of severe asthma ex-
acerbations. Future studies should use standardized methodology to assess adherence and 
exacerbations, and should consider inhaler competence.
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INTRODUCTION
Asthma is a chronic inflammatory airway disease with a high prevalence, around 10% in chil-
dren and 5% in adults in Western countries. 1, 2 Asthma is a major cause of disability, health 
resource utilization, and reduces quality of life. 3 This is partly caused by asthma exacerbations 
which have a huge impact on patients and their families. To minimize asthma exacerbations, 
treatment should be stepwise adjusted, driven by the patient’s asthma control level. 4 Asthma 
treatment includes daily use of a controller drug and as needed use of short-acting bronchodi-
lators for quick symptom relief. 5 Adherence to treatment is essential to optimize the benefits of 
therapy. Poor adherence has been associated with outcomes like mortality 6, asthma symptoms 7, 
(in)direct costs of care 3 and quality of life. 8 In asthma, adherence to treatment tends to be poor 
with rates of less than 50% in children 9 and 30-70% in adults 4, 10, 11, depending on country, 
age, gender, and ethnicity. 12 These low adherence rates have been attributed to safety concerns 
about inhaled corticosteroids (“steroid phobia”) by both the patients and the caregivers. 13 
Indeed, use of ICS has been associated with growth impairment in children and other systemic 
adverse effects, such as an increased risk of pneumonia. 14 In addition, most ICS need to be 
administered twice daily, which increases the risk of poor adherence compared to once daily 
administration. 5 It has been suggested that poor adherence to ICS increases the risk of exacer-
bations. However, the literature on this topic is conflicting. With this systematic review, we aim 
to provide a critical appraisal of the literature examining the association between adherence to 
asthma controller therapy and the risk of severe asthma exacerbations in children and adults. 
METHODS
Electronic searches
An extensive electronic literature search was conducted to identify all relevant articles, pub-
lished from inception up to the 1st of January 2014, as indexed by PUBMED, Web of Science 
and EMBASE. (Supplementary data Table 1) Article reference lists were searched for additional 
potentially relevant articles. 
Review criteria and data extraction
All original articles were considered, excluding case reports, audits, guidelines, editorials, man-
agement/implementation strategies, conference abstracts and study protocols. We excluded 
animal studies. No limits were set on study design, sample size, location, or follow-up. Eligible 
patient populations included both children and adults using asthma controller therapy; ICS, 
long-acting β2-agonists (LABAs), or fixed combination therapies of LABA and ICS. Because of 
incomparability, we excluded studies that looked at leukotriene receptor antagonists or xan-
thines only.
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Studies were included if they met the following 3 criteria;
(1) The exposure variable of interest was medication adherence to asthma controller therapy. 
Medication adherence is an umbrella term that encompasses both the concepts of compliance 
and persistence. Compliance is defined as the extent to which a patient acts in accordance 
with the prescribed interval and dosing regimen, and persistence, as the duration of time from 
initiation to discontinuation of therapy, according to the International Society for Pharma-
coeconomics and Outcomes Research (ISPOR). 15
Only studies with objectively measured adherence, including electronic monitoring devices, 
pill counting, and prescription/refill data were included. Adherence measured through sub-
jective measures, such as patient self-reports, questionnaires and physician’s judgments were 
excluded as we considered these to be less reliable and not comparable to objective adherence 
measures. 
(2). The outcome of interest was severe asthma exacerbation. According to the joined Global 
Initiative for asthma (GINA) 4, American Thoracic Society (ATS) 16 and European Respiratory 
Society (ERS) 17 asthma guidelines, this outcome was defined as “the occurrence of either an 
asthma-related hospitalization or visit to the emergency department (ED) or an urgent care 
facility, leading to treatment with systemic (oral, intramuscular, or intravenous) corticosteroids 
for at least 3 days”. 
(3) Evaluation of the association between adherence and exacerbations as primary or second-
ary endpoint. 
The first author (ME) assessed the eligibility of studies from their titles and abstracts, excluding 
those that were not relevant. The full texts of eligible papers were assessed independently 
for eligibility by two authors (ME and KV) and data were extracted into a customized data 
extraction Excel form. Third party adjudication was foreseen in case of disagreement.
Assessment of methodological quality
All included studies underwent a formal evaluation according to the Newcastle Ottawa Scale 
(NOS), a set of criteria established and used in previous systematic reviews of observational 
studies 18, 19, that was modified for the purpose of this review. 
All studies were independently rated by 2 reviewers (ME and KV), to assess the quality based 
on 5 parameters: overall design, selection of participants, exposure assessment, outcome as-
certainment and control for extraneous factors. Each parameter received 0, 1, or 2 points. 
(Supplementary data Table 2). The total score represented the sum of all 5 parameters. This 
score was used as relative measure of data quality.
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Data analysis
Pooling of studies was considered in case of adequate similarity, with respect to exacerbation 
definitions, adherence definitions, and methods to assess the relationship between adherence 
and exacerbations. In case of heterogeneity, the results of each study were reported individually.
RESULTS
Overview of the included studies
The search strategy identified 2,319 articles. Upon title and abstract review, 2,268 of these 
were excluded, mainly for the following reasons: lack of information on medication adherence, 
no severe asthma exacerbation or no evaluation of the relation between adherence and exac-
erbation (>1000), articles on intervention, management or implementation strategies (370), 
audit/guidelines (122), focus on other diseases (139), animal studies (106), cell biology/im-
munology (62), no original articles (40). A total of 23 articles were finally included in the 
review. (Figure 1) 
Details of the 23 studies are shown in Table 1. Briefly, all 23 studies were published between 
1993 and 2013. The sample sizes ranged from 24 to 97,743 individuals. 9, 20 Two studies were 
multicenter, 7 were single center and 14 were based on healthcare (pharmacy/insurance/
claim) databases. Most studies were from the United States. The included studies mainly used 
a cohort design (n=19) with the remainder utilizing a cross-sectional (n=1) 9, case control 
(n=1) 21 or randomized design (n=2). 22, 23 Studies analysed adherence rates over a follow-up 
period ranging from 13 weeks (9) to 4 years. 23 Ten studies included only children, 7 both 
adults and children/adolescents and 6 studies only adults. 
Measures of medication adherence
The assessment of medication adherence varied across studies. Most studies (n=11) used the 
Medication Possession Rate (MPR) as measure which is the number of days of medication 
supplied divided by the number of days between the first and the last refill. 24 Most studies 
chose a fixed time frame for the refill interval rather than using the last refill as the end point 
for the refill interval and did not exclude the last refill. MPR calculated across multiple refills 
is also called the continuous measure of adherence (CMA). In addition to the MPR, 2 studies 
also calculated a controller-to-total- ratio. 25, 26 Williams et al. used an unique method to cal-
culate adherence, by calculating a moving 6-months-average ICS adherence for each day of 
follow-up. 27 Furthermore, 6 studies used number of (requested) refills in a certain period to 
assess adherence. Of the remaining studies, 3 used canister weighing/counting and 3 used 
electronic monitoring via a specific device. 
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Measures of severe asthma exacerbations
Of the 23 studies using objective measures to assess adherence, 5 defined exacerbation as 
emergency department (ED) visit and/or hospitalization and/or OCS, 16 defined exacerbation 
as 2 out of 3 criteria. Five studies defined the need of OCS as a separate outcome. Only one 
study had need of OCS as the only outcome. 
Asthma diagnosis 
In 4 studies, the asthma diagnosis was based on physician diagnosis. In the remaining studies, 
diagnoses were based on disease codes (ICD-9) (n=9), disease codes and prescriptions (n=2), 
asthma controller therapy prescriptions (n=3), guidelines (n=4), or on study specific asthma 
definitions (n=1).
Figure 1 - PRISMA(63) flow diagram describing the steps for including studies in the review.
Pubmed
(n = 1525)
Web of Science
(n = 1074)
Embase
(n = 1267)
Prescriptions / ﬁlls 
(n = 17)
Electronic monitoring 
(n = 3)
Counting / weighning
(n = 3)
3866 titles
2319 unique titles and abstracts
identiﬁed and reviewed
34 studies under review
23 studies included in review
51 full text articles
obtained for screening
Subjective adherence (n = 9)
Xanthine levels (no ICS/LABA) (n = 2)
Removed duplicates
(n = 1547)
Not meeting inclusion criteria
(n = 2268)
Association not measured 
(n = 17)
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MAIN RESULTS: adherence and exacerbations
Due to differences in design, exposure, outcome, cut-off values, assessments and definitions, 
studies differed substantially in effect magnitudes and this precluded a formal meta-analysis 
with pooling of results. We therefore report the findings separately for each type of objective 
adherence measure. The order of reporting within each category is based on quality score, 
indicated with the letter q. We separately reported results for children and adults. Details of the 
23 studies included in the review are summarized in Table 1. The overall conclusions remained 
similar when papers with low quality (q≤6) were excluded.
An overview of the range of risk estimates, for those studies that reported risk estimates for the 
association between adherence and asthma exacerbation is shown in Figure 2 (for children) 
and Figure 3 (for adults). 
Objective adherence measurements
To assess overall treatment adherence 17 studies used refill data, of these 11 used MPR mea-
surements 20, 25-34 and 6 used number of prescription refills. 21, 22, 35-38 The remaining studies used 
either electronic monitoring devices (n=3) 9, 39, 40 or weighted canisters (n=3). 23, 41, 42
The overall treatment adherence was low in pediatric and adult studies. In children, adherence 
measured as average MPR was only 20%-33.9% for ICS. 31, 40 Number of prescription fillings 
over the course of 1 year ranged from 4.7 to 5.5 times for fluticasone. 22, 38 In adults, MPR for 
ICS ranged between 15 31, 32 and 54% 29.
Williams et al. demonstrated with a moving 6-months-average ICS adherence for each day of 
follow-up, that adherence to ICS medications began to increase just before the first asthma 
exacerbation, and continued to increase after the event. 27
Association between exacerbation and objective adherence in paediatric studies (refill data) 
Four out of 6 paediatric cohort studies using refill data reported that the risk of asthma exac-
erbation was 21-68% lower for children who were more adherent to their asthma controller 
medication compared to those who were less adherent. 25, 28, 31, 35 Rust et al. (q=8) observed 
this protective effect only if adherence was measured as controller to total ratio. In contrast, if 
adherence was measured as proportion of prescription days predicted (PPDC), lower PPDC was 
associated with lower ED/Hosp exacerbations. 25
A previous study in 2003 by Bukstein et al. (q=7) found no significant differences between flu-
ticasone and montelukast users (who were more adherent) in the frequency of asthma attacks 
requiring hospital admissions, acute office visits or ED-visits, but found a significant difference 
in the amount of OCS, which was higher for fluticasone than for montelukast. 22
Finally, Elkout et al. (q=7) reported that the risk of being prescribed OCS in the year after first 
prescription of controller therapy was 2-43% higher in children with adequate MPR than those 
with inadequate MPR, although this difference was not statistically significant. 30
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Author Q N outcome adherence OR adherent vs non adherent
Rust et al. 8 43.166 hosp Controller to total Ratio <0,5 or >0,5 0,59
ed Controller to total Ratio <0,5 or >0,5 0,83
Bukstein et al. 8 11.407 comb:ed/hosp prescriptions: ≥2 vs 1 0,60
Camargo et al. 8 10.976 comb:ed/hosp median MPR 0,08 is cut off 0,32
Herndon et al. 7 18.456 hosp MPR: >50% vs <19% 0,96
ed MPR: >50% vs <19% 0,56
Elkhout et al. 7 3.172 ocs MPR: 80-120% vs less 1,02
Author Q N outcome adherence OR adherent vs non adherent
Stern et al. 8 97.743 comb: ed/hosp 75th percentile vs less MPR 0,86
Delea et al. 8 12.907 ocs 25%increase mean MPR 0,97
comb: ed/hosp 25%increase mean MPR 0,90
Balkrishnan et al. 8 751 comb: ed/hosp 2 vs 0 refills 0,62
Williams et al. 8 405 OCS 25% increase median cma *RR 0.75
Williams et al. 8 298 comb:ed/hosp/ocs >75% vs <25% MPR 0,58
McMahon et al. 7 4.535 hosp+ocs 90 vs 1-89 days adh 1,02
hosp 90 vs 1-89 days adh 0,91
Smith et al. 7 3.013 comb: ed/hosp >80% vs <50% MPR 0,47
Figure 2 - Overview of pediatric studies publishing odds ratios (OR), sorted by quality score, number of participants and year 
published. (ctr = controller to total medication ratio, Comb = combined, ed = Emergency department visit for asthma, hosp = 
hospitalization for asthma, mpr = medication possession rate)
Figure 3 - Overview of adult studies publishing odds ratios (OR) or relative ratio (RR), sorted by quality score, number of 
participants and year published. (Comb = combined, perc = percentile, ed = Emergency department visit for asthma, hosp = 
hospitalization for asthma, mpr = medication possession rate, cma = cumulative medication availability, adh = adherence)
Association between exacerbation and objective adherence in adult studies (refill data)
Six out of 11 studies reporting on refills in adults showed that better adherence was associated 
with a reduced risk of severe asthma exacerbations. The 4 adult studies of good quality (q=8), 
reporting MPRs 20, 27, 29, 34 concluded that 25% increased adherence was associated with approx-
imately 10% reduction of severe exacerbations. (HRadj 0.89 27, RR 0.75 34, ORadj 0.90 29, ORadj 
0.86 20)Similar associations were reported by Mattke et al. (q=8) for LTRA users but not for 
ICS users. 32 Interestingly Balkrishnan et al. (q=8) showed in ICS users a 40% decreased risk 
of an ED/hospitalization in adherent vs. non-adherent elderly patients with chronic pulmonary 
illnesses, including asthma. 21
In contrast, five cohort studies (q=5-9) reported that the risk of OCS use and/or, hospitaliza-
tion and/or ED visits increased with better adherence. 26, 33, 36-38 
0 1 2
0 1 2
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Association between exacerbation and other measures of objective adherence
Three studies, 2 pediatric (q=5-9) and 1 adult (q=3) study, measured adherence by counting/
weighing pills and canisters at the pharmacy or outpatient clinic. 23, 41, 42 Only one of these re-
ported that adherence was associated with a reduced risk of asthma exacerbation. 41 
Three pediatric studies (q=3-6) measured adherence through electronic device monitoring, 
and all of these reported an association between low adherence and increased risk of severe 
asthma exacerbations; hospitalizations/ED visits 39, 40 or OCS 9. 
Association between OCS courses and objective adherence
Seven studies, 3 paediatric and 4 adult studies, assessed adherence in relation to the need of 
an OCS course as a separate outcome. In 4 of these (q=7-8), the need of OCS courses was 
inversely related to the controller adherence rate, both in children 22 and adults. 22, 27, 29, 34 In the 
remaining 3 studies (q=7-9) this association was not significant in 1 paediatric study 23 and in 
1 paediatric and 1 adult study an opposite, non-significant trend was observed. 30, 38 
DISCUSSION
To our knowledge, this is the first systematic review on the association between treatment 
adherence and severe asthma exacerbations. In the identified articles, we observed that low 
adherence was common. Despite heterogeneity amongst studies in terms of definitions of ad-
herence and asthma exacerbations, the majority of the high quality studies consistently report-
ed an association between low adherence and higher risk of severe asthma exacerbations, both 
in adults and children.
We identified important differences and limitations in the included studies. Firstly, the majority 
of studies were classified as moderate to low quality, largely because of flaws in the study 
methods, e.g. small sample sizes, which may compromise power, and cross sectional designs 
that are prone for bias. When excluding studies of poor or moderate quality (q<6) or excluding 
studies that used another design than cohort studies, the overall conclusion remained namely 
that good adherence was associated with fewer severe asthma exacerbations.
Secondly, included studies varied widely with regard to the definition of adherence. In-
deed, there is no standardized method to measure adherence, and each measure has its own 
strengths and limitations. 11, 43, 44 Objective measures are considered to be more reliable and 
accurate than indirect measures. 11 Electronic device monitoring is usually considered the gold 
standard because of a detailed assessment of adherence patterns. Although it has the benefit to 
identify and exclude “dumping” (deliberate emptying of inhaler before study visits to conceal 
non-adherence) from analyses, unfortunately such monitoring is expensive and often prone to 
device failure. 11, 33 
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The most cost-effective method to assess adherence is by self-report. However, the reliability of 
this method is questionable 45 as it is well known that patients over-report their adherence, 9, 11, 46 
even in a clinical trial setting. 23 Hence self-report was not included in this study.
The majority of studies calculated the MPR, a common way to measure medication adherence 
from claims or pharmacy data and has been found to be useful and reasonably accurate. 47, 48 
These data have the advantage to be easily accessible and inexpensive. 44 The drawback of 
these databases is that details about devices and day-to-day patterns of adherence are not 
always recorded. 11, 44 
In a pragmatic trial, patients are randomized within a real life setting which combines the 
sound methodology of RCT with daily practice enlarging the external validity of study results. 
This external validity is crucial for study investigating treatment adherence and associated 
factors. 49 
All methods have their sets of benefits and limitations. 50 It was suggested that the best design 
would probably be a combination of observational studies, pragmatic trials and RCTs, as all 
have advantages and drawbacks and they are not designed to answer the same questions. 51
Furthermore, the number of prescriptions is highly influenced by the level of asthma control. 
Indeed, patients appear to self-titrate their medication, showing more adherence to therapy 
with worse level of control. 26 Additionally the number of prescriptions is also influenced by the 
quality and reliability of physicians prescribing. The best method to tease this out is by using 
a ratio of long-term controller to total asthma medications, in which the denominator and 
numerator increase with increasing severity, but the numerator is more specifically reflective 
of adherence to therapy. 25
Even if studies used a common methodology to assess adherence, a wide variety in cut-off 
values to define “adherent patients” was observed. This arbitrary selection of adherence cut 
points is of considerable concern. Traditionally, medication adherence is dichotomized using a 
cut-off value (e.g. 80%) which is derived from studies in other chronic diseases, like HIV and 
hypertension 52, but not necessarily holds for asthma. 
We noted heterogeneity in outcome definitions, despite international guidelines on the defini-
tions and assessment of severe asthma exacerbations. 53 This might partly be explained by the 
data being used, e.g. pharmacy data not always have detailed information on disease codes 
and/or symptoms and diagnosis. As asthma is a difficult diagnosis, especially in children, risk 
of asthma misclassification, if based on prescription data only, is high.
It was quite remarkable that most studies did not attempt to measure whether and how medi-
cation was actually taken. This inhaler competence, the skill to inhale correctly, is particularly 
relevant for asthma medication as inhaling of drugs requires considerable skill and practice. 54 
Even if medication is taken daily, deposition in the lungs will be low in case of incorrect inha-
lation technique. 55 Newer devices such as breath-actuated inhalers and smart nebulizers, that 
impose breathing patterns and record lung deposition, may partly overcome this problem, but 
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still require a high level of co-operation. Smart-nebulizers are expensive and the experience in 
children with asthma is limited. 56
Still, all of these methods can overestimate adherence and there remains a number of complex 
issues affecting optimal medication use in children with asthma e.g. a lack of parental knowl-
edge about asthma medications, parental beliefs and fears, and the child’s self-image. (57) 
Some of the studies were at risk of bias and/or did not adjust for potential confounders. There 
are limitations arising from the observational nature of the included studies. One important 
bias is the ‘‘healthy adherer effect’’, where healthier people are predisposed to follow medical 
advice, because they are more concerned about their health. Other biases in this type of research 
are recall bias and observer/investigator bias when using questionnaires. 58 Furthermore, mis-
classification of adherence caused by dumping or over-reporting might have contributed to an 
underestimation of the role of adherence in mediating the observed treatment effects. 
“Asthma-severity” is an important confounder that is difficult to control for, as details on asth-
ma severity are often lacking in database studies. Other potential confounders are environmen-
tal factors such as pollution or smoking habits of the parents. 
Although the majority of papers of good quality indicated that higher levels of adherence were 
associated with a reduced risk of severe asthma exacerbations, this was not confirmed in all 
studies. Some studies even reported an inverse association between treatment adherence and 
risk of severe asthma exacerbations. This might be explained by the fact that the number of 
prescriptions was used as a proxy for adherence 33, 38, or because unusual cut off values for 
adherence were used. 37 Furthermore, there are a couple of general potential explanations for 
this inverse association. Treatment need is higher in patients with poorly controlled asthma, 
who are by definition at risk of asthma exacerbation. This higher need of treatment will result 
in increased prescription of asthma controller therapies with hence a higher MPR. 38, 45 Another 
explanation is self-titrating of medications; patients show more adherence to therapy with 
worse levels of control, thus positively influencing the MPR. 26 A third explanation could be 
the heterogeneity amongst asthma patients in treatment response; some patients reduce their 
prescribed controller medication without negative consequences 38 whereas other patients con-
tinue to have poor outcomes despite good adherence. 59 Additionally, there is no known dose 
of medication, or duration of treatment. Hence, the “low” adherence for some people may be 
adequate for them most of the time. 
The main strengths of this review are the comprehensiveness of the searches and our standard-
ized approach to study selection, data extraction and quality assessment.
However, our review has some limitations that need to be considered. Only published data was 
included, but the relatively small number of relevant publications suitable for this review war-
rants caution given the possibility of publication bias. Publication bias, is a type of error that 
may affect the results of a meta-analysis because studies with statistically significant positive 
findings are more likely to be published than studies with negative results. 60 However, given 
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the heterogeneity, inclusion of additional studies would have been unlikely to undermine our 
overall conclusion. 
Overall, this review highlights the importance of adherence to prevent severe asthma exacerba-
tions. This is in agreement with recent predictive models, which observed that improvements 
in medication adherence could lead to significant improvements in asthma outcomes. 61 It is 
clear that better studies about adherence treatments are needed but also more homogeneous 
outcomes and study design would be useful in order to reach conclusions.
For clinicians, it seems evident that efforts directed at improving, evaluating and measuring 
adherence should be a routine component of asthma care. 62 The recognition of non-adherence 
is an important first step towards optimal asthma control. 
CONCLUSION
Despite the limitations, in this review the majority of the papers of good quality indicated that 
higher levels of adherence were associated with a reduced risk of severe asthma exacerbations. 
Adherence to asthma controller therapy was generally very low.
To further elucidate the association between adherence and risk of asthma exacerbations, 
there is a need for new, well designed real-life prospective studies, using consistent standard-
ized measures for both treatment adherence (preferably electronic monitoring) and asthma 
exacerbations. 
Future research should also include inhaler competence as it is an important confounder in 
the association of interest, and essential to disentangle the association between adherence and 
treatment outcomes.
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SUPPLEMENTS
Online Table 1 - Search strategy per library.
Online Table 2 - Quality criteria adapted from the NOS criteria (19).
PubMed :
(asthma*[tw] AND (exacerbat*[tw] OR oral corticosteroid*[tw] OR systemic corticosteroid*[tw] OR hospitali*[tw] OR 
acute[tw] OR emergen*[tw] OR attack*[tw])) AND (adheren*[tw] OR adhaeren*[tw] OR complian*[tw] OR cooper-
at*[tw] OR co-operat*[tw] OR nonadheren*[tw] OR nonadhaeren*[tw] OR noncomplian*[tw] OR noncooperat*[tw] OR 
concordance[tw])
EMbase: human, short survey/article/article in press
((asthma* AND (exacerbat* OR ((oral OR systemic) NEAR/1 corticosteroid*) OR hospitali* OR acute OR emergen* OR 
attack*)) AND (adheren* OR adhaeren* OR complian* OR cooperat* OR (co NEAR/1 operat*) OR nonadheren* OR non-
adhaeren* OR noncomplian* OR noncooperat* OR concordance)):ti,ab,de
Web of Science: article
((asthma* AND (exacerbat* OR ((oral OR systemic) NEAR/1 corticosteroid*) OR hospitali* OR acute OR emergen* OR 
attack*)) AND (adheren* OR adhaeren* OR complian* OR cooperat* OR (co NEAR/1 operat*) OR nonadheren* OR non-
adhaeren* OR noncomplian* OR noncooperat* OR concordance))
Points
1. Overall study design: 
Cross-sectional studies 0
Cohort & case-control studies, non-randomized experiments 1
Randomized trials or crossover experiments 2
2. Participant selection: 
Evidence of selection in study e.g. high loss to follow-up 0
Evidence of selection in setup study database, like database of specific insurance company, or a 
specific referral hospital. 
1
Study with complete follow-up or studies with ≥80% participation 
and no evidence of selection.
2
3. Exposure assessment: 
Self-reports of adherence 0
Documented evidence (e.g. medical records) 1
Objective assessment of adherence (e.g. claims, refills, electronic monitoring) 2
4. Outcome ascertainment:
Self-reports of exacerbations 0
Documented exacerbations (other than GINA; additional doctor visit/symptoms) 1
Documented exacerbations (e.g. GINA definition: OCS, ER, hospitalization) 2
5. Adjustment of results for confounding:
No adjustment 0
Some adjustment 1
Detailed multivariate modeling, randomization
or cross-over design or stratification or model fitting
2
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ABSTRACT
  BACKGROUND   The expiration of the patent of brand inhalation medications and the ongoing pres-
sure on the healthcare budget resulted in a growing market for generic inhalation medications. 
Switching between generic and brand medications often implies change of inhalation device, 
which might jeopardize adherence and inhalation technique, ultimately resulting in poor asth-
ma control. Few data are available on the frequency of switching between generic and brand 
inhalation medications and between devices and the effect on adherence. 
  AIMS   To study the frequency of brand and generic use, of switching between device and of 
switching between brand and generic inhalation medication as well as its effect on adherence.
  METHODS   Data from the Dutch PHARMO Database Network was used. All inhaled medications 
dispensed between 2003-2012 in patients aged ≥5 years were extracted. Switching was de-
fined as either changing from brand to generic or vice versa, or change in device. Adherence to 
maintenance inhaled medication was calculated using the medication possession ratio (MPR) 
namely the sum of the days dispensed divided by treatment duration. 
  RESULTS   The total cohort comprised 70,053 patients with 1,604,488 dispenses. The percentage 
of patients in the switching cohort (n=56,853) who switched between brand and generic inha-
lation medication was 5% per year. Of the patients using medication with possible switch in de-
vice, 5% per year switched between devices. Median MPRs over the first 12 months following 
the first brand or generic dispensing of maintenance medication were between 33 and 55%. 
MPR was higher in the first 12 months after switch to generic budesonide and beclomethasone, 
compared to the 12 months before switch. (59 vs 75% p=0.015, and 51 vs 59% p=0.011)
  CONCLUSIONS   Switching between brand and generic inhalation medication per calendar year 
was occurred in 5% of the patients. However generic dispensing is increasing. Switching be-
tween devices occurred in 5% and 16% of the patients used more than 1 device in 1 year. 
Adherence to both generic and brand inhalation medication was considerably low. The finding 
that there is no net negative impact on adherence in patients who switch from brand to generic 
is promising, however adherence was low. Further research of switching is needed to investi-
gate potential clinical consequences on disease control. 
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INTRODUCTION
Asthma is a major problem with 334 million people having asthma worldwide. 1 In the Neth-
erlands with a total population of 16,9 million, over half a million people are diagnosed with 
asthma. Asthma treatment requires individually tailored therapy and selection of the most 
appropriate treatment, which is dependent on both the choice of drugs and inhaler device. 2 
Good inhalation techniques for proper use of these devices are crucial to obtain asthma control. 
To control healthcare costs, Dutch health authorities encouraged a preference policy by the 
health insurance companies which started in 2005, adopted as a law in 2008 but still causes a 
lot of debate. 2-4 The policy favours the use of generic drugs as alternatives to more expensive 
brand-name products, substitution to generic can be done in the pharmacy independent of the 
physician’s prescription, unless it is indicated that brand needs to be dispensed. 
Switching of inhalation therapy often coincides with a change of inhalation device. The choice 
of type of inhaler is based on patient characteristics (like age and inspiratory force), on the 
characteristics of the inhaler (like multidose/single dose, powder/aerosol) and patient pref-
erence. 5 Each device requires a different inhalation manoeuvre, which needs to be carefully 
instructed. Unexpected change in inhaler device may lead to confusion, and incorrect use, 
which may lead to no or less drug inhaled. 
Before generic medications are marketed, demonstration of clinical bioequivalence is needed. 
As the drug delivery and intended action of orally inhaled drug products for local action, such 
as dry powder inhalers (DPI) do not rely on the systemic circulation, the bioequivalence cannot 
be demonstrated based on drug concentration in blood/plasma. 6 Therefore demonstration of 
bioequivalence of these products is more challenging. The guideline from the European Medi-
cines Agency on requirements for clinical documentation of orally inhaled products for asthma 
and COPD states that for inhalers with the same substance and required flow rate, similar in 
vitro performance is sufficient to show equivalence. 7 In vitro performance includes particle 
size distribution, fine particle fraction of emitted dose, flow rate dependency tested under 
validated circumstances. 
In other therapeutic domains, there are doubts about the bioequivalence of generic drugs. 8 In 
addition, there is evidence that generic substitution has a negative impact on adherence and 
disease control through changes in appearance (colour, size, and packaging). 9-12 In asthma 
and COPD the type of device is important as it is tailored to the patient’s characteristics with 
respect to age, capability and inspiratory flow. 13 The change of inhalation device may increase 
confusion and mistakes in inhalation technique, and discourage appropriate use of the device. 
Few data were reported on the frequency of use and switching between generic and brand 
inhaled medication and whether generic substitution affects treatment adherence, in New-Zea-
land 14-16 and in the UK. 17, 18 Driven by the need to assure the quality of care, we need to under-
stand the impact of switching between brand and generic inhalation medications. 
In this study we aim to investigate the effects of preference policy by studying (1) the frequency 
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of use, and switching between generic and brand inhalation medication, and (2) of switching 
between devices and (3) to compare adherence before and after switching to generic inhala-
tion medications in real life in the Netherlands. 
METHODS
Setting
We conducted a population-based cohort study using data from the PHARMO Database Net-
work (www.pharmo.nl). This population-based patient centric data network of healthcare da-
tabases combines data from different healthcare settings, including general practitioner (GP), 
in- and outpatient pharmacy and hospitals. It includes high quality and complete information 
linked on a patient level of, among other data, patient demographics, drug dispensing records 
from community pharmacies, hospital discharge records, and GP diagnoses of more than two 
million individuals throughout the Netherlands. 19 The Out-patient Pharmacy Database com-
prises detailed information on the dispensed package, the type of prescriber, the dispensing 
date, the amount dispensed, and the written dose instructions. The drugs are coded according 
to the Anatomical Therapeutic Chemical (ATC) Classification as well as sales registry number. 20 
Study population 
The dynamic study population comprised all patients aged 5 years or older, using inhaled 
medication for at least 1 year during the study period. Medication use was defined as at least 
1 year between start of the first prescription and start of the last prescription. All patients were 
followed from study entry (1st of January 2003 or 5th birthday, whichever came last) until the 
end of the study period (1st of January 2013 or leaving the pharmacy, whichever occurred first. 
When restricted to only patients with asthma, (with a disease code for asthma (ICPC code 
‘R96’) and without disease code for COPD (ICPC code ‘R95) follow-up started on the date of 
disease code or on the 1st of January 2003, whichever was last.
Because switching is only possible with when a generic or other device is available, we con-
structed subcohort to study switching between brand-generic medications and the adherence 
before and after switch, as well as switching between devices. 
Brand-generic cohort
From the study population, we identified all patients, who used inhalation medication for 
which generic substitutes were available at any time between 2003 and 2012. The information 
about availability of generic substitutes during the study period was retrieved from the medi-
cines information bank from the Dutch Medicines Evaluation Board. 21 The inhalation medica-
tions for which generic substitutes were available included short-acting beta agonists (SABA), 
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shot acting muscarinic antagonists (SAMA) and inhaled corticosteroids (ICS), and long-acting 
beta agonists (LABA). (Table 1) If less than 0.5% of the total dispenses were generic dispenses, 
this ATC is not included in the generic analyses.
To calculate use of generic and brand medication and the frequency of switching per calendar 
year we selected only patients who had 1 year of follow-up and had at least 1 dispensing in 
that specific calendar year. Mixed use was defined as both generic and brand dispenses in 1 
calendar year. Switch was defined as change from brand to generic brand dispensing or vice 
versa compared to the prior dispensing of a medication with the same ATC code in the previous 
365 days, but not necessarily in the same calendar year. (Online Figure 1)
We categorized patients into 3 groups, 1. patients exclusively using brand name inhalation 
medication 2. patients exclusively using generics and 3. patients using both generic and brand 
medication in a specific calendar year. (=mixed users). 
Device cohort
From the study population, we identified all patients who used inhalation medication for which 
different devices per ATC code were available between 2003 and 2012.
ATC code Generic Brand
R03BA02 Budesonide Pulmicort®
R03BA01 Beclomethason Aerobec®, Becotide®, Becloforte®, QVAR®
R03BB01 Ipratropium bromide Atrovent®
R03AC13 Formoterol Atimos®, Foradil®, Oxis®
R03AK04 Ipratropium/salbutamol Combivent®
R03AC02 Salbutamol Aerolin®, Aeromir®, Ventolin®
ATC code Medication DPI device
R03AC02 salbutamol, Ventolin® Cyclocaps, diskus, novolizer, rotadisk
R03AC12 Serevent®, salmeterol Diskus, rotadisk
R03AC13 Foradil®, formoterol, Oxis® Clickhaler, cyclocaps, diskus, easyhaler, novolizer, turbuhaler
R03BA01 beclometason, Becotide® Cyclocaps, rotadisk
R03BA02 budesonide, Pulmicort® Clickhaler, cyclocaps, easyhaler, novolizer, turbuhaler
R03BA05 Flixotide®, Fluticason, Flutide® Diskus, rotadisk
R03BB01 Atrovent®, ipratropium Aerocaps, cyclocaps, inhalette
ATC code Medication pMDI device
R03BA01 Beclomethason, Becloforte®, Qvar® Autohaler (breath-actuated), extrafine, becloforte, beclomethason 
Table 1 - Overview of brand inhalation medication and generic substitute available between 2003 and 2012 per ATC code.
Table 2 - Overview of subcategories for all dry powder inhales (DPI) and pMDI (only beclomethasone) available between 
2003-2012.
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We classified the type of device per dispensing, into one of the following; pressurized metered 
dose inhalers (pMDI), dry powders inhalers (DPI), or nebulizers. Switching was defined as 
switch between devices with the same ATC code. 
To gain more insight into switching within device groups, we classified the DPI into Click-
haler®, Cyclocaps®, Diskus®, Easyhaler®, Inhalette®, Novolizer®, Rotadisk®, and Turbu-
haler®. For the pMDI’s only beclomethasone (ATC code R03BA02) was subcategorized into 
Becotide®, Becloforte®, Extrafine® and Autohaler®. (Table 2)
Switching was defined as switch between devices with the same ATC code.
Adherence 
Adherence was calculated for the three maintenance medications for which a generic substi-
tute was available namely beclomethasone, budesonide, and formoterol. Adherence was calcu-
lated by using the medication possession rate (MPR). MPR was defined as the sum of the days 
for which inhalation medication was dispensed divided by the total number of days between 
the first and the last prescription plus the duration of the last prescription, multiplied by 100 
and expressed as a percentage. A periodMPR was calculated in the 6 and 12 month period 
following the first dispense for patients exclusively on brand or generic. To compare adherence 
before and after switching, only patients for whom an MPR could be calculated both before and 
after switch were included, to control for patient characteristics. MPR in patients with a switch 
was calculated in the 6 and 12 months before and after the switch date. (online Figure 2) We 
excluded the switch dispense from this analysis as this would introduce differential overesti-
mation of adherence in patients who switched. In case of multiple switching the follow-up time 
was censored at the next switch. 
Statistical methods
Descriptive statistics were used where numbers are provided by counts and percentages. For 
continuous variables we provided medians and interquartile ranges (IQR).
To describe the use of generic and brand medication, we divided the number of users with only 
generic, or only brand, or brand and generic dispenses by the total number of users per specific 
calendar year. 
To describe the switching patterns, in terms of generic or brand medication and also in terms 
of device, the prevalence of dispensing was calculated as percentage of users per calendar 
year, per ATC code and per device. We stratified by gender, frequency of use (1-3 versus >4 
dispenses per year), and by age (5-18 vs ≥18).
In a sensitivity analysis we repeated the analysis in patients who have a disease code for asthma 
and do not have a disease code for COPD, follow-up started from the date of asthma diagnose. 
To compare adherence before and after switch, we tested MPR differences by paired measure-
ments with the Wilcoxon signed rank test.
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All analyses were performed in SPSS version 21, SPSS Inc, Chicago. For difference in adher-
ence we considered a p-value <0.05 as significant.
RESULTS
The total study population included 70,052 patients with a total of 1,604,488 dispenses of 
inhalation medication. Median age at cohort entry was 44.5 years (IQR 25.5-59.7), and 47% 
were men. 14,975 (21%) patients had a disease code for asthma, 9,328 (13%) had a disease 
code for COPD. 636 (1%) of all patients had both disease codes. At cohort entry 13,365 (19%) 
were children <18 years old. An overview of the cohorts is shown in Figure 1. 
Figure 1 - Overview of the different cohorts.
Brand-generic switching
The brand-generic cohort, which was defined to estimate the prevalence of switching from 
brand to generic drugs and vice versa, consisted of 56,853 patients with 653,672 dispenses 
for which generic substitute was available. Of these 194,224 (29.7%) were generic dispenses. 
The highest generic dispensing rate was for Beclomethasone, 59% of the total beclomethasone 
dispenses from 2003-2013 were generics. 
In all calendar years the number of users and the dispenses per calendar year were lower for 
girls than for boys. (13,260 total users with 26,410 dispenses for girls versus 19,668 total users 
with 39,965 dispenses for boys). For adults the number of dispense per year as well as the total 
Total R03 cohort
n = 70,052 patients
Rx = 1,604,488
Device cohort (DPI, HFA, neb)
n = 69,943
Rx = 1,579,866
R03 included: AC02, AC03, AC12, 
AC13, AK03, AK04, AK06, AK07, BA01,
BA02, BA05, BB01, BB04, BC01
Generic brand cohort
n = 56,853 patients
Rx = 653,672
R03 included:
AC02, AC13, BA01, BA02, AK04
Generic brand cohort
Only asthma
n = 11,130 patients 
Rx = 92,643
R03 included: 
AC02, AC13, BA01, BA02, AK04
Subdevice cohort: DPI
n = 47,532
Rx = 568,796
R03 included: AC02, AC12,
AC13, BA01, BA02, BA05, BB01
Subdevice cohort: pMDI
n = 3,694
Rx = 25,105
R03 included: BA01
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number of dispenses was higher for women compared to men (women: 96,216 total users total 
dispenses 305,270 versus men: total users 78,405 and total dispenses 262,531.) However, the 
patterns of generic, brand, mixed use and switching were similar for gender. 
On average 10% of the patients in the brand generic cohort used both generic and brand 
inhaled medication (=mixed use), in all ATC codes, in one calendar year. (Figure 2). The pro-
portion of generic users increased from 18% in 2003 to 31% in 2012.
Switching between brand and generic medication with the same ATC code was observed in 5% 
of the brand generic cohort per year, and remained stable over time. (Figure 3) We observed 
that the proportion of switching per ATC code was highest in salbutamol, with on average 6% 
of the salbutamol users switched in the study period. The pattern of switching in salbutamol 
over calendar year is shown in Figure 4. When studying beclomethasone (ATC=R03BA01), the 
switching percentage in beclomethasone (R03BA01) was highest in 2003 and 2004, both from 
brand to generic as from generic to brand, but dropped from 2005 onwards. (Figure 5). The 
number of generic dispenses increased in 2003 and 2004, but decreased thereafter. (online 
Figure 3)
The above results were similar when we restricted to patients with an asthma disease code 
(n=14,339). Absolute numbers were much lower. 
All results were similar when stratified by use (high use (≥4 dispenses per calendar year) vs 
low use 1-3 dispenses per year). (data not shown)
Device switching
For patients within the device cohort (n=69,943) the use of pMDI, DPI and nebulizers is shown 
in Figure 6. In children most dispenses were pMDI’s (49%), while in adults DPI were dispensed 
most frequently (73%). On average 16% of the adult users in the device cohort used more than 
1 type of device per calendar year, in children this was 9%. On average 2% of the patients in 
the device cohort switched from device within 1 calendar year between 2003-2012. In adults 
switching was increasing over time, with most switches from DPI to pMDI. (Figure 7)
For patients within the subdevice cohort for DPI switching (n=47,532), on average 3% of the 
users switched between devices with the same ATC code per year. (Figure 8)
In patients in the beclomethasone subdevice cohort pMDI (n=3,694), on average 8% of the 
users switched. In 2003 and 2004 switching from becotide and becloforte to generic beclo-
methasone was most frequent. In September 2002 generic beclomethasone was licensed into 
the Dutch market, soon thereafter Becotide® en Becloforte® were off license. 
Medication possession rate
The mean MPR was low for the 3 maintenance inhalation medications for which generic sub-
stitute was available namely, budesonide, beclomethasone and formoterol. The median MPR 
(IQR) for the first 12 months following the 1st dispense for patients exclusively on brand was 
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Figure 2 - Proportion of users with generic only, brand only, or mixed use, of all ATC codes within the brand-generic cohort, 
stratified by calendar year. Pct = percentage, Mpct = mixed use, gpct = generic user, bpct = brand user
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Figure 3 - Patients with ≥1 switch (with the same ATC code) per calendar year.
S1 = switch from brand to generic, S2 = switch from generic to brand, Stot = S1 and/or S2
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Figure 4 - Patients with ≥1 switch in salbutamol by calendar year.
S1 = switch from brand to generic, S2 = switch from generic to brand, Stot = S1 and/or S2
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Figure 5 - Switching pattern for beclomethasone in the brand-generic cohort stratified by calendar year.
S1 = switch from brand to generic, S2 = switch from generic to brand, Stot = S1 and/or S2
Figure 6 - Proportion of children and adults per device per calendar.
pMDI = Metered dose inhaler, DPI = dry powder inhaler
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Figure 7 - Proportion of users with a switch in device per calendar year. 
sntot = users with ≥1 switch, shnp = switch from pMDI to nebulizer, shdp = switch from pMDI to DPI, sndp = switch from 
nebulizer to DPI, snhp = switch from nebulizer to pMDI, sdnp = switch from DPI to nebulizer, sdhp = switch from DPI to pMDI
Figure 8 - mix = mixed use (>1 device), switch = users with ≥1 switch to another device with the same ATC code per calendar 
year
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55% (41.1-82.2) for budesonide, 48% (27.4-68.5) for beclomethasone and 33% (23.4-49.3) 
for formoterol. The median MPR (IQR) for the first 12 months following the 1st dispense for 
patients exclusively on generic was 55% (41.1-82.2) for budesonide, 33% (16.4-57.0) for be-
clomethasone and 33% (21.9-49.32) for formoterol.
To control for patient characteristics, the analyses to compare adherence before and after 
switching was restricted to the same patients before and after switch with at least 6 or 12 
months of follow-up before and after switch and at least 2 dispenses in each 6 or 12 months. 
Patients (n=102) who switched from brand to generic beclomethasone were more adherent in 
the first 12 months after switching compared to 12 months before switching (median MPR 55% 
(IQR 27.6-82.2) vs 41% (IQR 27.4-60.84) (Wilcoxon signed rank test p=0.015). Also, patients 
(n=77) who switched from brand to generic budesonide were more adherent to budesonide in 
the first 12 months after switching compared to 12 months before switching (median MPR 59 
(IQR 41.1-97.4) vs 51% IQR (38.9-79.2), p=0.015). No differences in MPR before and after 
switch were observed in patients with dispensing of Formoterol. Numbers for switching from 
generic to brand were too low. Details are shown in Table 3.
DISCUSSION
In this study we provide population level data on the use of generic and brand inhalation med-
ication and the frequency of switching between brand and generic inhalation medication and 
switching of inhalation device. In addition, we calculated adherence and investigated whether 
switching was associated with changes in adherence. Although use of generic medication in-
creased over time. Very few patients switched from brand to generic or vice versa. Only 5% 
of patients in the brand generic cohort had 1 or more switches between brand and generic 
per year. We also observed that adherence to maintenance inhaled medication was low, and 
switching hardly affected adherence rates. 18% of all users had 2 or more different devices per 
calendar year. 
Our results provide evidence that despite the preference policy patients continued to use brand 
medication. In some drug classes, e.g. in beclomethasone there was quite some switch away 
from generic to new brand inhaled medication This phenomenon was also observed by Fraser 
et al. 22 In our study it was observed that the use of brand beclomethasone increased and gener-
ics decreased when Qvar® (=beclomethasone pMDI delivered with ultrafine particles) came 
into the market 23 An extra caution needs to be taken regarding the switch of Qvar to generic 
beclomethasone pMDI. Whereas Qvar contains extra-fine particles with median aerodynamic 
particle size 1.1 μm, generic beclomethasone contains particles around 3.5 μm. This may have 
implications for the dose and efficacy. 24
In addition the Becloforte and Becotide use decreased from 2004 onwards.
In line with previous research 25 adherence to both generic and brand inhalation medication 
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within the first 12 months following the first dispense was low for beclomethasone, formoterol 
and budesonide with MPR ranging between 40-55%. From adherence studies on chronic med-
ication, it is known that at initiation of medication most patients are adherent, but adherence 
decreases rapidly in the first 3–6 months. 26 
Some differences in adherence before and after switch were observed in users of budesonide 
and beclomethasone, where the median MPR was higher after switch to generics, but numbers 
were low (n=77 and n=102). In the Netherlands, generic substitution coincides with increased 
responsibilities of Dutch pharmacies with regard to educate patients about the reasons for 
generic substitution, the benefits of adherent drug use and correct use of inhalation device. 27 
Patient education has been demonstrated to increase the acceptance of generic prescribing. 12 
But the time needed to instruct a patient should be kept in mind, when substitution is a com-
mon policy.
Although the preference policy was implemented in 2005 for some medication and actively 
expanded by insurance companies to inhaled medications from 2008 onwards, it is still un-
der debate. Currently, the Netherlands Pharmacovigilance Centre Lareb reported concerns on 
possible decreased efficacy of the generic salbutamol aerosol after the revision of the device. 
Besides some external changes, the formulation of the propellant changed as well.28 Future 
research is needed to study the cost effectiveness of switching to this and other generic drugs. 
 We observed a low percentage of switching during our study period. Physicians might be 
reluctant to change from brand to generic in patients already on treatment and might preserve 
use of generic drugs in patients newly diagnosed with asthma. 
Our study period was from 2003-2012, since 2012 new generic asthma drugs came into the 
market implying that the current proportion of generic medication use and the proportion of 
switching is probably higher than what we observed. 29
 This is an observational study: the limitations of which are well recognized and uses pharmacy 
database as primary data source, adding limitations; such as the fact that dispensing of a medi-
cine does not equate actual use, nor guarantees a good inhalation technique. In addition, as the 
proportion of patients with a disease code for asthma (and without a code for COPD) was low, 
it is difficult to make a strong statement on the characteristics of the patients that were treated. 
Also, this database could not be used to investigate the indication of switching. 
CONCLUSION
Generic dispensing in the Netherlands is increasing. Patients on inhaled medication have con-
siderably low adherence rates and there was no net negative impact on adherence rates in 
patients who switched from brand to generic, which is promising. In near future with more 
generic drugs coming into the market, chance of switching is more likely. Further research on 
reasons of switching and potential impact on clinical outcomes is warranted.
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SUPPLEMENTS
Online Figure 1 - Patient 1 with a switch and Patient 2 with switch and mixed use.
Online Figure 2 - MPR calculations for patients with a switch, with 2 dispenses in 12 months before switch and 2 dispenses 
in 12 months after switch. The switching dispense is excluded from the MPR calculations.
Patient 1 in 2007:
Switch = 1 (switch to generic in 2007)
Generic only = 1
Patient 2 in 2007:
Switch = 1
Mixed = 1 (brand and generic in 2007)
Patient 1
2006 2007
Start of follow up End of follow up
Rx brand Rx generic Rx generic
switch
Patient 2
2006 2007
Start of follow up End of follow up
Rx brand Rx brand Rx generic
switch
Adherence in 12 months before switch:
Rx1 + Rx2 = 100 + 120 / 365 = 66% MPR
Adherence in 12 months after switch:
Rx4 + Rx5 = 100 + 60 / 365 = 44% MPR
The switching Rx (Rx3) is not contributing to the MPR calculations.
2006
12 months 12 months
20082007
Start of follow up End of follow up
Rx1 brand
100 days
Rx4 generic
100 days
Rx5 generic
60 days
Rx2 brand
120 days
Rx3 generic
120 days
switch
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ABSTRACT 
  AIMS   To study whether switching between generic and brand inhaled asthma medica-
tions or switching between inhalation devices affects the risk of moderate to severe asthma 
exacerbations.
  METHODS   We conducted two observational case-control studies nested in a cohort of asthma 
patients in data from the PHARMO Database Network between 2003 and 2013. Cases were 
patients ≥5 years of age with asthma who had a first moderate to severe asthma exacerbation, 
defined as need of systemic corticosteroids or requiring hospitalization for asthma (case-con-
trol set 1), or severe asthma exacerbation, defined as requiring hospitalization (case-control set 
2). To each case, up to 10 controls were matched on age, gender, and index date. All dispensing 
of inhaled respiratory drugs were categorized into generic or brand use. At the index date, cur-
rent or past exposure to generic or brand drugs was assessed. Switching was defined as either 
a change from brand to generic or vice versa, or as change in device. Switching was assessed 
during the 30 days or 1 year preceding the index date. Data were analysed using multivariate, 
conditional logistic regression. 
  RESULTS   The first case-control set consisted of 3,796 cases. Current use of generic inhaled medi-
cation was associated with an increased risk of moderate to severe asthma exacerbations (ORadj 
1.33 (95% CI 1.20-1.47) most pronounced for β2-agonists. Switching from brand to generic 
(or vice versa) salbutamol increased the risk of moderate to severe asthma exacerbations with 
68%. (ORadj 1.68 (95% CI 1.34-2.10), with highest risks in patients <18 and ≥45 years of age. 
(<18: ORadj 1.95 (95% CI 1.16-3.27) and ≥45 ORadj 2.14 (95% CI 1.51-3.03). The association 
with current use of generics was higher in the case control analysis on severe exacerbations 
(104 cases) (ORadj 2.05 (95% CI 1.20-3.52). But no significance was reached when data were 
analysed by drug class or switching type. 
  CONCLUSIONS   Our study showed that current use of generic inhaled β2-agonists might be asso-
ciated with an increased risk of exacerbations when compared to current use of brand β2-ago-
nists, in particular when switched between generic and brand. To elucidate whether this asso-
ciation is real, or confounded by lack of asthma control, we suggest to replicate our findings in 
more recent, international data, with detailed information on asthma control.
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INTRODUCTION
Asthma is a major health problem with 334 million patients worldwide. 1 In the Netherlands 
with a total population of 16,9 million, half a million people are diagnosed with asthma. 2 
Asthma treatment requires individually tailored therapy and selection of the most appropriate 
treatment is dependent on the choice of drugs and inhaler device. 3 Proper use of these devices 
is crucial to obtain asthma control. 3, 4 Asthma is a considerable burden on the healthcare bud-
get: three brands of inhaled medication are in the top 10 of drugs with the highest expenses. 5 
To control healthcare costs, Dutch health authorities encouraged a preference policy by the 
health insurance companies which started in 2005 and was adopted as law in 2008 but still 
causes a lot of debate. 3, 6, 7 This policy favours the use of generic drugs by the pharmacy inde-
pendent of the physician’s prescription. 
Switching to generic often coincides with a change of inhaler. The choice of inhaler is based on 
patient characteristics, like age and inspiratory force, characteristics of the inhaler, like multi 
or single dose, powder or aerosol and patient preference. 8 Each inhaler requires a different 
inhalation manoeuvre, which needs to be carefully instructed. 
Prior to registration of generic medications, demonstration of clinical bioequivalence is needed. 
As the effect of the inhaled drug do not depend on the systemic activity, bioequivalence cannot 
be demonstrated based on drug concentrations in blood. 9 The guidelines from the European 
Medicines Agency on requirements for clinical documentation of orally inhaled products for 
asthma and COPD states that for inhalers with the same substance and required flow rate, 
similar in vitro performance is sufficient to show equivalence. 10 In vitro performance includes 
particle size distribution, fine particle fraction of emitted dose, and flow rate dependency test-
ed under validated circumstances. 10
In other therapeutic domains, there are doubts about the bioequivalence of generic drugs. 11 
In addition, there is evidence that substitution by generics has a negative impact on adherence 
and disease control through changes in appearance (colour, size, and packaging). 12-15 
Health care professionals are concerned about substitution of asthma drugs because it may 
have negative effects on disease control through lower adherence, and potential lack of efficacy 
in case of inappropriate use of inhalers. 3, 16 Indeed, data from a questionnaire study showed 
that patients, who switched asthma medication, experienced more often problems with use of 
the device (23% vs. 13%), were less likely to be adherent (55 vs. 68%) and were less likely to 
report being disease controlled (69 vs. 83%) compared to patients who did not switch. 17 
To assure the quality of care, we need to know the impact of switching between brand and 
generic inhalation medications. Therefore we investigated the association between the use of 
generic and brand drugs per drug class, including long-acting β2-agonists (LABA), short-acting 
β2-agonists, (SABA) and inhaled corticosteroids (ICS) switching between brand and generic 
and switching of the inhalers, and the risk of asthma exacerbations.
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METHODS 
Database 
We conducted two nested case-control studies within a cohort of patients with asthma iden-
tified in a large population-based patient centric network of healthcare databases (the Dutch 
PHARMO Database Network (www.pharmo.nl). This combines data from different healthcare 
settings, including general practice (GP), in- and outpatient pharmacy and hospitals. It includes 
high-quality complete information linked on a patient level, including, patient demographics, 
drug dispensing records from community pharmacies, hospital discharge records, and GP di-
agnoses of more than two million individuals throughout the Netherlands. 18 The Out-patient 
Pharmacy Database comprises detailed information on dispensed package, prescriber, dispens-
ing date, amount dispensed, and written dose instructions. The drugs are coded according to 
the Anatomical Therapeutic Chemical (ATC) Classification as well as sales registry number. 19 
This study was approved by the independent compliance committee of the PHARMO institute. 
Study design
The study cohort comprised all patients aged 5 years or older, diagnosed with asthma by the 
GP and using inhaled medication for at least 1 year. A patient was classified as having asthma 
from the date the asthma specific disease code (ICPC code=‘R96’) was first recorded. Patients 
with a medical history of COPD were excluded. The study period was from the 1st of January 
2003 until the 1st of January 2013. Follow-up started on the 1st of January 2003, the date of 
asthma diagnosis, the date on which the required 1year of inhalation therapy was obtained, 
or on the 5th birthday, whichever date occurred last. All patients were followed until their first 
exacerbation, until leaving the pharmacy, or at death or at the end of the study period, which-
ever occurred first.
Cases and controls
Within the study period, 15,289 asthma patients ≥5 years were identified and with at least 
1 year of exposure to asthma drugs. Within this cohort, severe asthma exacerbations were 
identified by discharge diagnoses for asthma (ICD 9 code 493). In addition, moderate asthma 
exacerbations were identified by dispensing of systemic corticosteroids (ATC H02AB). We only 
considered the first asthma exacerbation during follow-up. The number of asthma exacerba-
tions prior to the index date was considered as covariate. 
Controls were selected through incidence density sampling and cases could function as control 
up to 1 month prior to the asthma exacerbation. To each case, we identified up to 10 controls 
matched on age, gender and index date. Two separate sets were generated, the first containing 
all cases with a first hospitalization or use of systemic corticosteroids, whichever was earliest, 
the second only cases with a first hospitalization.
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Exposure 
From the Out-patient Pharmacy Database, we selected all dispensing of inhaled medications 
(ATC ‘R03’). From these we labelled drugs as either brand or generic based on drug name. 
(online Table 1) Information on the availability of generic substitutes during the study peri-
od was retrieved from the medicines information bank from the Dutch Medicines Evaluation 
Board 20 To control for differential prescribing, brand drugs for which no generic substitute was 
available were labelled as ‘no generic available’. As we focused on patients with asthma, we 
classified only drugs that were included in current evidence- based treatment guidelines. 21 We 
classified the drugs into drug classes ICS, LABA and SABA. We did not perform stratified analy-
ses on current use of other drugs (tiotropium, ipratropium, ipratropium+fenoterol, nedocromil 
or cromolyn sodium), because of their low prevalence.
For each dispensing, a legend duration was calculated based on the amount dispensed and the 
dosing instructions. Exposure at index date was categorized into ‘current use’, when the last 
dispensing covered the index date or ended less than 30 days prior to the index date, or ‘past 
use’. Past use was further categorized into “recent past” use defined as 30 days up to 1 year 
before the index date and for switching “past use” was defined as longer than 1 year prior to 
the index date. 
A switch was defined as a change between generic and brand within the same ATC level 7 code 
within 365 days of the previous dispensing. Switching was assessed in two time windows, 365 
days prior to the index date or 30 days before the index date. (online Figure 1)
Switching of inhaler was defined as either switching within metered dose inhalers (pMDI) or 
within dry powder inhalers (DPI). (online Table 2)
Covariates
As covariates and potential risk factors of asthma exacerbation, we considered smoking history, 
obesity (BMI>30) or overweight (BMI between 27-30), anxiety/depression and gastro-oesoph-
ageal reflux disease (GERD), all assessed before the index date. Comorbidities were identified 
based on disease codes in the GP records. Concomitant drug use was assessed within 1-30 
days prior to the index date for the following drug classes: antacids (ATC A02B), hypnotics or 
anxiolytics (ATC N05), antidepressants (N06), antihistaminic agents (R06A), antibiotics (J01) 
or nasal preparations (R01). 
Statistical analysis 
Descriptive statistics were used to provide numbers by counts and percentages. For continuous 
variables we calculated mean and standard deviation. Conditional logistic regression analysis 
was used to estimate associations. First a crude conditional logistic regression was conducted 
where matched odds ratios (OR) with corresponding 95% CI were provided. For the adjusted 
analyses, all factors with clinical relevance or associated with exacerbations in the univariate 
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analysis (p<0.05) were included. 
Effect modification by calendar time, before and after 2008 as the preference policy became 
effective from 2008, and by age (per agegroup <18, 18-45 and ≥45 years) was investigated. 
Odds ratios were not provided in case of less than 3 exposed cases. All statistical analyses were 
conducted with the statistical software packages SPSS/PC 21.0 (SPSS Inc, Chicago, III).
RESULTS
We identified 3,796 cases with an exacerbation during follow-up. The median age of the cases 
was 48.7 (35.2-61.7) years. The characteristics of cases and controls are described in Table 1.
Risk factors for exacerbations were underlying comorbidities of anxiety/depression, obesity, 
overweight, GERD, obesity, smoking, and prior exacerbations. Concomitant use of antacids, 
hypnotics and sedatives/anxiolytics/antipsychotics/antidepressants, nasal preparations, anti-
histamines, and antibiotics were all associated with an increased risk of exacerbation. 
A prior history of asthma exacerbation was the strongest risk factor of subsequent exacerba-
tions. The use of antibiotics within 30 days before exacerbation was strongly associated with 
exacerbation. (Table 1)
Current use of generic asthma inhalation medication was associated with an increased risk of 
exacerbations (ORadj 1.34 (95% CI 1.21-1.48) when considering all brand use, including brand 
for which no generic substitute was available, as reference category. (online Table 3) This 
risk remained when considering only brands for which a substitute was available as reference 
category. (ORadj 1.33, 1.20-1.47). When splitting the drugs in individual drug classes, the risk 
tended to be higher for SABA and LABA and reduced for ICS, when adjusted for the other 
classes. For SABA this risk was mainly driven by the use of generic salbutamol.
Switching between brand and generic
In total, 145 cases (3.8%) switched between brand and generic compared to 690 controls 
(1.8%) (online Table 4). Switching was associated with an increased risk of exacerbations. 
(ORadj 1.62, 1.34-1.97 Table 2) At the drug class level, the association was only significant 
for SABA (ORadj 1.66, 1.32-2.08), while numbers for ICS and LABA were low. Switching was 
mainly reported for salbutamol, which was associated with an increased risk of 1.68 (95% CI 
1.34-2.10). This was not modified by concomitant ICS use, interaction term of ICS and switch-
ing and risk of exacerbations (p=0.121).
Switching between devices was infrequent in the one year prior to the index date, in total 28 
cases (0.7%) switched device compared to 227 controls (0.6%). (online Table 4) No associa-
tion between inhaler switching and risk of exacerbations could be observed. (online Table 5) 
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Moderate to severe exacerbations
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR* 
(95% CI)
Gender
Male 1,451(38.2) 14,294(38.3)
Female 2,345(61.8) 23,073(61.7)
Age (median, IQR) 48.7(35.2-61.7) 48.3(35.1-61.1) nap
Smoking 154(4.1) 1,064(2.8) 1.47 (1.24-1.75)
History of exacerbations
Severe exacerbations (hospitalization)
0 3,709(97.7) 37,071(99.2) reference
1 62(1.6) 263(0.7) 2.42 (1.83-3.21)
2 17(0.4) 18(0.0) 10.31 (5.25-20.23)
>2 8(0.2) 15(0.0) 5.33 (2.26-12.58)
All exacerbations
0 1,857(48.9) 26,802(71.7) reference
1 773(20.4) 5,689(15.2) 2.03 (1.85-2.22)
2 393(10.4) 2,150(5.8) 2.79 (2.48-3.15)
>2 773(20.4) 2,717(7.3) 4.40 (4.00-4.85)
Co-morbidity
Gastro oesophageal reflux disease 132(3.5) 994(2.7) 1.34 (1.11-1.61)
Psychological disease 455(12.0) 3,531(9.4) 1.32 (1.19-1.47)
Obesity 78(2.1) 580(1.6) 1.20 (0.96-1.49)
Overweight 90(2.4) 756(2.0) 1.33 (1.05-1.70)
Concomitant medication**
Antacids 715(18.8) 4,379(11.7) 1.84 (1.68-2.02)
Antibiotics 678(17.9) 2,092(5.6) 3.68 (3.35-4.05)
Psycho-therapeutics 602(15.9) 3,891(10.4) 1.58 (1.43-1.75)
Nasal preparations 689(18.2) 4,596(12.3) 1.61 (1.46-1.78)
Antihistamines 530(14.0) 3522(9.4) 1.59 (1.45-1.74)
Table 1 - Characteristics of moderate to severe asthma exacerbations and matched controls.
* matched on age, gender and index date
** measured at 1 to 30 days before index date, nap = not applicable
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Table 2 - Association between use of inhalation medication by generic or brand, by generic, brand, and brand no generic 
available and by drug class (ICS, LABA and SABA) and moderate to severe asthma exacerbation.
Switch generic/brand 
in 1 year before index date
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
ICS        
no switch and use in 1-365 days before index date 2,550 (67.2) 22,249 (59.5) reference reference
Switch and use in 1-365 days before index date 11 (0.3) 152 (0.4) 0.64 (0.35-1.19) 0.70 (0.37-1.30)
Use 1-365 days before index date of brand with no 
generic available
56 (1.5) 576 (1.5) 0.85 (0.65-1.13) 0.80 (0.60-1.07)
LABA        
no switch and use in 1-365 days before index date 345(9.1) 2,313(6.2) reference reference
Switch and use in 1-365 days before index date 4(0.1) 23(0.1) 1.26 (0.43-3.65) 1.43 (0.47-4.36)
Use 1-365 days before index date of brand with no 
generic available
5(0.1) 29(0.0) 1.21 (0.46-3.16) 1.02 (0.37-2.80)
SABA    
no switch and use in 1-365 days before index date 1,845 (48.6) 15,231 (40.8) reference reference
Switch and use in 1-365 days before index date 111 (2.9) 451 (1.2) 2.01 (1.62-2.49) 1.66 (1.32-2.08)
Use 1-365 days before index date of brand with no 
generic available
2 (0.1) 12 (0.0) n.a.p n.a.p
SABA salbutamol    
no switch and use in 1-365 days before index date 1,622 (42.7) 13,337 (35.7) reference reference
Switch and use in 1-365 days before index date 110 (2.9) 444 (1.2) 2.01 (1.62-2.50) 1.68 (1.34-2.10)
SABA terbutaline
no switch and use in 1-365 days before index date 238 (6.3) 2,055 (5.5) reference reference
Switch and use in 1-365 days before index date 0 (0.0) 7 (0.0) n.a.p n.a.p
SABA salbutamol+ ipratropium
no switch and use in 1-365 days before index date 33 (0.9) 109 (0.3) reference reference
Switch and use in 1-365 days before index date 1 (0.0) 0(0.0) n.a.p n.a.p.
Switch SABA generic/brand 
in 30 days before index date 
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
SABA all    
No switch and current use 1,293 (34.1) 7,917 (21.2) reference Reference
Switch and current use 8 (0.2) 16 (0.0) 3.00 (1.28-7.03) 2.20 (0.90-5.37)
Use 1-30 days before index date of brand with no 
generic available
1 (0.0) 3 (0.0) Nap nap
SABA salbutamol    
No switch and current use 1,121 (29.5) 6,732 (18.0) reference reference
Switch and current use 8 (0.2) 16 (0.0) 2.94 (1.26-6.90) 2.17 (0.89-5.29)
ICS = inhaled corticosteroids, LABA = long-acting β2-agonists, SABA = short-acting β2-agonists
* Adjusted for past use of respiratory drugs, current use of all other drug classes, smoking history, follow-up time, severe to 
moderate exacerbations, GERD, anxiety/depression, obesity, overweight prior to index date and concomitant medications; 
antacids use of hypnotics or anxiolytics, use of antidepressants, nasal preparations, antihistamines used in the 30 days before 
index date. 
** all respiratory drugs = ICS, LABA, SABA, and other (= tiotropium, ipratropium, ipratropium+fenoterol, cromoglycaat and 
nedocromil)
Numbers of the different drug classes (ICS, LABA, SABA) are not adding up to total number of "all", as for each treatment 
class we started with selecting patients currently using a drug in that treatment class. One patient could be present in all 
treatment classes. Current use = 1-30 days before index date.
n.a.p.: not applicable as number of exposed cases lower than 3
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Effect modification
Effect modification by calendar year was not observed. Effect modification by age was signifi-
cant (p<0.05). No significant association was observed for current use of ICS, LABA or SABA 
separately, or numbers were very low. (online Table 6) 
Switching salbutamol was associated with an increased risk of exacerbations for patients 
younger than 18 or older than 44 years. This association was stronger for switching within 30 
days for patients older than 44 years, but numbers are low. (Table 3) Switching from brand to 
generic (or vice versa) LABA was associated with an increased risk of exacerbations for patients 
between 18 and 45 years of age, but numbers are very low.
The second case-control set was limited to cases with exacerbations leading to hospitalization. 
(n=104 cases, median age 35.7 years) The characteristics of cases and controls are described 
in Table 4. Risk factors were comparable to those of the first case-control set. A previous asth-
ma exacerbation was the strongest risk factor for subsequent asthma exacerbations. (ORmatched 
12.76, 7.02-23.21)
Current use of generics, compared to brand inhalation medication with generic available, dou-
bled the risk of severe asthma exacerbations. (ORadj 2.05, 1.20-3.51). (Table 5). Numbers were 
too low for individual medication classes and no further associations were found. (Table 5 and 
online Table 7) 
DISCUSSION
In this study we provide population level data on the association between use of brand or 
generic asthma drugs, switching between brand and generic drugs and switching of inhalers 
and the risk of asthma exacerbations in the Netherlands during a 10-year period. The risk of 
exacerbations was higher with generic asthma drugs and the strength of association increased 
for severe exacerbations. Switching in the year before the index date was associated with an 
increased risk of exacerbations, and it was most pronounced for SABA. The risk tended to be 
higher in children and in patients older than 44 years. It is unclear whether the association 
between switching and exacerbation risk is causal, or due to residual confounding by asthma 
severity or protophatic bias, i.e. prescription or switching because of first symptoms of an asth-
ma exacerbation. Device competence may be particular important when switching therapy, in 
younger and older patients. If switching coincides with ineffective use of the drug, this could 
explain an increased risk of asthma exacerbation.
By our definition of switching, there might be a window of maximum 1 year between the 
indexdate and the start of the last dispense with a switch. This makes it unlikely that the associ-
ation between switching and risk of exacerbation is causal. When we considered switches with 
start of the last dispense within 30 days prior to indexdate, the association became stronger, 
but we lacked power to reach statistical significance. 
176 Chapter 5.2
Table 3 - Association between switching between generic and brand salbutamol and moderate to severe asthma exacerbation 
by agegroup.
Switching Generic brand salbutamol 
1 year
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
Salbutamol        
<18    
No switch and use in 1-365 days before index date 229 (71.1) 1,633 (50.7) reference reference
Switch and use in 1-365 days before index date 24 (7.5) 83 (2.6) 2.00 (1.24-3.23) 1.95 (1.16-3.27)
18-45
No switch and use in 1-365 days before index date 662 (52.2) 5,498 (43.6) reference reference
Switch and use in 1-365 days before index date 34 (2.7) 208 (1.7) 1.34 (0.92-1.95) 1.16 (0.79-1.72)
>45
No switch and use in 1-365 days before index date 731 (33.2) 3,206 (28.8) reference reference
Switch and use in 1-365 days before index date 52 (2.4) 153 (0.7) 2.79 (2.00-3.88) 2.14 (1.51-3.03)
Switching Generic brand salbutamol 
30 days
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
Salbutamol        
<18    
No switch and use in 1-30 days before index date 178 (55.3) 807 (25.1) reference reference
Switch and use in 1-30 days before index date 2 (0.6) 3 (0.1) Nap Nap
18-45
No switch and use in 1-30 days before index date 447 (35.2) 2,849 (22.6) reference reference
Switch and use in 1-30 days before index date 2 (0.2) 7 (0.1) Nap Nap
>45
No switch and use in 1-30 days before index date 496 (22.5) 3,076 (14.3) reference reference
Switch and use in 1-30 days before index date 4 (0.2) 6 (0.0) 2.87 (0.47-17.71) 2.27 
(0.34-15.18)
* Adjusted for past use and current use of other drug classes, follow-up, smoking, asthma exacerbations, GERD, anxiety/
depression, obesity, overweight prior to index date and concomitant medications antacids use of hypnotics or anxiolytics, use 
of antidepressants, nasal preparations, antihistamines used in 30 days before index date. Current use = 1-30 days before index 
date. Past use = >30 days before index date. 
Nap = not applicable as number of exposed cases lower than 3
** all respiratory drugs = ICS, LABA, SABA, and other (= tiotropium, ipratropium, ipratropium+fenoterol, cromoglycaat and 
nedocromil)
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Table 4 - Characteristics of patients with severe exacerbations (asthma exacerbation requiring hospitalization) and matched 
controls.
Moderate exacerbations
cases 
n=104 (%)
controls 
n=1,040(%)
matched OR* 
(95% CI)
Gender
- Male 43 (41.3) 430 (41.3)
- Female 61 (58.7) 610 (58.7)
Age (median ,IQR) 35.7 (9.7-56.8) 35.7 (9.7-56.0) Nap
Smoking 4 (3.8) 18 (1.7)
History of exacerbations
cases 
n=104 (%)
controls 
n=1,040(%)
matched OR* 
(95% CI)
Severe exacerbations (hospitalization)
0 86 (82.7) 1,019 (98.0)
1 9 (8.7) 18 (1.7) 5.49 (2.42-12.45)
2 4 (3.8) 3 (0.3) nap
 >2 5 (4.8) 0 (0.0) nap
All exacerbations (hospitalization or OCS)
0 28 (26.9) 640 (61.5)
1 14 (13.5) 156 (15.0) 2.49 (1.25-4.96)
2 16 (15.4) 106 (10.2) 4.57 (2.35-8.90)
 >2 46 (44.2) 138 (13.3) 12.76 (7.02-23.21)
Co-morbidity
Gastro oesophageal reflux disease 5 (4.8) 21 (2.0) 2.53 (0.91-7.03)
Anxiety/depression/ psych 9 (8.7) 116 (11.2) 0.75 (0.36-1.54)
Obesity 1 (1.0) 28 (2.7) nap
Overweight 3 (2.9) 23 (2.2) nap
Concomitant medication**
Antacids 24 (23.1) 128 (12.3) 3.06 (1.77-5.30)
Psycho-therapeutics 20 (19.2) 106 (10.2) 3.07 (1.76-5.36)
Nasal preparations 11 (10.6) 111 (10.7) 0.99 (0.55-1.78)
Antihistamines 13 (12.5) 97 (9.3) 1.29 (0.71-2.35)
Antibiotics 30 (28.8) 64 (6.2) 7.34 (4.38-12.3)
* matched on age, gender and index date
** use in the 1-30 days before the index date
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Table 5 - Association between use of inhalation medication (generic/brand) and severe asthma exacerbation.
Generic/brand/brand no generic
cases 
n=104 (%)
controls 
n=1,040 (%)
matched OR 
(95% CI)
adjusted OR*1 
(95% CI)
Current use        
Brand 46 (44.2) 377 (36.3) reference reference
Generic 38 (36.5) 141 (13.6) 2.22 (1.36-3.61) 2.05 (1.20-3.52)
Brand no generic available 2 (1.9) 10 (1) nap nap
Past use        
Generic 7 (6.7) 207 (19.9) 0.28 (0.13-0.65) 0.36 (0.15-0.87)
Brand 11 (10.6) 301 (28.9) 0.30 (0.15-0.59) 0.40 (0.19-0.82)
Brand no generic available 0 (0) 4 (0.4) nap nap
Generic/brand 
ICS/LABA/SABA Current use
cases 
n=104 (%)
controls 
n=1,040 (%)
matched OR 
(95% CI)
adjusted OR*2 
(95% CI)
Current use of ICS        
Brand 44 (42.3) 333 (32) reference reference
Generic 3 (2.9) 13 (1.3) 1.66 (0.45-6.08) 1.66 (0.37-7.41)
Brand no generic available 2 (1.9) 12 (1.2) nap  nap 
Current use of LABA        
Brand 12 (11.5) 22 (2.1) reference reference
Generic 1 (1) 3 (0.3) nap  nap 
Brand no generic available 1 (1) 0 (0) nap  nap 
Currrent use of SABA        
Brand 26 (25) 139 (13.4) reference reference
Generic 32 (30.8) 120 (11.5) 1.50 (0.82-2.74) 1.59 (0.81-3.14)
Brand no generic available 2 (1.9) 7 (0.7) nap  nap 
Currrent use of salbutamol        
Brand 21 (20.2) 117 (11.2) reference Reference
Generic 32 (30.8) 120 (11.5) 1.56 (0.83-2.93) 1.63 (0.80-3.29)
Currrent use of salbutamol+ipratropium
Brand 1 (1.0) 0 (0.0) reference Reference
Generic 0 (0.0) 0 (0.0) nap nap
Currrent use of terbutaline
Brand 5 (4.8) 24 (2.3) reference Reference
Generic 0 (0.0) 0 (0.0) nap nap
*1 Adjusted for past use of all respiratory drugs**, smoking, follow-up, asthma exacerbations, GERD, anxiety/depression, obesity, 
overweight prior to index date and concomitant medications antacids use of hypnotics or anxiolytics, use of antidepressants, 
nasal preparations, antihistamines used in 30 days before index date. Current use = 1-30 days before index date. Past use = 
>30 days before index date.
*2 Additionally adjusted for current use of all other respiratory drugs** 
** all respiratory drugs= ICS, LABA, SABA, and other (=tiotropium,ipratropium, ipratropium+fenoterol, cromoglicic acid and 
nedocromil)
Numbers of the different drug classes (ICS, LABA, SABA) are not adding up to total number of "all" as for each treatment 
class we started with selecting patients currently using a drug in that treatment class. One patient could be present in all 
treatment classes. Current use = 1-30 days before index date.
nap: not applicable as number of exposed cases lower than 3
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Although the preference policy was implemented in 2005 and expanded in 2008, we observed 
a relatively low percentage of switching during our study period 2003-2012. Since 2012, new 
generic asthma drugs came on the market and the current proportion of switching may well 
be higher now than before 2012. 3 The fact that we did not observe many device switches is 
promising, and in line with the substitution guidelines in the Netherlands. 22 
Our findings on increased risk of generic salbutamol are in line with recent case reports on 
decreased efficacy of the generic salbutamol aerosol after the revision of the device that were 
reported to the Netherlands Pharmacovigilance Centre Lareb. Besides some external changes 
of the device, the formulation of the propellant was changed as well.23 However these cases 
were reported in 2015 and our latest dispensing information is from 2012. Our data confirm a 
previous cross over study in 36 asthmatic adults from New Zealand in whom asthma stability 
was significantly worse with generic salamol compared to brand. 24 In contrast, other studies 
found no difference in FEV1 25, 26 or doubtful clinical effect. 27 
We did not observe an association between the use of generic ICS and risk of asthma exacer-
bations, which is in line with an 8-week therapeutic equivalence study of brand and generic 
beclomethasone in adult asthmatic patients. 28
The main strengths of this study are the large size (15,289 patients with asthma), the detailed 
information on comorbidity and life style factors, the access to dispensing rather than prescrip-
tion data and the real life data, collected as part of routine patient care, which reinforces the 
external validity.
The limitations of an observational study are obvious. We used pharmacy data, implying that 
we only have information on dispensing and not on actual use nor inhalation technique. Diag-
nostic bias might have occurred as we did not validate comorbidities but relied on ICPC disease 
codes and hospital registration codes to identify asthma, exacerbations and comorbidities. We 
have no reason to assume that this bias would be differential, and if bias affected our results it 
would probably underestimate the studied associations. Smoking status was not systematically 
reported in all patients whereas we know that it is an important covariate in respiratory re-
search. In addition, differential prescribing driven by factors such as asthma control, prescriber 
preferences and other unmeasured factors is likely. Unfortunately, we did not have access to 
the complete medical records of the patients which makes it difficult to assess why a certain 
drug was prescribed or switched. As we did not have information on GP practice, we could not 
match on GP practice to control for preferential prescribing. 
In conclusion, dispensing of generic drugs was associated with an increased risk of exacerba-
tions, when compared to brand drugs. Moreover, switching between brand and generic drugs 
was associated with an increased risk of exacerbations, especially for β2-agonists, and in partic-
ular when the switch occurred within 1 month before the exacerbation. To elucidate whether 
this association is real, or confounded by lack of asthma control, we suggest replicating our 
findings taking asthma control into account.
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SUPPLEMENTS
Online Table 1 - Categories of inhalation medication with generic and brand.
Online Table 2 - Categories of inhalation medication where switching between inhalation device is available.
Medication 
Class ATC code Generic name 
Generic 
Available Brand
SABA R03AC02 Salbutamol Yes Aerolin®, Aeromir®, Ventolin®
SABA R03AC03 Terbutaline Yes Bricanyl®
SABA R03AC04 Fenoterol No Berotec®
LABA R03AC12 Salmeterol Yes Serevent®
LABA R03AC13 Formoterol Yes Atimos®, Foradil®, Oxis®
LABA R03AC18 Indacaterol No Onbrez®, Hirobriz®
Other R03AK03 Ipratropium + fenoterol No Berodual®
SABA R03AK04 Salbutamol + ipratropium Yes Combivent®
ICS R03AK06 Salmeterol + fluticasone Yes Viani®, Aliflus®, Seretide®
ICS R03AK07 Beclomethasone + 
formoterol
Yes Symbicort®, Assieme®, Flutiform® , 
Sinestic®, Foster®
ICS R03BA01 Beclomethasone Yes Aerobec®, Becotide®, Becloforte®, QVAR®
ICS R03BA02 Budesonide Yes Pulmicort®
ICS R03BA05 Fluticason Yes Flixotide®, Flutide®
ICS R03BA08 Ciclesonide No Alvesco®
Other R03BB01 Ipratropium Yes Atrovent®
Other R03BB04 Tiotropium No Spiriva®
Other R03BC01 Cromoglicic acid Yes Lomudal®
Other R03BC03 Nedocromil No Tilade®
ATC code Generic name Device Device
R03AC02 Salbutamol DPI Cyclocaps, diskus, novolizer, rotadisk
R03AC02 Salbutamol pMDI Autohaler, ivax, mylan, redihaler, salbutamol, Ventolin, aerolin, 
airomir
R03AC12 Salmeterol DPI Diskus, rotadisk
R03AC13 Formoterol DPI Clickhaler, cyclocaps, diskus, easyhaler, novolizer, turbuhaler
R03AC13 Formoterol pMDI Aerolizer, atimos
R03AK07 Beclomethasone+formoterol pMDI Flutiform,foster,beclomethason
R03BA01 Budesonide DPI Cyclocaps, rotadisk
R03BA01 Budesonide pMDI Autohaler, extrafine, becloforte, beclomethason 
R03BA02 Beclomethasone DPI Clickhaler, cyclocaps, easyhaler, novolizer, turbuhaler
R03BA02 Beclomethasone pMDI Pulmicort, budesonide
R03BA05 Fluticason DPI Diskus, rotadisk
R03BA05 Fluticason pMDI Flixotide,flutide
R03BB01 Ipratropium bromide DPI Cyclocaps, inhalette
R03BC01 Cromoglicic acid pDMI Lomudal, cromoglicaat
ICS = inhaled corticosteroids, LABA = long-acting β2-agonists, SABA = short-acting β2-agonists
DPI = dry powder inhaler, pMDI = metered dose inhaler
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* Adjusted for follow-up time, smoking, asthma exacerbations, GERD, anxiety/depression, obesity, overweight prior to index 
date and concomitant medications antacids use of hypnotics or anxiolytics, use of antidepressants, nasal preparations, anti-
histamines used in 30 days before index date. Current use = 1-30 days before index date. Past use = >30 days before index date. 
Online Table 3 - Association between use of inhalation medication by generic or brand, by generic, brand, and brand no 
generic available and by drug class (ICS, LABA and SABA) and moderate to severe asthma exacerbation.
generic brand
cases
n=3,796 (%)
controls
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
current use any*
brand 1,914 (50.4) 14,821 (39.7) reference reference
generic 620 (16.3) 3,690 (9.9) 1.30 (1.18-1.44) 1.34 (1.21-1.48)
past use*
generic 374 (9.9) 5,764 (15.4) 0.50 (0.44-0.56) 0.59 (0.52-0.66)
brand 888 (23.4) 13,092 (35) 0.52 (0.48-0.57) 0.60 (0.55-0.66)
Brand/Generic
No generic available
cases
n=3,796 (%)
controls
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
current use any*
Brand 1,820 (47.9) 14,081 (37.7) reference reference
Generic 620 (16.3) 3,690 (9.9) 1.3 (1.18-1.44) 1.33 (1.2-1.47)
No generic available 94 (2.5) 740 (2) 0.96 (0.77-1.2) 0.86 (0.68-1.09)
Generic/brand
ICS/LABA/SABA
cases
n=3,796 (%)
controls
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR*#
(95% CI)
Current use of ICS
Brand 1,498 (39.5) 11,258 (30.1) reference reference
Generic 81 (2.1) 769 (2.1) 0.8 (0.63-1.01) 0.87 (0.68-1.11)
No generic available 45 (1.2) 441 (1.2) 0.78 (0.57-1.06) 0.71 (0.51-0.98)
Current use of LABA
Brand 171 (4.5) 1,015 (2.7) reference reference
Generic 12 (0.3) 56 (0.1) 1.35 (0.71-2.58) 1.55 (0.78-3.07)
No generic available 2 (0.1) 13 (0) nap nap
Current use of SABA
Brand 808 (21.3) 5,160 (13.8) reference reference
Generic 494 (13) 2,773 (7.4) 1.14 (1.01-1.29) 1.13 (0.99-1.28)
No generic available 1 (0) 3 (0)
Current use of salbutamol
Brand 641 (16.9) 3,976 (10.6) reference reference
Generic 489 (12.9) 2,772 (7.4) 1.10 (0.96-1.24) 1.10 (0.96-1.26)
Current use of terbutaline
Brand 165 (4.3) 1,187 (3.2) reference reference
Generic 0 (0.0) 1 (0.0) nap nap
Current use of salbutamol+ipratropium
Brand 18 (0.5) 74 (0.2) reference reference
Generic 5 (0.1) 0 (0.0) nap nap
Generic/brand
no generic available
cases
n=3,796 (%)
controls
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
past use**
Generic 374 (9.9) 5,764 (15.4) 0.5 (0.44-0.56) 0.58 (0.52-0.66)
Brand 879 (23.2) 12,988 (34.8) 0.52 (0.48-0.57) 0.6 (0.55-0.65)
No generic available 9 (0.2) 104 (0.3) 0.68 (0.34-1.34) 0.71 (0.35-1.43)
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Online Table 4 - Patients with a switch from brand to generic (s1), from generic to brand (s2) or with switch in device, in 365 
days before index date, and in 30 days before index date, categorized by drug class.
Switch Generic Brand 
in 1 year before index date
Switch Generic Brand 
in 30 days before index date
Cases Controls Cases Controls
(N) % (N) % (N) % (N) %
s1_ics 7 0.2% 118 0.3% 1 0.0% 1 0.0%
s2_ics 7 0.2% 58 0.2% 0 0.0% 2 0.0%
s1_laba 4 0.1% 20 0.1% 0 0.0% 1 0.0%
s2_laba 0 0.0% 11 0.0% 0 0.0% 1 0.0%
s1_saba 72 1.9% 237 0.6% 4 0.1% 8 0.0%
s2_saba 56 1.5% 279 0.7% 5 0.1% 9 0.0%
s1_salbutamol 72 1.9% 233 0.6% 4 0.1% 8 0.0%
s2_salbutamol 56 1.5% 274 0.7% 5 0.1% 9 0.0%
s1_terbutaline 0 4 0.0% 0 0
s2_terbutaline 0 5 0.0% 0 0
s1_salbutamol + 
ipratropium
0 1 0.0% 0 0
s2_salbutamol 
+ipratropium
0 0 0 0
Total 145 2.4% 690 1.1% 10 0.3% 24 0.1%
Switch Generic Brand 
in 1 year before index date
Switch Generic Brand 
in 30 days before index date
Cases Controls Cases Controls
(N) % (N) % (N) % (N) %
Total 28 0.7% 227 0.6% 2 0.1% 14 0.0%
ICS 15 0.4% 114 0.3% 1 0.0% 6 0.0%
LABA 1 0.0% 16 0.0% 0 0.0% 0 0.0%
SABA 10 0.3% 72 0.2% 1 0.0% 8 0.0%
S1 = switch from brand to generic. S2 = switch from generic to brand. ICS = inhaled corticosteroids, LABA = long-acting 
β2-agonists, SABA = short-acting β2-agonists. N = number, % is percentage of total patients 
** Total switch is not adding up as the sum of saba, laba and ics as patients could switch more than once and switch was also 
possible in drugs not included in ics.laba or saba, namely ATC codes BB01, BB04, BC01, AK03 and BC02.
# Adjusted for past use of respiratory drugs and current use of all other respiratory drugs** 
** all respiratory drugs = ICS, LABA, SABA, and other (= tiotropium,ipratropium, ipratropium+fenoterol and cromoglicic acid 
and nedocromil)
Numbers of the different groups are not adding up to total number of "all", as for each treatment class we started with se-
lecting patients currently using a drug in that treatment class. One patient could be present in all treatment classes. Current 
use = 1-30 days before index date.
Online Table 3 Continued - Association between use of inhalation medication by generic or brand, by generic, brand, and brand 
no generic available and by drug class (ICS, LABA and SABA) and moderate to severe asthma exacerbation.
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Online Table 5 - Association between switch in inhalation device switch and moderate to severe asthma exacerbation.
Switch device
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
ICS
no switch and use in 1-365 days before index date 2,731 (71.9) 23,546 (63.0) reference reference
Switch and use in 1-365 days before index date 15 (0.4) 114 (0.3) 1.11 (0.64-1.91) 1.11 (0.63-1.96)
Use 1-365 days before index date of drugs with 
no switch possibility
66 (1.7) 606 (1.6) 0.94 (0.73-1.22) 0.89 (0.68-1.16)
LABA
no switch and use in 1-365 days before index date 382 (10.1) 2,445 (6.5) reference reference
Switch and use in 1-365 days before index date 1 (0) 16 (0.1) nap nap
Use 1-365 days before index date of drugs with 
no switch possibility
7 (0.2) 29 (0.1) nap nap
SABA
no switch and use in 1-365 days before index date 1,807 (47.6) 14,192 (38.0) reference reference
Switch and use in 1-365 days before index date 10 (0.3) 72 (0.2) 1.13 (0.58-2.20) 0.96 (0.48-1.90)
Use 1-365 days before index date of drugs with 
no switch possibility
241 (6.3) 1,951 (5.0) 0.97 (0.84-1.12) 1.00 (0.86-1.16)
ICS = inhaled corticosteroids, LABA = long-acting β2-agonists, SABA = short-acting β2-agonists
* Adjusted for past use of respiratory drugs, current use of all other respiratory drugs**, smoking history, follow-up, severe to 
moderate exacerbations, GERD, anxiety/depression, obesity, overweight prior to index date and concomitant medications 
antacids use of hypnotics or anxiolytics, use of antidepressants, nasal preparations, antihistamines used in the 30 days before 
index date. 
** all respiratory drugs = ICS, LABA, SABA, and other (=tiotropium,ipratropium, ipratropium+fenoterol, cromoglycaat and 
nedocromil)
Numbers of the different groups are not adding up to total number of "all", as for each treatment class we started with se-
lecting patients currently using a drug in that treatment class. One patient could be present in all treatment classes. Current 
use = 1-30 days before index date.
nap: not applicable as number of exposed cases lower than 3
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Online Table 6 - Association between use of inhalation medication by drug class and moderate to severe asthma exacerbation 
by agegroup <18, 18-45 and ≥45 years.
Current use
Brand/generic
cases 
n=3,796 (%)
controls 
n=37,367 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
Current use of ICS        
<18 322  3,219     
brand 6 (1.9) 706 (21.9) reference reference
generic 142 (44.1) 46 (1.4) 0.70 (0.29-1.68) 1.04 (0.42-2.56)
brand without generic substitution 0 (0.0) 3 (0.1) nap nap
18-45 1,269  12,605     
brand 479 (37.7) 3,296 (26.1) reference reference
generic 51 (1.6) 5 (1.6) 0.60 (0.38-0.94) 0.67 (0.42-1.06)
brand without generic substitution 12 (0.9) 87 (0.7) 0.98 (0.53-1.80) 0.89 (0.47-1.68)
>45 2,205 21,543     
brand 877 (39.8) 7,256 (33.7) reference reference
generic 53 (2.4) 475 (2.2) 0.93 (0.70-1.25) 1.00 (0.74-1.35)
brand without generic substitution 33 (1.5) 351 (1.6) 0.78 (0.54-1.13) 0.71 (0.49-1.03)
Current use of LABA        
<18 322  3219     
brand 5 (1.6) 12 (0.4) reference reference
generic 0 0 nap nap
brand without generic substitution 0 0 nap nap
18-45 1,269  12,605     
brand 55 (4.3) 289 (2.3) reference reference
generic 3 (0.2) 4 (0.0) 3.93 (0.85-18.09) 4.97 (1.04-23.68)
brand without generic substitution 2 (0.2) 2 (0.0) nap nap
>45 2.205 21,543     
brand 111 (5.0) 714 (3.3) reference reference
generic 9 (0.4) 52 (0.2) 1.18 (0.56-2.46) 1.29 (0.60-2.80)
brand without generic substitution 0 (0.0) 11 (0.1) nap nap
Current use of SABA        
<18 322  3219     
brand 98 (30.4) 447 (13.9) reference reference
generic 94 (29.9) 437 (13.6) 1.00 (0.72-1.38) 1.14 (0.80-1.61)
brand without generic substitution 0 0 nap nap
18-45 1,269  12,605     
brand 339 (26.7) 2,189 (17.4) reference reference
generic 169 (13.3) 1,116 (8.9) 0.97 (0.80-1.19) 1.03 (0.84-1.27)
brand without generic substitution 1 (0.1) 3 (0.0) nap nap
>45 2,205 21,543     
brand 371 (16.8) 2,425 (11.7) reference reference
generic 231 (10.5) 1,220 (5.7) 1.27 (1.06-1.52) 1.20 (0.99-1.44)
brand without generic substitution 0 0 nap nap
* Adjusted for past use of all other drugs, current use of other drug classes, follow-up, smoking, asthma exacerbations, GERD, 
anxiety/depression, obesity, overweight prior to index date and concomitant medications antacids use of hypnotics or anxi-
olytics, use of antidepressants, nasal preparations, antihistamines used in 30 days before index date. Current use = 1-30 days 
before index date. 
** all respiratory drugs = ICS, LABA, SABA, and other (= tiotropium, ipratropium, ipratropium+fenoterol, cromoglycaat and 
nedocromil)
nap = not applicable as number of exposed cases lower than 3
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Online Table 7 - Association between generic and brand switch in inhalation medication and moderate to severe asthma 
exacerbation.
Switch generic/brand 
in 1 year before index date
cases 
n=104 (%)
controls 
n=1,040 (%)
matched OR 
(95% CI)
adjusted OR* 
(95% CI)
ICS        
no switch and use in 1-365 days before index date 70 (67.3) 628 (60.4) reference Reference
Switch and use in 1-365 days before index date 0 (0.0) 2 (0.2) Nap Nap
Use 1-365 days before index date of brand with 
no generic available
2 (1.9) 11 (1.1) Nap Nap 
LABA
no switch and use in 1-365 days before index date 17 (16.3) 54 (5.2) reference Reference
Switch and use in 1-365 days before index date 0 (0.0) 1 (0.0) Nap Nap
Use 1-365 days before index date of brand with 
no generic available
1 (1.0) 1 (0.1) Nap Nap 
SABA
no switch and use in 1-365 days before index date 72 (69.2) 483 (46.4) reference Reference
Switch and use in 1-365 days before index date 1 (1.0) 13 (1.2) Nap Nap
Use 1-365 days before index date of brand with 
no generic available
0(0.0) 1(0.1) Nap Nap 
ICS = inhaled corticosteroids, LABA = long-acting β2-agonists, SABA = short-acting β2-agonists
* Adjusted for past use and current use of all other respiratory drugs and smoking history, follow-up time, severe to moderate 
exacerbations, GERD, anxiety/depression, obesity, overweight prior to index date and concomitant medications antacids use 
of hypnotics or anxiolytics, use of antidepressants, nasal preparations, antihistamines used in the 30 days before index date. 
** all respiratory drugs = ICS, LABA, SABA, and other (= tiotropium, ipratropium, ipratropium+fenoterol, cromoglycaat and 
nedocromil)
Nap: not applicable as number of exposed cases lower than 3
Online Figure 1 - Switching between brand and generic medication (or vice versa). Figure shows the 3 criteria for switching 
(1) use of medication in 365 days before exacerbation and (2) switch in 365 days before exacerbation and (3) the window 
between the start of dispense with switch and start of the prior dispense is maximum 365 days.
12 months
12 months
Maximum time window 365 days
prior to exacerbation / indexdateMaximum time window 365 days
between start current dispensing with
switch and start prior dispensing
Study start Study end
Rx brand Rx generic
switch exacerbation
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GENERAL DISCUSSION
Asthma is a highly prevalent and chronic respiratory condition. 1 According to the most recent 
comprehensive analysis of the WHO, an estimated 334 million people worldwide suffer from 
asthma. 2 Its prevalence has increased globally during the last decades according to results of 
the ISAAC questionnaires by 0.28% per year in the 13-14 year age group and 0.18% per year 
in the 6-7 year group. 3 However, there is some evidence that this increase came to an end, 
at least in Western Europe. 2, 3 Asthma is a chronic, episodic, heterogeneous disorder of the 
airways, characterized by wheezing, shortness of breath, chest tightness and cough that vary 
over time. This chronic airway inflammation is an important aspect of asthma pathophysiology, 
therefore asthma is most effectively treated with anti-inflammatory drugs, inhaled corticoste-
roids and leukotriene receptor antagonists, by inhibiting multiple components of the inflam-
matory cascade, including the production of prostaglandins and leukotrienes by their action 
of phospholipase. 4 Despite the proven efficacy of anti-inflammatory drugs in clinical trials, 
asthma control in clinical practice is suboptimal, as some asthmatics suffer from uncontrolled 
symptoms and exacerbations. 5 Several factors may contribute to this individual variation in 
treatment response, such as disease severity, co-morbidities, environmental factors, therapy 
adherence 6 and genetic factors. 7 
In this thesis we contributed to the knowledge on the epidemiology, medication use and dis-
ease outcome in patients with asthma using data from routinely electronic health care data-
bases, reflecting real life. 
In this chapter we discuss the main findings of this thesis and the methodological challenges 
that we encountered. In addition, we place the relevance of our findings and the potential 
implications in a broader context. Finally, some future perspectives of research with respect to 
epidemiology, treatment and outcomes of asthma are provided. 
Main findings
Epidemiology of asthma
As a consequence of the lack of European longitudinal studies in children with asthma, data on 
the incidence of asthma in children in Europe are sparse. Using data from the Dutch general 
practice Integrated Primary Care Information database (IPCI), we identified 14,303 children 
with asthma, 2,542 were incident. The overall asthma prevalence at start study was 6.7% (95% 
CI 6.6-6.8%). The overall asthma incidence rate was 6.7 per 1000 person years (PY) (95% CI 
6.45-6.97/1000 PY) with lower incidence rates for girls compared to boys. This gender differ-
ence in incidence became less obvious with increasing age. In IPCI the incidence rate increased 
significantly between 2000 and 2008 and tended to decrease after 2008. A recent study based 
on the ‘National Health Interview Survey’ data from the US observed a decrease in asthma inci-
dence in recent years. 8 However, data on the time trends in asthma incidence are conflicting. 9-11 
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Asthma medication use in children
In the paediatric asthma cohort, we studied prescription patterns of asthma medication and 
medication adherence. SABA and ICS were most frequently prescribed, whereas LABA (as 
monotherapy) was rarely prescribed and the prevalence of LABA monotherapy decreased over 
time, which is in line with treatment guidelines that warn against LABA use as monotherapy. 1, 12 
Treatment adherence is important, especially in chronic diseases like asthma. There are differ-
ent ways to assess adherence, each with their own set of advantages and limitations. 13-15 In 
database research, the medication possession rate (MPR) is most commonly used. 16 Adherence 
to asthma medications in the paediatric asthma cohort was suboptimal as only 31% of the ICS 
users had an MPR>0.8. This low MPR falls within the MPR range that was reported in other 
studies. 17, 18, 19 In reality, MPRs are probably even lower, as we only considered prescription 
and not dispensing data. In addition, even if all prescribed medication would be dispensed, 
this would not guarantee that all dispensed medication is correctly taken. This low MPR how-
ever, reflects reality, where in contrast to current asthma guidelines, controller therapy is often 
taken on an as-needed basis driven by the patient’s symptom control. 20 According to asthma 
guidelines, a follow-up visit is needed upon initiation of ICS or upon an increase of dose. 
However it is known that follow-up visits are not scheduled in all patients, putting patients at 
risk of unmonitored discontinuation of therapy and therefore lower MPR. 21 Another factor that 
may explain low adherence is that asthma in childhood is transient in some children which is 
reflected in transient medication use patterns. 22
It is well known that adherence is influenced by many factors. 1 In our study, characteristics of 
children with good adherence suggested that these children were having more severe asthma. 
This good adherence was potentially driven by treatment need or tighter medical follow-up.
To put our findings in context to what has already been published and to study whether adher-
ence has an impact on exacerbations in real life, we conducted a systematic review on asthma 
medication adherence and the risk of severe asthma exacerbations. (chapter 3.2) This review 
showed that there is large heterogeneity in adherence measures. In addition it reveals that de-
spite heterogeneity amongst the studies, high quality studies, which used objective adherence 
measures, reported that good adherence to asthma drugs was associated with a reduced risk 
of severe asthma exacerbations.
Asthma Exacerbations
In spite of a wide choice of different asthma medications, asthma exacerbations may still occur 
due to a variety of reasons, like inadequate treatment, nonresponse, non-adherence or other 
triggers such as lower respiratory tract infections. 23 In our research, moderate to severe asth-
ma exacerbations were defined according to the ATS/ERS guidelines as worsening of asthma 
symptoms which requires hospitalisation or emergency department visit or use of systemic 
corticosteroids. 24 Severe asthma exacerbations, hospitalisation or emergency department visit, 
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are associated with considerable morbidity and even mortality. 25 Little is known about the 
incidence of moderate to severe exacerbations, as data from RCTs are often underpowered in 
terms of sample size and follow-up. In the paediatric cohort from the IPCI database the over-
all incidence rate of moderate to severe asthma exacerbations was 2.1/100 PY (95% CI 1.9-
2.2/100 PY) in the total asthma cohort and 4.1/100PY (95% CI 3.8-4.4/100 PY) in children 
who were on asthma treatment. (chapter 4.1) This is in line with the incidence rate observed 
in the CAMP study, a RCT in children with mild to moderate asthma who were treated with 
budesonide, nedocromil or placebo for 4-6 years. 26 In the CAMP study, the incidence rate 
of asthma exacerbations requiring hospitalisation was 2.5/100 PY in the budesonide group, 
4.3/100 PY in the nedocromil group and 4.4/100 PY in the placebo group. In our study asth-
ma re-exacerbation occurred in 2% (95% CI 1.3-4.3%) of all patients within 1 month, and in 
25% (95% CI 20.6-28.8%) within 1 year and the risk remained constant over calendar time. 
Significant predictors for (frequent) exacerbations were age, gender, specialist visits, ICS pre-
scriptions and prior exacerbations. Our data conform previous studies that also showed that 
prior exacerbations were an important risk factor for future exacerbations. 27-29 This emphasizes 
the importance of close monitoring of children after moderate to severe asthma exacerbations. 
Mortality
As recent mortality rates in patients with asthma in Europe are sparse, we assessed all-cause 
mortality rates, mortality rates following severe asthma exacerbation and risk factors of mor-
tality. (chapter 4.2) For this study, data from 6 European electronic healthcare databases were 
used, all members of the EU-ADR alliance. 30 The cohort consisted of 855,806 patients with 
asthma aged 5 years or older and the study period was from 2008 to 2013. The proportion 
of patients with severe asthma, defined as use of high dose ICS during 120 days, ranged be-
tween 1.7-10.0%, and all-cause mortality rate in this severe asthma cohort ranged between 
16.0-33.4/1000 PY in the different databases. The mortality rate in the 1st week following 
a moderate to severe asthma exacerbation was 26.3-109.5/1000 PY. This mortality rate was 
twofold higher when restricting to severe asthma exacerbations (ED-visit/hospitalisation). 
(57.9-239.4/1000 PY). In most databases, risk factors of death in patients with asthma were 
increasing age, concomitant diseases (COPD, diabetes, cerebrovascular diseases, and cancer), 
smoking and underlying asthma severity. Prior moderate to severe asthma exacerbation was 
associated with a 76% increase in the risk of death. This finding underlines the importance of 
asthma control, as by preventing asthma exacerbations the risk of mortality may be reduced.
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Preference policy 
In Chapter 5.1 and 5.2 we studied the effects of the Dutch preference policy. This policy favours 
the use of generic drugs as alternatives to more expensive brand-name products. Before generic 
medications are marketed, demonstration of clinical bioequivalence is needed. As the drug de-
livery and intended action of orally inhaled drug products for local action, such as dry powder 
inhalers (DPI) do not rely on their effect in the systemic circulation, the bioequivalence cannot 
be demonstrated based on drug concentration in blood/plasma. 31 Therefore demonstration 
of bioequivalence of these products is more challenging. The guideline of the European Medi-
cines Agency on requirements for clinical documentation of orally inhaled products for asthma 
and COPD states that for inhalers with the same substance and required flow rate, similar in 
vitro performance is sufficient to show equivalence. 32 In vitro performance includes particle 
size distribution, fine particle fraction of emitted dose and flow rate dependency tested under 
validated circumstances. 32 Health care professionals are concerned about generic substitution 
because fear of negative effects on disease control through non-adherence, and potentially lack 
of efficacy because of inappropriate use of inhalation devices. 
Although generic substitution is widely implemented, it still remains to be answered whether 
generic use or switching influences persistence to long-term treatment and clinical outcomes. 
For this study we used data from the PHARMO Database Network, which links different sourc-
es of data (e.g. drug dispensing, hospital discharge diagnoses, and medical diagnosis and pre-
scriptions of the GP) and includes information on 2 million residents in the Netherlands. First, 
we defined a population based cohort to study the prevalence of generic and brand use and 
switching between brand, generic inhalation medication and its effect on adherence. (chapter 
5.1) The total cohort of patients who used inhalation medication for which a generic alternative 
was available, consisted of 56,853 patients. The annual proportion of patients who switched 
from generic to brand medication or vice versa was 5%. About 16% of all patients used more 
than 1 device in 1 calendar year. No net negative impact on adherence in patients who switch 
from brand to generic was observed, which is promising, however adherence remained low. 
To investigate potential clinical consequences of use of generic inhalation medication and 
switching between generic and brand inhalation medication (or vice versa) on disease control 
we conducted two case control studies. (chapter 5.2) Cases were patients ≥5 years of age with 
asthma who had a first moderate to severe asthma exacerbation, defined as need of systemic 
corticosteroids or requiring hospitalization for asthma (case-control set 1), or severe asthma 
exacerbation, defined as requiring hospitalization (case-control set 2). To each case, up to 10 
controls were matched on age, gender, and index date. 
The first case-control set consisted of 3,796 cases. Current use of generic inhaled medication 
was associated with an increased risk of moderate to severe asthma exacerbations (ORadj 1.33 
(95% CI 1.20-1.47) Switching from brand to generic (or vice versa) salbutamol increased the 
risk of moderate to severe asthma exacerbations with 68%. (ORadj 1.68 (95% CI 1.34-2.10), 
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with highest risks in patients <18 and ≥45 years of age. (<18: ORadj 1.95 (95% CI 1.16-
3.27) and ≥45 ORadj 2.14 (95% CI 1.51-3.03). The association with current use of generics 
was higher in the case control analysis on severe exacerbations (104 cases) (ORadj 2.05 (95% 
CI 1.20-3.52). But no significance was reached when data were analysed by drug class or 
switching type. This study showed that current use of generic inhaled β2-agonists might be 
associated with a small increased risk of exacerbations when compared to current use of brand 
β2-agonists, in particular when switched between generic and brand. However, it is unclear 
whether the association that was observed is causal. Unfortunately, we could not investigate 
the indication of switching in this database. In the asthma domain conflicting results with both 
protective as well as adverse effects of generic drug use were observed. 33-41 Another limitation 
was that our study period was from 2003-2012, a period in which the availability of generic 
respiratory drugs was still relatively low. Since 2012 new generic inhalation drugs came into 
the market implying that the current proportion of generic medication use and the proportion 
of switching should probably be higher than what we observed. 41
Pharmaco-Genetics
There is evidence that genetic factors play a role in inter-individual differences in therapeutic 
responses to the common classes of asthma therapy such as β2-agonists, corticosteroids, and 
leukotriene modifiers. 42 Unfortunately, it is difficult to conduct pharmaco-genetic research us-
ing the data from existing Dutch paediatric cohort studies, because only few children enrolled 
in these cohorts regularly used asthma medication. 43-45 Therefore, we are presently recruiting 
children with asthma to be included in a new paediatric cohort which will be used for future 
pharmacogenetics studies: the ESTATe -cohort. (www.estate-studie.nl) This ESTATe cohort has 
its origins in the IPCI asthma-cohort, which was used for many of our studies. Within the 
IPCI asthma cohort, we selected patients on asthma controller therapy and identified patients 
experiencing an asthma exacerbation as case. Each case was matched up to 4 controls on age, 
sex, general practice (GP) and asthma therapy. Patients were recruited via their GP and if they 
agreed to participate, they provided a saliva sample (for DNA extraction and genetic analysis) 
and completed a questionnaire including the Asthma Control Questionnaire. 46 As recruitment 
was more difficult than anticipated, we expanded the recruitment to patients in the PHARMO 
Database Network. 
Until now 111 patients (cases and controls) provided a saliva sample and are included in the 
ESTATe cohort. We continue patient inclusion for the study, however we did not attain the 
foreseen sample size. Currently efforts are being made to combine our data with data from the 
PACMAN cohort 47 to guarantee sufficient power to conduct pharmaco-genetic studies on the 
association between genetic variability in treatment response and risk of asthma exacerbations. 
Eventually this data will be integrated with the Pharmacogenomics in Childhood Asthma consor-
tium (PICA) 48, to guarantee enough power for genome wide association analyses in the future. 
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Methodological considerations 
Different data sources for population based asthma research 
All studies, except for the systematic review described in chapter 3.2 were conducted using 
data from electronic healthcare databases. For chapter 2.2, 3.1 and 4.1 we used the IPCI da-
tabase, a general practitioner database containing the complete medical records of 1,5 million 
patients, with detailed information on patient characteristics, comorbidities and treatment. 49 
One of the unique features of the IPCI database is that IPCI includes both structured and 
unstructured information, since much details are still described as narratives in the medical 
record. For some of the practices, referral and/or discharge letters were incorporated in the 
medical record. Previous research showed that IPCI is representative of the Dutch population 
with regard to age and gender. 50
For chapter 5.1 and 5.2 the Dutch PHARMO Database Network (www.pharmo.nl) was used. 
This population-based patient centric data network combines data from different healthcare 
setting, including general practitioner (GP), in- and outpatient pharmacy and hospitals. It in-
cludes high quality and complete information linked on a patient level of, among other data, 
patient demographics, drug dispensing records from community pharmacies, hospital discharge 
records, and GP diagnoses of more than two million individuals throughout the Netherlands. 51 
The PHARMO database was used to study the use of generic and brand inhalation medication 
because this database, in contrast to the IPCI database has data on dispensing data in addition 
to prescribing data and has the possibility to link to hospital data. Dispensing information was 
important, as pharmacists may substitute brand medications to generics or vice versa. 
In chapter 4.2 we studied mortality rates following asthma exacerbations in Europe, therefore 
we used data from 6 different electronic healthcare databases which are managed or licensed 
by partners in the EU-ADR Alliance. The 6 databases were the Integrated Primary Care Infor-
mation Project (IPCI) from the Netherlands, the Health Search Database (HSD) and Pedianet 
from Italy, the Clinical Practice Research Datalink (CPRD) from the UK, the Sistema d’Infor-
mació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP) from Spain 
and the Aarhus University Prescription Database (AUH) from Denmark. Detailed description 
of these databases has been published before.49, 52-56 All databases contain electronical medical 
records from primary care, apart from AUH which is a prescription database that links to the 
national registry. Each database has their own strengths and limitations in terms of sample size, 
dosing information, drug and disease coding systems, and the ability to link data. 
Validation of asthma 
For the studies described in chapter 2.2 and 4.1 we defined a population based paediatric 
asthma cohort in the IPCI database between 2000 and 2012. This cohort comprised all patients 
between 5-18 years of age, diagnosed with asthma. A patient was considered to have asthma 
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if diagnosed by the specialist, or in the presence of an asthma disease code in combination 
with at least two prescriptions of asthma drugs during follow-up. As the initial search returned 
over 60 thousand records, we used text mining for concept retrieval in the medical records, 
which was categorising subjects into “definite” or “probable” asthma cases, or patients without 
asthma based on machine learning techniques. (chapter 2.1) In order to train the machine a 
manually validated training set is needed. These techniques lead to a reduction of the false pos-
itives that are retrieved if only text strings are searched. Upon return of the machine classified 
asthma cases, manual validation was done for of 100% of the potential definite cases and 25% 
of the probable cases, as fully automated search would still lead to inclusion of false positives. 
The resulting prevalence at cohort entry was 6.8% which is in line with prevalences as reported 
in other studies. 3 
For the study in the EU-ADR alliance, the definition of patients with asthma was based on 
disease and medication codes, without manual validation. As each database had their own 
coding system (ICPC for IPCI; READ codes for HSD, ICD9 for Pedianet and HSD and ICD10 for 
AUH), a harmonisation of disease codes had to be conducted prior to data extraction. This har-
monisation was done through use of the Unified Medical Language System. 57 A set of disease 
codes was created from disease concept mappings, which were then verified by the different 
databases prior to data extraction. Although some results were comparable between databases, 
i.e. mortality rates, differences were observed with regard to the incidence of moderate asthma 
exacerbations. The difference between databases in the incidence of moderate asthma exacer-
bations can be explained by different factors, for example by differences in coding systems or 
availability of data (i.e. indication of use missing in some of the databases). An earlier study 
on information on asthma drug use in Italy, UK and the Netherlands, clearly demonstrates the 
similarities and differences in prescription rates. 58 This study observed very heterogeneous 
prescription rates of systemic corticosteroids between countries, with user rates exceeding 
10/100 PY in Italy, whereas user rates were five to eightfold lower in the UK and almost 20 fold 
lower in the Netherlands. Like in our study, the health care provider in the studied countries 
differed, with GP data from the UK and NL and family paediatrician data from Italy. However, 
we do not believe that this would hinder comparability between databases as the nature of 
the databases is the same. If there are differences between countries, this reflects differences 
in primary care prescribing behaviour and not in the type of data. This prescribing behaviour, 
reflecting the use of oral corticosteroids, might be explained by cultural differences. This was 
shown by Wahlstrom et al. where 100 physicians per country in 5 European countries, in the 
Netherlands, Germany, Sweden, Norway and the Slovak Republic, were asked to give their 
treatment decision for two sets of case simulations. One case on treatment of an exacerbation 
and one on adjustment of suboptimal maintenance treatment. When the decisions of all doc-
tors of a country were pooled, they significantly differed in their recommendations concerning 
OCS prescriptions despite having been given similar case descriptions. 59
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Methodological challenges 
The use of large real life databases was important for our research on asthma outcomes like 
severe asthma exacerbations and mortality as the incidence of these outcomes is relatively 
rare. Furthermore it gives the opportunity to study real life practice. However, observational 
research is prone for bias and-or confounding. Bias is generally categorized into selection bias 
and information bias. 60
Selection bias, due to lack of participation or response in the study is probably minimal in these 
population based databases, as this does not require consent. 
The bias which was probably most relevant to our research is information bias. Information bias 
might have resulted from our assessment of drug exposure, comorbidity and disease outcomes. 
With regard to assessment of drug exposure, information on drug dispensing was not available 
in some databases (IPCI, HSD, Pedianet, CPRD). This implies that prescriptions initiated by the 
specialist, or prescriptions during hospitalization might be missed. As the GP plays a gatekeep-
er role for patient care, prescriptions as initiated by the specialist will often be continued by 
the GP, which limits the amount of misclassification. 61 Additional misclassification of exposure 
relates to the fact that we did not have information on actual drug intake nor on correct use 
of the drugs. 
Second, misclassification of outcomes and comorbidity is a concern in those studies where no 
manual validation of outcomes was done. Indeed, for those studies where other databases were 
used than IPCI, it was not possible to conduct a free text search followed by manual validation. 
Misclassification of outcomes like hospitalisation or ED visits for asthma exacerbation is a con-
cern for those databases that do not automatically link to hospital data like IPCI, Pedianet and 
HSD. For those databases where linkage was not feasible, data on asthma exacerbations was 
indirectly retrieved either via disease-specific codes in combination with codes for hospitaliza-
tion or via review of the discharge letters. 
Finally, confounding is a concern in all observational research and could result in spurious 
associations. A confounding factor is a factor that is both associated with the exposure and with 
the outcome but that is not in the causal pathway. 62
Important confounding factors in our research were asthma severity and smoking status. Asth-
ma severity is a confounder because it is related to the exposure (choice of asthma drugs, 
driven by asthma control) and to the outcomes as patients with severe asthma are at risk of 
asthma exacerbations. Asthma severity scores are unfortunately not systematically recorded 
in the databases. Because of current treatment guidelines and GPs incentives to improve the 
quality of reporting, we observe an improvement with regard to registration of lung function 
data, smoking status and asthma symptom severity, nowadays. 63, 64 
Confounding can be controlled for either in the design of the study by restriction or matching 
or in the analysis through stratification or the use of multivariate techniques (e.g. multivariate 
logistic regression or proportional hazard analysis), and time-dependent covariables, which 
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ideally requires marginal structural modelling. 65
In our research we applied several techniques like multivariate analysis, with time dependent 
variables in chapters 4.1 and 4.2 and matching on age, gender, practice and index date in 
chapters 5.1 and 5.2. 
Although we tried to correct for confounders where available, unknown or unmeasured resid-
ual confounders might still have affected our associations. 
Clinical implications and future research
The main aim of this study was to acquire real life data on the incidence and prevalence of 
asthma, treatment of asthma, asthma exacerbations and mortality. 
In the studies as presented in this thesis, we showed that the asthma incidence seems to de-
cline since 2008, but that asthma still imposes a significant burden on the population because 
of mortality and asthma exacerbations, implying the lack of adequate asthma control. Prior 
asthma exacerbations are the main risk factor for future exacerbations. 
The ultimate goals of asthma treatment are to achieve and maintain clinical control, to identify 
potential risk factors for asthma exacerbations and enable the patient to lead a life without re-
strictions due to the disease. 1, 66 Asthma control will result in a reduction of morbidity and a re-
duction in health care costs. Possibly, lack of adherence to treatment or poor inhaler technique 
are the key factors for poor asthma control. Correct inhaler technique is necessary for adequate 
medication delivery, and should be clearly explained and well demonstrated, as we know that 
in real life patients make critical errors in using their inhaler. Preferably, therapy regimen and 
inhalation techniques should be taught and checked repeatedly during follow-up appointments 
to correct mistakes. 67 This is of particular importance in case of complex treatment regimens 
(use of more than one inhaler) or in case of switching from drug and/or device. 
Pharmacists play a critical role in informing patients on the mode of action, correct device use 
and the importance of good adherence to reach sufficient asthma control. 68 Detecting and dis-
cussing non adherence through monitoring of refill prescription rates or by the use of electronic 
monitoring devices, increases awareness about adherence and correct medication use, with as 
ultimate goal to improve adherence and outcomes. 69 
Patients’ (and parents’) views and beliefs on the goals of treatment are essential in monitoring 
children with asthma. It is generally assumed that patients know whether their asthma is under 
control, however a recent online survey research suggested otherwise. 5 Underestimation of 
the symptoms may lead to inadequate treatment. Easy accessible attractive information on 
judgment of symptoms by smart phone applications or social media, might help children and 
their parents in symptom evaluation. 
The burden of asthma on health care budget is considerable. Generic substitution of brand 
medications was implemented to reduce asthma health care costs. However some recent data 
suggest that generic substitution might increase the risk of asthma exacerbations. In September 
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2015 the Netherlands Pharmacovigilance Centre Lareb reported case reports on decreased 
efficacy of a generic salbutamol aerosol after the revision of the device. Besides some exter-
nal changes, the formulation of the propellant was changed as well. 70 We also observed a 
small increased risk of asthma exacerbations for generic use of salbutamol. However the cases 
were reported to Lareb in 2015 and our latest dispensing information is till 2013. It remains 
questionable whether the association with increased risks of asthma exacerbations is real or 
confounded by other factors such as underlying asthma severity. We observed in our studies 
that substitution and device switch (which are not recommended) were low. We observed an 
association between use of generic salbutamol (and switching between generic and brand 
salbutamol (and vice versa)) and exacerbations, and not with ICS. Further studies should 
replicate these findings.
Directions for future research
First, as data on the incidence of asthma over time are conflicting, further research, preferably 
international population based incidence studies, are needed to find out how the pattern of 
asthma is changing by calendar time and age. Furthermore, most prevalence estimates outdat-
ed. Fortunately, the Global Asthma Network announced in their report in 2014 that it plans to 
continue worldwide studies to find out how the pattern of asthma is changing in children and 
adults. 2 To facilitate comparison of data, we strongly recommend that further efforts be taken 
to harmonize definitions of asthma when using electronic health care databases. In most of 
the prevalence and incidence studies of asthma in children, asthma is considered as a chronic 
disease whereas asthma can be intermittent and has the potential to change phenotype with 
age, growth and environmental exposures. 71 Since the prevalence is a resultant of the inci-
dence and the duration of disease, it should be investigated how intermittent asthma affects 
the prevalence and incidence of asthma. 
Second, we need to better understand how treatment adherence impact outcomes such as 
moderate to severe asthma exacerbations. Future studies should investigate optimal adher-
ence measures based on asthma phenotypes, as MPR measures might be too conservative for 
patients with intermittent asthma. Ideally, not only treatment adherence but also inhalation 
techniques should be considered, although this is difficult to assess in electronic record data-
base studies. Several studies on different strategies e.g. education, monitoring by pharmacists, 
electronical medical devices, to improve adherence already have been performed. 18 However 
real life studies are needed to demonstrate that these strategies not only lead to better adher-
ence, but might also improve symptom control and prevent exacerbations. 72
Third, we observed a possible association between switching between generic and brand SABA 
(or vice versa) and asthma exacerbations. In our study, data on asthma severity and reasons 
for switching were not available. This information is of utmost importance to disentangle 
whether switching occurred because of worsening of respiratory symptoms leading to asthma 
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exacerbations, or whether switching by itself results in poorer asthma control. The impact on 
clinical outcomes and the cost effectiveness of the preference policy by the Dutch health insur-
ances should be investigated in newer data, as more generics are upcoming. 
Fourth, to tailor treatment strategies, there is also need for better monitoring of asthma, and 
to detect poor control and risk of exacerbations. 73 Use of structured interviews incorporating 
objective symptom assessment might uncover unmet needs, and would detect poor control. In 
our research we characterised patients at risk of non-adherence, at risk of asthma exacerba-
tions and at risk of mortality on population level. More individual characterisation, for example 
data on biomarkers i.e. exhaled breath condensate, may lead to better targeted treatment 
strategies. 72
Finally, to reach the goal of individualized prescribing in asthma, more research into the vari-
ability of treatment response and knowledge of genetic influences on drug response is needed. 74 
Characterisation of patients could be done at an individual level through pharmacogenetic 
research which may open the way for personalized medicine in children with asthma. Early 
recognition of patients who do not sufficiently respond to ICS treatment may reduce asthma-re-
lated outcomes. In future studies we hope to identify new loci through genome wide analysis 
of DNA collected in participants of the ESTATe study and the PACMAN study. 47 Findings will be 
replicated in databases of the PICA consortium. 48 
CONCLUSION
Asthma is a heterogeneous disease, with many risk factors. To some extent there is room for op-
timism, as the incidence of asthma tended to decrease and treatment guidelines were followed 
in general (e.g. LABA monotherapy is rare), however the burden of asthma with respect to 
mortality and exacerbations remains large, symptom control and adherence being suboptimal. 
The asthma outcomes are worse in real life than they could be and much worse than achieved 
in clinical trials. To improve these outcomes, future research should focus on prevention of 
exacerbation and improved symptom control. Therefore studies on strategies to ensure that 
patients are prescribed, receive and take appropriate treatments correctly, studies on opti-
mizing adherence and studies on further characterizing patients at risk for exacerbations are 
warranted. 
Hopefully the above mentioned directions for future research will lead to a personalized ap-
proach of patients with asthma improving their lives with better adherence and fewer asthma 
exacerbations.
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SUMMARY
In this thesis we focused on the epidemiology, treatment, exacerbations and mortality of asth-
ma in daily practice. In addition we studied risk factors for non-adherence and asthma exacer-
bations. For this research, we used different Dutch and other European electronic health care 
databases.
Chapter 1 provides a brief overview of asthma and its aetiology and treatment. It also provides 
the aims of the performed studies and describes the outline of the thesis. 
Chapter 2 describes the epidemiology of asthma. In Chapter 2.1 we describe the selection of 
the paediatric asthma cohort (= ESTATe cohort: Effectiveness and Safety of controller Therapy 
of Asthma in the Treatment of childrEn with asthma) within the Integrated Primary Care In-
formation (IPCI) database. This cohort was created by carefully exploring all medical records 
from potential asthma patients identified through "machine learning" techniques. The automat-
ed algorithm showed good performance in detecting potential cases of asthma utilizing both 
free-text and coded data, yielding a positive predictive value (PPV) of 0.82, sensitivity of 0.96, 
and specificity of 0.90 when identifying both definite and probable asthma cases. In Chapter 
2.2 we use this validated dataset of 14,303 children with asthma (35,118 patient years (PY) of 
follow-up) to describe the incidence, prevalence and trend of age at asthma diagnosis in 2000-
2012. We showed that the incidence rate of physician diagnosed asthma was 6.7 per 1000 PY 
in children in the Netherlands. The incidence for girls was lower than for boys till puberty, after 
puberty this gender difference reversed. The asthma incidence rate increased until 2008, from 
2008 onwards a non-significant decrease was observed. The cumulative prevalence of asthma 
was 8.1% (95% CI 8.0-8.2). The age-specific cumulative prevalence of asthma was higher in 
boys than in girls in all age categories.
In Chapter 3.1 we describe the epidemiology and risk factors of asthma exacerbations. In the 
ESTATe cohort we identified 732 exacerbations. The overall incidence rate of asthma exacer-
bations was 2.1/100 PY, 4.1/100 PY for children on asthma treatment. A seasonal trend was 
observed with highest incidence rates in spring and fall. Asthma re-exacerbation occurred in 
2% of patients within 1 month and in 25% within 1 year. Predictors for (frequent) asthma 
exacerbations were age, gender, specialist visits, inhaled corticosteroid (ICS) prescriptions and 
prior exacerbations, suggesting more severe asthma. 
In Chapter 3.2 we analyse the mortality in patients with asthma and the risk of mortality 
following a severe asthma exacerbation in 6 European electronic healthcare databases. The 
cohort consisted of 855,806 asthma patients. The all-cause mortality rate ranged between 4.8-
13.2/1000 PY and in patients with severe asthma between 16.0-36.2/1000 PY for the different 
databases. Mortality in the 1st week following exacerbation was 26.3-109.5/1000 PY and was 
higher following an ED-visit/hospitalization (57.9-239.4/1000 PY). We studied risk factors for 
mortality in a subgroup of adult patients with incident asthma. Increasing age, concomitant 
207Summary
7
diseases (COPD, diabetes, cerebrovascular diseases and cancer), smoking, asthma severity and 
previous asthma exacerbations were associated with mortality in most databases. 
In Chapter 4.1 we describe treatment patters and adherence in patients with asthma. The 
ESTATe cohort was mainly treated with short-acting β2-agonists (SABA; 40 users/100 PY) and 
ICS (32/100 PY). The adherence was low with a median medication possession rate (MPR) for 
ICS of 56%. Children with good adherence were younger at initiation of ICS treatment, more 
often visited specialists and had more exacerbations during follow-up compared to children 
with low adherence, suggesting that children with good adherence have more severe asthma. 
Chapter 4.2 describes the results of a systematic review on the relationship between low ad-
herence and risk of severe asthma exacerbations. We observed high levels of heterogeneity 
across studies with regard to adherence and exacerbation measurements, designs and analysis. 
Although effect measures varied widely, good adherence was associated with fewer severe 
asthma exacerbations in high quality studies.
In Chapter 5 we report the prevalence and effectiveness of the Dutch preference policy of 
inhalation medications in the study period 2003-2012. Chapter 5.1 shows that the occurrence 
of switching between brand and generic inhalation medication per calendar year was low, as it 
occurred only in 5% of the patients. Generic dispensing increased with calendar time. Switch-
ing between devices occurred in 5% of the patients who used an inhalation medication with an 
alternative device available. 16% of the patients used more than 1 device in 1 year. Adherence 
to both generic and brand inhalation medication was considerably low, with median MPRs 
over the first 12 months ranging between 33 and 55%. In Chapter 5.2 we report that current 
generic use of β2-agonists was associated with an increased risk of asthma exacerbations when 
compared to current use of brand inhaled β2-agonists. This association was stronger when 
studying switching between generic and brand (or vice versa) inhaled β2-agonists. This associ-
ation was not observed for use of generic ICS nor for switching between brand and generic ICS. 
Finally, in Chapter 6 we discuss the main findings of the studies included in this thesis and the 
methodological aspects. In addition, we provide suggestions for future research.
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In dit proefschrift onderzochten we de epidemiologie, de behandeling, de incidentie van astma 
exacerbaties en mortaliteit bij patiënten met astma in de klinische praktijk. Bovendien werden 
de risico factoren van een lage therapietrouw, van astma exacerbaties en van mortaliteit bestu-
deerd. In dit onderzoek hebben we gebruik gemaakt van verschillende Nederlandse en andere 
Europese electronische patiëntendossier databases.
Hoofdstuk 1 geeft een kort overzicht over de etiologie en behandeling van astma. Het be-
schrijft ook de doelen van de uitgevoerde studies en de opzet van het proefschrift.
Hoofdstuk 2 beschrijft de epidemiologie van astma. In hoofdstuk 2.1 beschrijven we de selec-
tie van het pediatrische astma cohort (= ESTATe cohort; Effectiveness and Safety of controller 
Therapy of Asthma in the Treatment of childrEn with asthma) in de Integrated Primary Care 
Information (IPCI) database. Dit cohort werd samengesteld door het zorgvuldig bekijken van 
alle medische dossiers van potentiële astmapatiënten, die werden geïdentificeerd met behulp 
van “machine learning” technieken. Het geautomatiseerde algoritme, waarbij gebruik werd 
gemaakt van zowel vrije tekst als gecodeerde data, liet goede resultaten zien in het detecteren 
van potentiële cases. Dit algoritme had een positief voorspellende waarde van 0,82, een sen-
sitiviteit van 0,96 en een specificiteit van 0,90, indien zowel zekere als mogelijke astma cases 
werden geïdentificeerd. In hoofdstuk 2.2 werd de gevalideerde dataset van 14.303 kinderen 
met astma (totaal 35.118 persoonsjaren (PJ) follow-up) gebruikt om de trend in incidentie, 
prevalentie en leeftijd waarop de astma diagnose werd gesteld, te beschrijven tussen 2000 
en 2012. De incidentie van dokter-gediagnosticeerd astma was 6,7 per 1000 PJ bij kinderen 
in Nederland. Deze incidentie was lager bij meisjes dan bij jongens vóór de pubertijd, na de 
pubertijd was dit verschil omgekeerd. De incidentie van astma nam toe tot 2008, en vanaf 
2008 werd een niet significante afname geobserveerd. De cumulatieve prevalentie van astma 
was 8,1%. De leeftijd specifieke cumulatieve astma prevalentie was hoger bij jongens dan bij 
meisjes in alle leeftijd categorieën. 
In hoofdstuk 3.1 beschrijven we de epidemiologie en risico factoren van astma exacerbaties. 
In het ESTATe cohort identificeerden we 732 astma exacerbaties. De incidentie van astma exa-
cerbaties was 2,1/100 PJ en was 4,1/100 PJ bij kinderen die tijdens follow-up astma medicatie 
kregen voorgeschreven. Een seizoen trend werd gezien, met hoogste incidenties in het voor- en 
najaar. Astma herexacerbaties traden op bij 2% van de patiënten binnen 1 maand na de exacer-
batie en bij 25% binnen 1 jaar na de exacerbatie. Risicofactoren voor frequente astma exacer-
baties zijn leeftijd, geslacht, specialist-bezoeken, voorschriften voor inhalatiecorticosteroïden 
(ICS) en eerdere astma exacerbaties. 
In hoofdstuk 3.2 analyseerden we de sterfte bij patiënten met astma alsook de risicofacto-
ren op overlijden na een ernstige astma exacerbatie. Voor dit onderzoek maakten we gebruik 
van elektronische patiëntendossiers in 6 Europese databases. Het cohort bestond uit 855.806 
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astmapatiënten. De incidentie van overlijden varieerde tussen 4,8-13,2/1000 PJ in de verschil-
lende databases. Deze incidentie was hoger bij patiënten met ernstig astma (16,0-36,2/1000 
PY). Sterfte in de eerste week na een astma exacerbatie was 26,3-109,5/1000 PJ en was hoger 
na een ernstige astma exacerbatie (eerste hulp bezoek/ ziekenhuis opname) (57,9-239,4/1000 
PJ). Risico factoren voor mortaliteit werden onderzocht in een subgroep van volwassenen 
met incident astma. Een oudere leeftijd, onderliggend lijden (COPD, diabetes, cerebro- en 
vasculaire ziekten en kanker), roken, ernst van astma, en eerdere astma exacerbaties waren 
geassocieerd met een verhoogd risico op overlijden in de meeste databases. 
In hoofdstuk 4.1 beschrijven we de behandelingspatronen en therapietrouw bij kinderen met 
astma. Voor dit onderzoek werd opnieuw gebruik gemaakt van het ESTATe cohort. Kinderen 
in dit cohort werden vooral behandeld met kortwerkende ß2-agonisten (SABA; 40 gebrui-
kers/100 PJ) en inhalatie corticosteroïden (ICS) (32/100 PJ). De therapietrouw aan ICS was 
laag met een mediane ‘medication possession ratio’ (MPR) van 56%. Kinderen met een goede 
therapietrouw aan ICS waren jonger bij de start van de ICS- behandeling, bezochten vaker een 
specialist en hadden vaker een astma exacerbatie tijdens follow-up, ten opzichte van kinderen 
met een slechtere therapietrouw. Dit suggereert dat kinderen met een goede therapietrouw een 
ernstigere vorm van astma hadden. 
Hoofdstuk 4.2 vat de beschikbare literatuur tot 2012 samen met betrekking tot de relatie 
tussen therapietrouw en het risico op ernstige astma exacerbaties. We observeerden veel he-
terogeniteit in de publicaties met betrekking tot de definities van therapietrouw, astma exa-
cerbaties, designs en analyses. Uit de studies met een goede kwaliteit blijkt dat een goede 
therapietrouw geassocieerd is met een lager risico op ernstige astma exacerbaties.
In hoofdstuk 5 rapporteren we de prevalentie en doeltreffendheid van het Nederlandse prefe-
rentie beleid rond inhalatiemedicatie in de studieperiode 2003-2012. Hoofdstuk 5.1 laat zien 
dat het switchen tussen merk en generieke inhalatiemedicatie weinig voorkomt, namelijk bij 
5% van alle patiënten per kalenderjaar. Het aantal generieke afleveringen van inhalatieme-
dicatie nam toe in de tijd. Switchen tussen inhalatoren kwam voor bij 5% van de patiënten, 
die inhalatiemedicatie gebruikten waarvoor verschillende inhalatoren beschikbaar waren. 16% 
van alle patiënten gebruikten meer dan 1 inhalator in een kalenderjaar. Therapietrouw aan 
zowel generieke als merk inhalatiemedicatie was laag, met een mediane MPR gemeten over de 
eerste 12 maanden van 33 tot 55%. In hoofdstuk 5.2 rapporteren we dat het huidig gebruik 
van generieke inhalatie β2-agonisten geassocieerd is met een verhoogd risico op astma exacer-
baties vergeleken met merk inhalatie β2-agonisten. Deze associatie was sterker wanneer dit 
werd onderzocht bij patiënten die switchen tussen generieke en merk inhalatiemedicatie. Deze 
associatie werd niet gezien bij het gebruik van generieke ICS of switchen tussen generieke en 
merk ICS. 
Tenslotte, bediscussiëren we in hoofdstuk 6 de resultaten en de methodologische aspecten van 
de studies in dit proefschrift. We sluiten af met suggesties voor toekomstig onderzoek. 
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